The localisation and regulation of phosphatidylinositol-4-phosphate 5-Kinase gamma splice variants and the discovery of a new mammalian splice variant, PIP5KIγ_v6 by Xia, Yang
  
 
The Localisation and Regulation of 
Phosphatidylinositol-4-phosphate 5-Kinase Gamma Splice 
Variants and the Discovery of a New Mammalian Splice Variant, 
PIP5KIȖ_v6 
 
 
Yang Xia 
 
PhD Thesis 
 
 
 
Trinity College 
and 
Department of Pharmacology 
University of Cambridge 
Declaration
All the experiments described in this dissertation were carried out solely by the author 
unless otherwise stated, in the Department of Pharmacology, University of Cambridge, 
between January 2008 and September 2010. This dissertation is not substantially 
identical to any other submitted for a degree, diploma or other qualifications, and no 
part of it has been, or is currently being, submitted for any such degree, diploma or 
other qualifications. This dissertation does not exceed the prescribed limit of 60000 
words. 
 
 
Yang Xia 
 
 
April 2011 
Acknowledgments
I gratefully acknowledge the personal guidance, inspiration, and appreciation of my 
supervisor, Professor Robin Irvine FRS, for guiding me into the fascinating field of 
inositol signalling. It is only because of his sharp insight, incredible experiences and 
great patience that my PhD studies could become an intellectually thrilling and 
thoroughly enjoyable journey. Again and again during the hardest times of my 
research, he has always been there, nurturing, considerate and upright, teaching me far 
beyond sciences. There are no words to match my gratitude. 
I am greatly indebted to Dr Maria-Luisa Giudici, who pioneered important 
investigations that led to the present study, for her hands-on teaching and selfless help. 
I would also like to express my gratitude to other members of the Department 
(especially Dr Jon Clarke, Dr Gerry Hammond and Mr Andy Letcher in our lab) for 
their support, very helpful discussions and tremendous encouragement. 
My personal expense during the present study has been generously covered by the 
Dorothy Hodgkin Postgraduate Award, Trinity College Cambridge and Shandong 
Yingcai Education Trust, China. 
It has been almost ten years since I first left China to pursue my passion in science. 
Every single day I miss my parents back at home. As the only child of the family, I 
was never blamed for not being able to look after them better all these years, nor did I 
have any pressure stopping me from doing what I loved. They have provided me with 
a world of freedom, far more than a son could have ever asked for. Thank you, Father 
and Mother, for you have always had faith in me. I dedicate this thesis to you both, 
with my sincerest and deepest love. 
Summary
Type I PIP kinases (phosphatidylinositol 4-phosphate 5-kinases, PIP5Ks) catalyse the 
majority of cellular synthesis of PI(4,5)P2. To date, three mammalian isoforms (Į, ȕ, Ȗ) 
have been found. PIP5KIȖ is subject to complex C-terminal splice variation, enhancing 
its transcriptional diversity through evolution and producing at least 5 known 
spliceoforms in the mammals*. 
This study addresses several important questions. (1) Several remarkable differences 
have been discovered between the neuronal splice variant PIP5KIȖ_i3 and its close 
variant, IȖ_i2, whose peptide lacks a 26-AA insert near its C-terminus. This study 
attempts to map these behavioural differences onto motifs within the peptide insert. 
Furthermore, a site of point mutation is identified near the activation loop, which 
amplifies the above differences. (2) This study documents properties of the more 
recently discovered PIP5KIȖ_i3, about which relatively little is known, for example, 
the regulation of its subcellular localisation, kinase activity and post-translational 
modifications. By site-directed mutagenesis and examining more closely several 
crucial motifs, insight is gained into the putative relationship between the enzyme’s 
phosphorylation state, cellular localisation, lipid kinase activity and 
autophosphorylation. (3) The discovery of a new PIP5KIȖ splice variant, IȖ_v6, is 
described. First discovered in rodents, PIP5KIȖ_i6 encompasses the 26-AA insert of 
IȖ_i3, but lacks the common C-terminus of IȖ_i2 and IȖ_i3 which contains peptide 
motifs that have several roles in vivo. A polyclonal antibody against the C-terminus of 
IȖ_i6 was also developed. Preliminary characterisation of IȖ_i6 demonstrates a similar 
subcellular localisation, but a wider expression profile than its close relative, IȖ_i3, 
suggesting potentially differential functions across tissues and at various 
developmental stages. (4) The existence of IȖ_v3 and IȖ_v6 is also confirmed in 
humans. In light of recent findings of other novel human spliceoforms, this is shown 
to be a case of intra-exonic splicing producing “alternative 5’ splice site” exons in the 
human. Overall, this thesis should help to better understand the regulation and 
physiological roles of PIP5KIȖ and, specifically, its different splice variants. 
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* For the purpose of consistency, I adopt the HUGO guidelines of nomenclature, as suggested by Schill and 
Anderson (2009). For example, IȖ_v3 denotes the mRNA, and IȖ_i3 the protein of the same splice variant. For a 
review of other historical names of PIP5KIȖ in the literature, e.g. in the forms of IȖ93, IȖc or IȖ687, please refer to 
Table 2 in the Introduction. 
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1. Introduction 
 
1.1. Inositol Derivatives 
1.1.1.InositolandInositolPhosphates
Inositol and inositol derivatives (inositides) have been an active topic of research for 
decades[1, 2]. A huge surge of interest in them has occurred in the lst 30 years, 
particularly since the discovery of IP3 (inositol 1,4,5-trisphosphate) as a Ca2+-
mobilising second messenger[3]. Following this discovery, further exploration took 
place which led to the discovery of dozens of higher inositol phosphates and lipids. 
The inositol phosphates are composed of inositol and phosphates and are therefore 
water-soluble. The inositol ring can be covalently bonded to a phosphate group at 
each of its 6 carbon positions, potentially allowing for the existence of more than sixty 
phosphate derivatives of inositol (see Figure 1 for some of those so far detected in 
cells). In this study, as with virtually all biological studies on inositol derivatives, I 
use the D-configuration for numbering the carbon atoms on the inositol ring[4]. The 
range of inositol phosphates is expanded by the possibility of adding pyrophosphates 
instead of monophosphates, resulting in derivatives such as IP7 and IP8. This thesis 
addresses the inositol lipids, of which there are, mercifully, fewer. 
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Figure 1 Eukaryotic inositol phosphate metabolism 
Courtesy of Professor Robin Irvine (2008). Arrows in black indicate universal eukaryotic 
pathways, while pathways in purple and blue have only been identified in slime moulds/plants 
and metazoans, respectively, to date. In this figure, inositol is denoted as Ins (instead of I, 
which is adopted throughout the rest of this thesis). 
 
 
1.1.2.InositolǦderivedLipids
It is speculated that inositol 3-phosphate may have been the first eukaryotic inositide 
to emerge, as a metabolic product from glucose 6-phosphate. Perhaps shortly after, the 
chemical combination (esterification) happened between inositol and activated 
phosphatidic acid (CMP-PA), to form the water-insoluble phosphatidylinositol (PI)[5]. 
In all eukaryotes, as far as we know, PI may be phosphorylated on the D-3, D-4 and 
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D-5 positions of the inositol ring, giving rise to 7 phosphorylated inositol lipids 
(Figure 2). 
It is now widely appreciated that this diverse family of inositol phosphates and 
inositol lipids exists as a complex, interconnected metabolic network in the cell, and 
each member may be converted into others by a spectrum of more than 80 isoforms of 
kinases, phosphatases, phospholipases and so on. In this way, the inositides form a 
highly dynamic metabolic and signalling network in the cell, instead of a linear 
cascade as originally thought. They are important for many aspects of the cellular 
function, and here I will focus on those most relevant to the topic of this thesis, the 
phosphatidylinositol-4-phosphate 5-kinases (PIP5Ks). 
 
 
 
Figure 2 Inter-conversion of phosphorylated phosphatidylinositols 
PI(4,5)P2 is emphasised by a red circle in this complex signalling network of 
phosphoinositides. 
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1.1.3.Phosphatidylinositol4,5Ǧbisphosphate
Among the spectrum of inositol lipids (Figure 2), PI(4,5)P2  (hereafter referred to as 
PIP2) is a remarkably important signalling mediator that fulfils multiple intracellular 
functions. Its versatile roles are two-fold in principle. Firstly, it is the precursor of 
many second messengers including IP3, diacylglycerol (DAG) (both generated by 
phospholipase C isoforms) and PI(3,4,5)P3 (generated by Class I phosphoinositide 3-
kinases, PI3Ks). These messengers produced, in turn, are crucial for very important 
cellular processes. For example, IP3 releases Ca2+ from intracellular stores to raise the 
cytoplasmic concentration of Ca2+[6], DAG activates Ca2+/phospholipid-dependent 
protein kinase C[7], and PI(3,4,5)P3 is a key player in signalling pathways controlling, 
for example, the cell cycle[8]. A further proliferation of cell mediators/messengers 
from PIP2 stems from the conversion of IP3 into the many inositol phosphates shown 
in Figure 1. 
Secondly, PIP2 itself regulates a number of events, such as actin cytoskeletal 
modelling, membrane vesicle trafficking, motility regulation, process formation, ion 
channel activity, gene expression and apoptosis. This largely depends on the ability of 
PIP2 to interact with diverse proteins, for example actin-binding proteins, clathrin-
dependent endocytic proteins, signal transduction proteins and enzymes such as 
phospholipase D and ARF GAP. These proteins contain PIP2-binding domains, such 
as pleckstrin homology (PH), Fab1, YOTB, Vac1 and EEA1 (FYVE), phox homology 
(PX) and epsin N-terminal homology (ENTH) domains[9-13]. In the first studies, the 
importance of such binding properties was implicated in cytoskeleton organisation. 
Through interactions with actin-binding proteins such as profilin and gelsolin, PIP2 
was demonstrated to regulate the free actin monomer concentration[14], and fine-tune 
the balance between elongation and breakdown of actin filaments[15]. This can result 
in rapid and local actin polymerisation, subject to Ca2+ and pH modulation. PIP2 was 
later identified as an upstream regulator of actin nucleation and an inducer of actin-
based vesicle movement through the WASP-Arp2/3 pathway[16]. In addition, PIP2-
binding to vinculin leads to bundling of the distal ends of actin filaments in focal 
adhesion contacts[17]. Conversely, when cellular PIP2 was reduced (by hydrolysis or 
protein/peptide sequestration), generally opposite effects were observed[17, 18]. 
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More recently, the roles of PIP2 have expanded into other areas of cell function. PIP2 
can either directly activate a target protein, as in the case of KATP channels[19] and 
phospholipase D[20], or help to recruit proteins such as epsin[21], AP180[22] and 
synaptotagmin-1[23] to PIP2 pools near the plasma membrane (PM), and thereby 
affect cellular processes, such as endocytosis (priming for clathrin-coat formation), 
exocytosis and vesicle motility. Using optical tweezers tether force measurements, it 
was suggested that PIP2 could control local adhesion energy between the PM and the 
underlying cytoskeleton, explaining the membrane dynamics and functional 
implications through its interactions with several cytoskeletal anchoring proteins, such 
as talin, vinculin and ERM family proteins[24]. 
The versatile functions of PIP2 imply an important role of its synthetic enzymes, 
phosphatidylinositol-4-phosphate 5-kinases, which will be discussed later as the 
central object of this study, but first attention will be given to how PIP2 could fulfil so 
many discrete roles. 
 
 
1.1.4.LocalisationofPIP2andAccummulationinSubcellular
Microdomains
PIP2 (along with PI4P) is the most abundant phosphoinositide at the plasma 
membrane[25].  Knowledge of PIP2 localisation can help to further understand its 
specific local function, e.g. [26]. Moreover, the presence of PIP2 at a specific 
subcellular location could imply the corresponding localisation of its synthetic 
enzyme(s), which is one of the main objectives of the present study. 
In the classic view, PIP2 is considered membrane-bound, primarily due to the 
hydrophobic nature of its phosphatidyl group on the D-1-position of inositol, which is 
a phosphoglycerol moiety linked to two long fatty acid chains. However, the overall 
level of intracellular PIP2 does not usually seem to change greatly, as a result of the 
dynamic equilibrium between its upstream and downstream metabolic pathways. 
Instead, it is usually local changes that mediate distinct effects and convey salient 
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information[27]. PIP2 is found in a variety of subcellular pools, serving a spectrum of 
functions that are potentially differentially regulated by various metabolic and 
signalling pathways. The local accumulation of PIP2 is therefore important, and can 
be achieved by two mechanisms: lateral sequestration and local synthesis. I will 
discuss local PIP2 synthesis later in Section 1.2.2, and here I focus on the former 
mechanism. 
The lateral sequestration by either lipids, phosphoinoside-binding effectors and/or 
selective, reversible phosphoinositide-sinks relies largely on the intrinsic property of 
the membrane heterogeneity, as opposed to that described by the classic fluid mosaic 
model[28]. In 1973, phospholipids were found by spin-label measurements to be 
present in a quasicrystalline halo, which enclosed the relevant enzyme system[29]. 
Supporting evidence was soon added by various means such as X-ray diffraction, 
electron microscopy, lateral diffusion measurements, differential partitioning of lipid 
probes and differential scanning calorimetry (e.g. [30, 31]). These types of clusters or 
glycolipoprotein microdomains of lipids and proteins were later formalised into the 
concept of “lipid rafts”[32, 33], putative planar or caveolar structures with uncommon 
lipid composition (enriched in cholesterol and sphingolipids), which are themselves 
free floating in the membrane but are supposed to be more ordered and tightly packed 
than the surrounding phospholipid bilayer. 
These structures exhibit locally regulated PIP2 turnover and restricted diffusion-
mediated exchanges with their environment. However, since inositol lipids typically 
contain polyunsaturated fatty acid tails (e.g. arachidonic acid), it is unlikely for them 
to partition in these rafts just through hydrophobic interactions. Indeed, variations in 
the cholesterol content alone seemed to have a dramatic modulatory effect on the 
membrane structure, which in turn influenced the mobility and function of the 
phosphoinositide kinases[34, 35]. Experimental techniques are starting to be able to 
isolate and discern the fine print of the content of these heterogeneous endomembrane 
systems, leading to useful structural and functional insight into the composition and 
signalling capacity of lipid rafts[36-42]. 
With the enriched lipids and associated proteins, the putative lipid rafts should not be 
regarded as mere sites for phosphoinositide storage, but rather as critical dynamic 
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membrane compartments for PIP2 turnover and generation of derived second 
messengers in response to various agonists. We should, however, note that there are 
key controversies and caveats with the lipid raft theory. For example, the use of model 
systems in vitro implies inherent oversimplifications and limitations. A line tension 
that should in theory exist between the two postulated phases has never been directly 
observed in the cell system. There is no consensus on the size of the rafts, which 
currently is thought to span across a huge range of options (e.g. [43, 44]). The time 
scale of their existence is not known, therefore the rafts may not necessarily be 
relevant to biological processes. Furthermore, it is unclear how lipid rafts in the outer 
leaflet of the membrane bilayer could organise signal-transducing molecules in the 
inner leaflet[45]. Therefore, it may be more helpful to consider the rafts not as 
generalised, loosely defined structures, but as a helpful experimental system and 
thought framework that may be useful for addressing certain questions in appropriate 
contexts. Meanwhile, other plausible mechanisms were also proposed to support 
membrane heterogeneity, such as the trapping by the actin cytoskeleton[46], which 
would still be compatible with observations on phosphoinositide mobility[47]. 
In addition, through electrostatic interactions, PIP2 can also be sequestered by proteins 
with a highly basic cluster of amino acids, such as MARCKS (myristoylated alanine-
rich C kinase substrate)[48, 49]. These proteins are thought to be present at a high 
enough local concentration, and possess a high affinity for PIP2, in order to sequester 
it[50]. Indeed, a recent study suggested that a major fraction of PIP2 in vivo was 
bound by slow or immobile membrane components[51], which could be polybasic 
proteins interacting electrostatically with the phosphoinositide’s head group. 
MARCKS, for instance, is myristoylated at its N-terminus, which anchors it into the 
plasma membrane in addition to other mechanisms such as a positively charged 
phosphorylation site domain[52]. It is itself reversibly controlled by PKC-mediated 
phosphorylation and binding to CaM, a mechanism for releasing the pre-formed PIP2 
pool following the appropriate signal[53]. It is hence possible for MARCKS to bind 
PIP2 globally, but release it locally upon PKC activation or a rise in Ca2+/CaM. 
Therefore, as well as being simple lipid backbones, phosphoinositides could often 
serve signalling functions, capable of rapidly interacting and recruiting specific 
effectors to help generate signals reliably. 
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Indeed, according to confocal microscopy using a GFP-conjugated pleckstrin-
homology (PH) domain which preferentially binds to PIP2, PIP2 is mostly enriched in 
highly dynamic, actin-rich regions[54] or unidentified clusters in the PM[55-59]. The 
localisation of PIP2 in caveolin-enriched membrane domains is supported by 
biochemical data[60]. In addition to the PM, there has been accumulating evidence 
confirming its presence (at low levels) also in the Golgi apparatus[58, 61-63], 
endosomes[58], the endoplasmic reticulum (ER)[58, 64] and the nucleus[58, 65]. The 
existence of such multiple, metabolically distinct subcellular PIP2 pools means that 
different microenvironments (consisting of both proteins and lipids) may cater for 
differential metabolic and signalling reactions, in spite of the usually unchanging total 
cellular PIP2 concentration[56, 66-69]. 
 
 
1.1.5.LocalisationofPI4P
The localisation of PI4P has been perhaps even more controversial. After the early 
stages when PI4P was considered only an intermediate in the PIP2 synthetic pathway, 
pioneering work showed that some processes regulated by PI4P could be dissociated 
from PIP2, and that PI4P could also be a signalling molecule in its own right. 
Interestingly, most of the early discovered PI4P-binding proteins were localised to the 
Golgi complex[70]. This led to the initial assumption that PI4P was mostly present at 
the Golgi. However, more recent investigations into this phosphorylated inositol lipid 
and its binding proteins suggested a far wider distribution of PI4P, compartmentalised 
into metabolically distinct pools, including the PM, trans-Golgi-network, ER, 
endosomes, synapse and exocytic vesicles[68, 71-73]. 
A large number of metabolic regulators and effectors of PI4P have been investigated. 
Importantly, PI4P has a central role in anterograde membrane trafficking at the exit of 
the Golgi complex, as well as sphingomyelin and glycosphingolipid metabolism[74]. 
Therefore, PI4P appears to be a crucial regulator of the protein and lipid flux towards 
the cell surface, and hence it is in charge of the PM composition itself. Meanwhile, its 
presence at the PM has been directly demonstrated by immunocytochemistry using 
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carefully designed experimental protocols to visualise the PM[68]. As parallel 
evidence, a fraction of both PI4KIIĮ and IIȕ were found at the PM, and this fraction 
(in the case of IIȕ) increased upon Rac-dependent stimulation with growth factor[75]. 
In addition, PI4KIIIĮ was also implicated in the control of a plasma membrane pool 
of PI4P, with itself residing in the ER, at sites of close apposition to the PM[72]. A 
similar case of ER-localised Sac1-mediated PI4P break down at the plasma membrane 
was recently reported, activated by Osh3 proteins located at the ER/PM contact 
sites[76]. So the majority of PI4P is now suggested to reside in the PM[68], and this 
makes sense, as local pools of PI4P must serve as synthetic precursors for the 
conversion by PIP5Ks into membrane-bound PIP2[77]. 
 
Having briefly described our present knowledge of the substrate and product of 
PIP5Ks, we need to bear in mind several caveats with the direct imaging of inositol 
lipids. First, the choice of inositide-binding domain from different proteins may 
possess additional targeting motifs that bias the detection. For example, the PH 
domain from PLCį1 localises with the PIP2 on the PM but fails to label the Golgi[78]. 
Secondly, low binding-specificity can cause an issue when a protein needs to 
distinguish among several morphologically similar inositol lipid species. PH domains 
fall into four categories based on their phosphoinositide binding specificity[79, 80], 
and despite those that specifically bind to PIP3 and PI(3,4)P2, exclusive PI(4,5)P2-
binding domains are not seen, although some do have high preference towards PIP2. 
Multi-specific binding actually accounts for 85% of PH domains, some with 
significant regulatory roles, e.g. increasing affinity through oligomerisation[81]. As 
another example, PLCį1-PH binds to IP3 with at least 10 times higher affinity than to 
PIP2 in vitro[82]. In fact, the PH domain of PLCį initially binds PIP2 with high 
affinity and specificity, leading to substrate recognition, which is then released due to 
competition from the IP3 product formed during the catalytic reaction. It was initially 
observed using reporter PLCį1-PH-GFP, that PIP2 concentration at the PM could 
decrease transiently following PAF receptor stimulation[55]; however, this apparent 
translocation was more likely to be a reflection of the cytosolic increase in IP3[83]. 
Therefore, proteins containing other phosphoinositide-binding domains may also be 
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explored that possess a suitable specificity (e.g. GAP1(IP4BP)[84, 85] and the 
transcription factor tubby[86]), as well as the antibiotic neomycin[87]. Another 
method used especially for cells not amenable to GFP-tagged probe transfection was 
by low temperature staining with a specific monoclonal antibody[65, 88]. Other 
methods such as fluorescence resonance energy transfer (FRET), total internal 
reflection fluorescence (TIRF), single molecule fluorescence microscopy, laser 
tweezer, nuclear magnetic resonance (NMR) and fluorescence correlation 
spectroscopy have also been used (for a review see [48]). Thirdly, binding of 
reporters may mask or distort the inositol lipid interaction with other endogenous 
proteins and/or interfere with regular cellular metabolism, thereby affecting its 
apparent physiological function[89, 90]. Finally, there may be a dependence of 
binding specificity on coincident factors e.g. ARF1[91, 92] or generally the in vivo 
environment[71]. 
Therefore, although it is informative and reassuring to have examined PI4P and PIP2 
localisation in the cell (particularly the PM-bound pools), this must be complemented 
by the direct detection of the actual PIP kinase protein. 
 
 
1.2. Phosphatidylinositol Phosphate Kinases 
1.2.1.TheSpectrumofPIPKinases
According to the canonical phosphoinositide pathway, PIP2 synthesis is achieved 
through sequential phosphorylation of D-4 and D-5 positions of inositol, by PI 4-
kinase (PI4K) and PI4P 5-kinase (PIP5K). Two PIP5Ks were originally isolated from 
erythrocytes by chromatographic procedures, and were found to have distinct 
immunological and biochemical properties[93]. The Type I PIP kinase had a 20 fold 
lower Km for PI4P than Type II, and was stimulated by phosphatidic acid, heparin and 
spermine[94]. It is now known that the “Type II PIP5K” had actually been misnamed, 
and was in fact a PI5P 4-kinase[95]. 
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Therefore, the synthesis of PI(4,5)P2 from PIP is mediated by two independent PIP 
kinase pathways. Type I PIP kinases (phosphatidylinositol 4-phosphate 5-kinases, 
hereafter referred to as PIP5K) phosphorylate PI4P on the D-5 position of the inositol 
ring, whereas Type II PIP kinases (phosphatidylinositol 5-phosphate 4-kinases, PIP4K) 
catalyse the phosphorylation of PI5P on the D-4 position. It is worth mentioning that 
PIP2 could also be generated by specific dephosphorylation of D-3 position of 
PI(3,4,5)P3 by the lipid phosphatase PTEN, but it is largely considered to terminate 
the PIP3 signal instead of contributing to the functional PIP2 pool, as it was from PIP2 
that the PIP3 was largely synthesised. 
Both types of PIP kinase actually possess broader substrate specificity than initially 
expected. For example, both types could phosphorylate PI3P, and Type I kinases can 
even phosphorylate PI3P on both D-4 and D-5 positions in a concerted double 
phosphorylation, leading to PI(3,4,5)P3[96, 97]. Moreover, the Type I kinases can also 
use PI(3,4)P2 and PI (though to a lesser extent) as the substrate in vitro[96]. In fact, 
the PIP kinase family has been through quite a few duplication events, and different 
paralogues have been divergently evolved to produce a whole array of related 
enzymes. Their kinase core domain have conserved catalytic residues for ATP and 
Mg2+ binding, spatially organised in a similar fashion to other lipid and protein 
kinases, implying a common phosphotransfer mechanism[98]. However, although PIP 
kinases are related between themselves, they share little sequence homology to other 
known phosphatidylinositide kinases or protein kinases[94, 99]. For example, another 
type of D-5 kinase preferably uses PI3P (and, to a much less extent, PI) as the 
substrate and shares no homology with Type I and II, so that the mammalian PIKfyve 
gene (orthologous to the yeast Fab1p) is proposed to be designated Type III. 
PIP5KIĮ has a conserved kinase homology domain that is, for example, 35% identical 
to PIP4KIIĮ. A more stringent alignent between PIP4KIIȕ (the only PIP kinase whose 
structure has been solved[98]) and other families of protein kinases (e.g. Fab1p, PI3K, 
PI4K, PKA[98], PK and ATP-grasp[100]) revealed structural similarity and short 
motifs reminiscent of protein kinases, despite the lack of significant primary sequence 
homology. Three residues were absolutely conserved across the kinases tested, i.e., 
Lys150, Asp278 and Asp369 (based on human IIȕ)[98]. These residues were identified as 
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responsible for ATP-binding, weak base transfer and Mg2+/Mn2+-binding, respectively, 
just as in PKA. The rest of the enzyme also contained a flat membrane attachment site 
and a dimerisation interface[98, 101]. 
In intact cells, pulse-radiolabelling experiments suggest that PIP2 is mostly 
synthesised via the Type I PIP kinase route[102]. This is consistent with the fact that 
PIP2 and its main precursor PI4P are ubiquitous in eukaryotes, and PI4P is the most 
abundant monophosphorylated derivative of PI, compared to PI5P which only 
accounts for about 2% of cellular PIP[25, 95, 103, 104]. Functional interactions 
between Type I and II PIP kinases have been observed – for instance, Type IIĮ PIP 
kinase associates with the PM via interaction with Type I isoforms[105]. 
It has long been observed that all PIP5Ks are mainly localised to the plasma 
membrane (as well as to a lesser extent Golgi, vesicles and internal nuclear matrix), 
while PIP4Ks are typically cytosolic or nucleus-targeted[105-110], though the Ȗ 
isoform associates with cellular vesicles[111]. It is clear that the nuclear 
phosphoinositide pools are independent of the cytosolic ones, likely to be regulating a 
unique set of cellular events. In this study I focus on the PIP5Ks outside the nucleus, 
which are typically found on the plasma membrane. 
 
 
1.2.2.PhysiologicalRegulationofPIP5K
I mentioned earlier in Section 1.1.4 that in addition to lateral sequestration by 
membrane microdomains, local synthesis of PIP2 by PIP5Ks is another mechanism for 
obtaining differentially regulated PIP2 pools. For example, transient accumulation of 
PIP2 at phagosomes is attributable to local synthesis by PIP5Ks, where PIP5KIȕ is 
recruited to produce a local, transient PIP2 pool that in turn leads to negative feedback 
on the kinase through PLC[112]. 
Indeed, a coincidence detection mechanism was postulated for PIP5K to localise to 
the membrane and its specific compartments, by the electrostatic interactions with 
both its substrate (PI4P) and the negatively charged membrane[113]. Both PI4P-
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binding and polycationic surfaces (formed by polybasic amino acid residues in PIP5K) 
are necessary for membrane localisation, while neither is sufficient on itself (also see 
later in Sections 1.3.3 and 1.3.4). In this way, the enzyme can be translocated to a 
membrane microdomain through a number of differentially regulated, low-affinity 
interactions. The membrane-binding energies of the domains often simply add in 
parallel, while the binding constants multiply[114]. At least three advantages are 
suggested to associate with such multi-motif interactions. 1) It promotes lateral 
organisation/sequestration; 2) It offers greater possibilities for reversible binding and 
adds extra layers of modulation; 3) It may underly synergistic, coincidence detection. 
The anchoring of PIP5K to the membrane is physiologically important, as it then 
brings the enzyme into the surface phase, a few nm adjacent to the membrane, where 
the catalytic site can experience an approximately 1000x higher effective 
concentration of PIP2, than if it was diffusing randomly through the cytoplasm[115-
117]. Such a rise in local concentration is termed reduction in dimensionality[118]. 
This must also mean that the regulation of PIP5K localisation would have been 
critically implicated in determining their Km for substrate through evolution. 
Additionally, membrane recruitment of PIP5K as a functional effector by the 
phosphoinositides is well supported by the mobility of other inositol lipid effectors. 
These were shown to have a relatively fast diffusion coefficient (~1 ȝm2/s) and short 
membrane dissociation time (2–7 s), which meant that the lipid-protein complex could 
rapidly explore the membrane once recruited, and make thorough, functional 
interactions, yet not stray too far from the site of locally directed lipid synthesis[47]. 
The accurate and timely localisation of the kinase is hugely important for achieving 
the appropriate specific function, and is tightly regulated in addition to direct 
modulation of the kinase activity itself. In vivo, spatially and temporally organised 
PIP2 synthesis by PIP5Ks is under sophisticated regulation of membrane receptors, 
phosphorylation and small Rho and ARF GTPases (both of the Ras superfamily), 
amongst other potential regulatory partners. Here I briefly touch upon these regulatory 
mechanisms in turn. 
14 
 
1) Membrane receptors. Upon pharmacological receptor activation, the formation of 
IP3 by PLC can lower the cellular PIP2 by as much as 80%[119], which then has to be 
regenerated in time to allow for reliable signalling through membrane receptors. 
Traditionally, modulation of PIP2 synthesis by GPCR was investigated in platelets, 
where thrombin stimulation resulted in elevated PIP2 formation and increased PIP5K 
association with the cytoskeleton[120]. Indeed, radiolabelling experiments suggested 
that PIP2 synthesis (through strong and long-lasting potentiation of repeated PLC 
activation) can be stimulated by GPCR and receptor tyrosine kinases[121, 122]. 
In addition, PIP5K is found to associate during B cell receptor activation in 
lymphocytes with Btk, a Tec family non-receptor tyrosine kinase which is recruited 
onto the membrane (through its PH domain and independent of its kinase activity) and 
which ultimately joins PLC-Ȗ2 to enable sustained calcium signalling[123]. Both Btk 
and PLC-Ȗ2 are anchored by the PIP3 produced by coincident activation of PI3K also 
docked in the complex, and the presence of PIP5K can therefore obviously ensure the 
local availability of PIP2 as a common substrate for both PLC-Ȗ2 and PI3K. 
Both PI4K and PIP5K are also found to interact with the activated EGF receptor[124, 
125]. Such stimulation and association could be a mechanism where PIP5K becomes 
assembled into signalling complexes in order to allow for efficient regulation, e.g. by 
PLC. Another example is the Wnt3A ligand, which activates PIP5KIȕ through 
Frizzled and Dishevelled, both part of the Wnt receptor complex on the cell 
surface[126]. 
2) Phosphorylation. Some phosphoinositide enzymes (including PIP5Ks) possess 
intrinsic protein kinase activity, which can lead to the phosphorylation of amino acid 
residues on the kinase molecule itself and, ultimately, changes in its catalytic activity 
that is largely shared between the two related catalytic mechanisms[127]. 
Phosphorylation is generally seen to negatively affect the enzyme’s kinase 
activity[127-129]. For instance, inactivation of PIP5Ks was observed with 
phosphorylation by PKA, and, in contrast, PIP5KIȕ activity was stimulated by its 
dephosphorylation through protein phosphatase 1[129]. Key positive residues were 
demonstrated to be necessary for the interaction with the phospho-head group of the 
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substrate, and serine phosphorylation near these residues was proposed to perturb 
substrate binding, hence reducing the catalytic activity[130]. However, another study 
on the Schizosaccharomyces pombe Type I homologue implicated a decrease in 
catalytic activity to a lower Vmax but no change in Km[128], somewhat in conflict with 
the above hypothesis. 
Alternatively, phosphorylation can also up-regulate the PIP5K in certain scenarios. As 
such potential regulatory mechanisms by protein phosphorylation are directly relevant 
to the present study, a more IȖ-related discussion will be presented in detail in Section 
1.3.1, as well as Results I (Section 3.2.5). 
3) Rho family GTPases. These small GTPases (such as Rho, Rac and Cdc42) control 
a wide spectrum of signalling pathways and have profound effects on cell morphology 
and the dynamics of the actin cytoskeleton, possibly partly through modulating 
phosphoinositide metabolism. Specific inactivation of Rho (which enhances PIP2 
synthesis) prevents the stimulation of PIP5K by GTP[131]. Dominant negative RhoA 
does not affect stress fibre induction by PIP5KIȕ, demonstrating that PIP5K functions 
downstream of RhoA in actin organisation[132], later shown to be mediated by the 
RhoA effector, Rho-kinase[133]. This transduction pathway was more recently 
demonstrated in neurons, where neurite retraction induced by receptor agonists, RhoA 
and Rho-kinase was completely blocked by a kinase-inactive PIP5K mutant[134]. 
In contrast, a stimulatory effect on PIP5K activity by Cdc42 and Rac1 was specific, 
and independent of RhoA and Rho-kinase. Rac, for example, is a stimulator of PIP2 
synthesis, and PIP5Ks are critical mediators of Rac-dependent actin remodelling, 
leading to isoform-specific uncapping and polymerisation of actin filaments[135]. 
Catalytically-inactive PIP5KIȕ blocked Rac-induced actin filament assembly[136] 
and membrane ruffle formation[137], again, functioning downstream of Rac. Rac has 
also been shown to contribute to targeting of PIP5Ks to the plasma membrane[138, 
139], and this is explored in some detail later in this thesis. Interestingly, PIP5KIĮ 
was reciprocally proposed to be an upstream regulator of Rac1, controlling its 
integrin-induced translocation and activation[139]. Meanwhile, PI4KIIȕ was also 
found to be activated by Rac and translocate to the plasma membrane[75]. Rac can 
therefore recruit and activate the enzymes responsible for colocalised PIP2 synthesis at 
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the membrane, allowing for functions in specific cellular compartments (such as 
pollen tube elongation[140]). 
All three PIP5K isoforms were also demonstrated to associate physically with RhoA 
and Rac1, but not Cdc42 or Rac2, both in vivo and in vitro[141]. Importantly, this 
association is independent of the nucleotide-binding state[142], while most other Rho 
GTPase effectors (e.g. PI3K) bind to the active, GTP-bound form exclusively[143]. It 
is important to note that such regulations of PIP5K by Rho GTPases can be under the 
control of membrane receptors and adhesion signals, allowing for e.g. receptor-
mediated PIP5K activation and translocation, involving sequential activation of GĮ, 
Rac1 and RhoA. 
4) ARF family GTPases. ADP-ribosylation factor (ARF) GTPases regulate 
intracellular vesicle trafficking. PIP5K can be directly activated by ARF proteins in 
the presence of phosphatidic acid (PA)[144]. For example, PIP5K is recruited by 
ARF1 to the Golgi complex as its direct effector[62, 63]. ARF6 also colocalises with 
PIP5K in ruffling membranes and endosomal structures[145], and the regulation of 
PIP5K activity and localised PIP2 turnover are critical for ARF6-induced membrane 
trafficking[145, 146]. 
During integrin-mediated phagocytosis, focal and transient accumulation of PIP2 by 
PIP5K revealed efficient collaboration between Rac1 and ARF6, where Rac1 
regulated the early recruitment of PIP5K, and ARF6 controlled the activity of 
membrane-docked kinase[147]. 
5) Other proteins. Many other factors regulate PIP5K too, besides the cases 
mentioned above. This is not surprising, since the cellular signalling pathways form a 
vast and complex network, in which PIP5K is an important node due to the versatile 
functions of PIP2. For instance, PIP5K can associate with pRB (a master regulator of 
cell cycle progression from G1 into S-phase), and this induces its own activation and 
hence PIP2 synthesis[148]. This can have important functions, since fractionation 
studies have demonstrated PIP5K activity in the inner nuclear matrix[106], later 
proposed to be nuclear speckles containing pre-mRNA processing factors[149]. Upon 
inhibition of mRNA transcription, both kinases and PIP2 reorganise along with other 
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speckle components. Notably, the nuclear phosphoinositides are presented to their 
enzymes in a non-membranous form[150], perhaps bound to proteins by the 
hydrophobic tail, exposing the head group for interactions with other targets[151]. 
Another example is the Phospholipase D (PLD). PLD catalyses the hydrolysis of 
phosphatidylcholine (PC) into PA, as an alternative PA-generating route to 1,2-DAG 
conversion by diacylglycerol kinase (DGK). Both DGK- and PLD-generated PA is 
able to stimulate PIP5K activity in vivo[26]. On the other hand, PLD is crucially 
dependent on PIP5K and PIP2[11, 152], and PLD1 is also directly regulated by Rho 
and ARF GTPases[153]. This interesting relationship between PIP5K and PLD of 
reciprocal stimulation and common regulation by the same GTPases allows for 
concerted positive feedback and feed-forward mechanisms leading to acute, localised 
PIP2-synthesis. 
 
 
1.2.3.TypeIPIPKinaseIsoforms
To date, three mammalian Type I PIP kinase (PIP5K) genes (Į, ȕ, Ȗ) have been found 
(Figure 4)[108, 154], sharing about 60% peptide sequence identity overall, and 
approximately 80% in the conserved central catalytic core. The amino- or carboxyl-
terminal sequences, on the other hand, are less homologous between PIP5Ks, 
potentially underlying isoform-specific functions. The C-terminus exhibits alternative 
splicing and adds diversity to the versatile signalling potentials of the enzyme, e.g. 
interaction with talin (see Section 1.3.5 below). The N-terminus, on the other hand, is 
responsible for other regulatory mechanisms, e.g. Rac-binding[138]. In this study, I 
will investigate detailed C-terminal variations of PIP5KIȖ, and also build upon the 
knowledge of this N-terminal Rac-interaction site on PIP5KIȖ. 
PIP5KIĮ and Iȕ have an apparent MW of 68 kDa, while IȖ has several splice variants 
ranging from 87 to 100 kDa (see next Section). Figure 3 depicts the divergent 
evolution through gene duplication (resulting in paralogues) and speciation (resulting 
in orthologues in other organisms), using IȖ as an example. Note that the more distant 
proteins such as MSS4 (Saccharomyces cerevisiae), ppk-1 (Caenorhabditis elegans), 
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PIP5K59B and sktl (Drosophila melanogaster) are also homologous to the 
mammalian PIP5Ks (Figure 3). The yeast MSS4, for instance, is membrane-localised 
and is required for cell-cycle-dependent actin reorganisation and cell wall integrity, 
which is not complemented by Type II PIP4Ks[155, 156]. 
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Figure 3 Gene tree illustrating the divergent evolution of PIP5KIȖ 
Image adapted from Ensembl. PIP5KIȖ is denoted “PIP5K1C” by consensus. Orthologues of 
PIP5KIȖ are expanded, while nodes corresponding to other paralogues of IȖ within the PIP 
kinase family are collapsed. Note that “PIP5KL1” is a class of generally non-active 
homologues to PIP kinases, whose physiological functions are still poorly understood. 
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Due to historical reasons, the names of IĮ and Iȕ genes were once reversed between 
humans and rodents. The human Iȕ, at the time of naming by Loijens and Anderson, 
happened to be orthologous to the murine IĮ as named by Ishihara and Shibasaki, and 
the human IĮ to the murine Iȕ[94, 154]. This unfortunate mismatch of isoform names 
caused considerable confusion, which accumulated in the literature until more 
recently (between April 2006 and October 2007), when the gene names of rodent 
(mouse and rat) isoforms were swopped to be consistent with those of the human 
counterparts (Table 1). Notably, the human PI5KIȕ was in fact previously known as 
the STM7 gene, implicated in Friedreich’s ataxia, which was later discovered to 
possess PIP5K activity[157]. 
For clarity, all names in the original literature are updated in this thesis to be 
consistent with the human system, based on the species used and the date of 
publication. IȖ, in contrast, was discovered later[108] and its naming has been 
consistent across the species (Figure 3). 
 
 
PIP5K 
isoform 
Gene 
name 
Mouse 
(Mus musculus) 
Rat 
(Rattus norvegicus) 
Human 
(Homo sapiens) 
Type I Į PIP5K1a ENSMUSG00000028126
P70182 
ENSRNOG00000021068 
D3ZSI8 
ENSG00000143398 
Q99755 
Type I ȕ PIP5K1b ENSMUSG00000024867
P70181 
ENSRNOG00000015232 
Q5CZZ9 
ENSG00000107242 
O14986 
Type I Ȗ PIP5K1c ENSMUSG00000034902
O70161 
ENSRNOG00000020577 
Q5I6B8 
ENSG00000186111 
O60331 
Table 1 Identity of Type I PIP5K genes in bioinformatic databases of the mouse, rat and 
human 
For every gene isoform entry, the upper row denotes the Ensembl identifier, while the lower 
row shows the most representative UniProtKB/Swiss-Prot identifier. The table above quotes 
the current, updated names of all genes. 
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To a large extent, the three isoforms of Type I PIP5K appeared to share similar 
regulatory properties. For example, they are all stimulated by PA[108, 158], and 
negatively regulated by PI-dependent autophosphorylation[127] and PKA[129]. 
Moreover, they all show specific interactions with binding partners, such as Rho 
GTPases[141] and PIP4KIIĮ[105]. 
However, the presence of various isoforms certainly implies differential regulation by 
multiple signal transduction components, leading to various non-redundent PIP2-
modulated processes, likely dependent on the subcellular distribution of isoform-
specific binding partners and discrete membrane microdomains. For example, it was 
suggested that ruffle formation in response to PDGF depended exclusively on the PIP2 
produced by translocated PIP5KIĮ, but not Iȕ[137]. IĮ was identified to be an 
upstream regulator of Rac1 in its integrin-induced translocation, a function not shared 
with other isoforms[139]. In contrast, only Iȕ mediated Rac-dependent actin filament 
uncapping in permeabilised platelets, although both IĮ and Iȕ associated with Rac1 in 
vitro[136]. Knockdown of PIPKIȕ (but no other isoforms) blocked adhesion turnover 
leading to the inhibition of cell migration[159]. In CV-1 cells, constitutive 
endocytosis specifically required the Iȕ subtype, but not IĮ or IȖ[160]. This is 
paralleled by the observation that the central kinase domain of IĮ and IȖ (but not Iȕ) 
was sufficient to prime endocytosis, correlated with their intrinsic lipid kinase 
activity[161]. Recently, a parallel study of all PIP5K isoforms revealed a striking 
redundancy of IĮ and Iȕ functions in the rapid synthesis of discrete pools of PIP2, 
required for second messenger formation after GPCR stimulation of platelets. The 
presence of IȖ did not rescue the phenotype of a Iȕ knockout. In contrast, IȖ knockout 
impaired the connection between cytoskeleton and PM in murine megakaryocytes, 
which was not reversed by Iȕ overexpression[162]. Furthermore, a single allele of IȖ 
was sufficient to support life to adulthood in the absence of IĮ and Iȕ, and IĮ (but not 
Iȕ) supported prenatal development, while Iȕ alone was implicated in neuronal 
differentiation[163]. The PIP2 pools generated by different PIP kinase isoforms may 
therefore be differentially compartmentalised, and distinguished by the local 
membrane composition in which they are embedded. 
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Different isoforms can collaborate too. For instance, during phagocytosis, PIP5KIĮ 
regulates actin polymerisation and bacterial internalisation, and localises to the 
forming phagosome by electrostatic interactions with the phagocytic membrane, while 
IȖ is required for clustering receptors that interact with bacteria, both isoforms 
increasing the local PIP2 concentration in the pseudopods[113]. 
Type I Į and ȕ isoforms are expressed in a relatively wide and partially overlapping 
range of tissues[94], implying ubiquitous functions in different cell types. 
Nevertheless, their differential localisation is also thought to be of functional 
significance. Type I Ȗ expression, on the other hand, is largely confined to the kidney, 
the lung, and especially the brain[108] (highly expressed in focal adhesion sites[164] 
and nerve terminals[165]). This makes sense in light of neurobiology, that IȖ has been 
shown as the major PIP2-synthesising enzyme at the synapse, and is probably crucial 
for clathrin-mediated endocytosis following synaptic vesicle secretion[165, 166], the 
maintenance of neuronal processes[167], adhesion junction formation and neuronal 
cell migration[168], as well as life from conception till at least before adulthood[163]. 
In other systems, knockdown of IȖ also suggested other functions, for example, in 
cardiovascular development[168]. Interestingly, many of its functions seemed to be 
splice variant-dependent. 
 
 
1.2.4.AlternativeSplicingofPIP5KIɀ
Alternative splicing of pre-mRNA gives rise to more variability at the protein level, 
potentially a mechanism for increasing the diversity of inositol signalling and its 
regulation[169]. PIP5KIȖ has 19 known exons and three splice variants identified in 
rodents prior to this study (Figure 5), namely Ȗ90, Ȗ87 and Ȗ93 according to their 
apparent molecular weight (in kDa). These spliceoforms are also known as Ȗ661, Ȗ635 
and Ȗ687, respectively, indicating their (mouse) polypeptide length in amino acid 
residues. However, a recent publication reported two further splice variants of 
PIP5KIȖ specific to humans, both with the IȖ87 core but unique C-termini largely 
unrelated to any of the above variants[170]. The authors named their novel splice 
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variants Ȗ4 and Ȗ5, while allowing for Ȗ87, Ȗ90 and Ȗ93 to be renamed Ȗ1, Ȗ2 and Ȗ3, 
respectively (Figure 4). According to the guidelines of the HUGO Genetic 
Nomenclature Committee, the mRNA of IȖ3, for example, is now denoted by IȖ_v3 
and the protein IȖ_i3. 
 
 
 
HUGO name 
(mRNA) 
HGVS name 
(protein) 
Corresponding exons 
(murine) 
Previous names 
IȖ_v1 IȖ_i1 1 – 16, 19 IȖ87, IȖ635, 
PIP5KIȖb 
IȖ_v2 IȖ_i2 1 – 16, 18, 19 IȖ90, IȖ661, 
PIP5KIȖa 
IȖ_v3 IȖ_i3 1 – 16, 17, 18, 19 IȖ93, IȖ687, 
PIP5KIȖc 
IȖ_v4 IȖ_i4 1 – 16, 16b*, 16c*  
IȖ_v5 IȖ_i5 1 – 16, 16c*  
IȖ_v6 IȖ_i6 1 – 16, 17, 19 # 
Table 2 Summary of synonymous nomenclature of PIP5KIȖ splice variants in the 
literature 
* exists only in humans, not in the rodents where the corresponding inter-exonic region is 
much shorter and therefore homology cannot be established. # is discovered in the present 
study (see Results III and IV), and therefore has no previous names. 
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Table 2 provides a concise summary of synonymous names of PIP5KIȖ splice variants 
in different naming systems. Hereafter, this thesis will consistently adopt the 
HUGO/HGVS nomenclature, when referring to the earlier literature and naming other 
newly discovered splice variants. 
Among these spliceoforms, IȖ_v1 and IȖ_v2 were cloned earlier, at the time when 
PIP5KIȖ was initially discovered[108]. Both contain the initial 16 exons (and end with 
Exon 19 that has a stop codon at its 5’ end), with IȖ_i2 having an additional 26 amino 
acid “tail” at the C-terminus, corresponding to Exon 18 (Figure 5). To date, a 
significant amount is known about them, and their functions seem to be spliceoform-
specific. For example, only IȖ_i2 interacts functionally with talin and is targeted to 
focal adhesion[171, 172] under the regulation of Src phosphorylation[164]. This 
ability to bind talin and other proteins e.g. AP-2 also leads to other roles, for example, 
in EGF-stimulated directional cell migration[173], integrity of membrane 
cytoskeleton in megakaryocytes[162], and endocytosis regulation[174, 175]. 
Moreover, IȖ_i2 binds directly to both E-cadherin and clathrin-adaptor protein 
complexes, enabling E-cadherin trafficking, whereas IȖ_i1 only binds to E-cadherin 
and is not sufficient to support trafficking on its own[176, 177]. While acting as a 
signalling scaffold for the adherens junction formation, IȖ_i2 also regulates trafficking 
events via the spatial generation of PIP2. On the other hand, IȖ_i1 (but not IȖ_i2) is 
involved in PLD2 stimulation of integrin-mediated adhesion[11]. This clearly 
demonstrates in the specific case of PIP5KIȖ, that alternative splicing is indeed a 
powerful way of generating functional diversity and regulatory complexity[178]. 
 
 
Figure 4 Schematic illustration of the IȖ_i3 splice variant in the PIP kinase family. 
25 
 
 
 
The third splice variant, IȖ_i3, was discovered more recently in our lab from the 
amplification of a rat hippocampal cDNA library (Figure 4)[167, 179]. It is similar to 
IȖ_i2, but has an additional 26 amino acid insert near the C-terminus, coded by Exon 
17. This exon has a plausible counterpart in the human genome[138], implying that 
the IȖ_v3 spliceoform may also be present in humans, which we shall address later 
(see Results IV). 
In the majority of this study, IȖ_i3 will be the focus of investigation, and in particular 
its tissue expression profiles and the regulation of its localisation, phosphorylation, 
lipid kinase activity and putative autophosphorylation. 
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Figure 5 Sequence of rat PIP5KIȖ and schematic illustration of peptide features of its 
three splice variants 
(a) Exon map of the rat PIP5KIȖ gene, where the distances between available exons are drawn 
to scale. (b) Corresponding amino acid residue numbers (of the rat gene) are noted below 
IȖ_v3 as landmarks. The conserved kinase domain containing ATP-binding (Lys188) and weak 
base catalytic (Asp316) sites, as well as the conserved activation loop, constitutes the kinase 
homology domain. Another conserved site responsible for Mg2+/Mn2+-binding (Asp398) is not 
shown. Detailed sequence alignment of this region is presented in Figure 6. The 26-AA-long 
insert in IȖ_i3 and the 26-AA-long IȖ_i2 tail are also illustrated. (c) Sequence of the rat 
PIP5KIȖ_v3 mRNA, illustrating exon junctions and numbering. 
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1.3. PIP5KIȖ_i3 
1.3.1.Phosphorylation
When detected by Western blot, wild type IȖ_i3 appeared as two bands, the slower 
running upper band completely disappearing after phosphatase treatment in vitro 
(unpublished observation by Dr Luisa Giudici; also see Results I). This mobility shift 
was also seen with IȖ_i2. Therefore, the presence of such two (or possibly more) 
bands in Western blot indicates, and conveniently assays, post-translational 
phosphorylation at one or multiple residues. 
So far, several important residues have been implicated in talin-binding in focal 
adhesion assembly, which are under transient Src and MEK phosphorylation (see 
Section 1.3.5). However, these phosphorylation sites were dependent on the specific 
kinase involved, and, in the PIP kinase pulldown of mutants that were not 
phosphorylated by Src and MEK, the overall phosphorylation was not altered, 
indicating the importance of phosphorylation at other unidentified residues[164]. To 
date, these putative phosphorylation sites remain to be discovered. 
Many lipid kinases (including all three PIP5K isoforms) have been demonstrated to 
show protein kinase activities, a classic example being PI3Ks[180]. It is still unclear 
whether the IȖ_i3’s in vivo phosphorylation observed is entirely due to interactions 
with other proteins kinases, or partly as a result of its own autophosphorylation, as 
exemplified by the putative protein kinase activity of PIP5KIȖ demonstrated in 
vitro[127]. Autophosphorylation is a widely observed phenomenon whereby a kinase 
can regulate its own activity, by inducing a conformational change through 
phosphorylation of the molecule itself (cis) or a dimerising partner (trans). Indeed, the 
crystal structure of PIP4KIIȕ interacted with membranes over a large flat patch of 
positively charged interface, formed jointly by two subunits assembling a 
homodimer[98]. Two of such dimerisation domains were also later identified in 
PIP5KIȕ[101]. Whether PIP5Ks autophosphorylate as monomers or 
crossphosphorylate as dimers is beyond the scope of the current study. In this study, I 
use the term autophosphorylation to mean the protein kinase activity of PIP kinases on 
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themselves without regard to mechanisms; whether they phosphorylated other protein 
substrates is also not a subject for investigation or discussion here. 
Autophosphorylation could potentially be a mechanism for autoinhibition. 
Autoinhibition has been structurally demonstrated in the Src, Abl, ZAP-70, and FAK 
families of cytoplasmic protein tyrosine kinases, AGC serine/threonine kinases (such 
as PKA), receptor tyrosine kinases, and calcium/calmodulin-dependent protein 
kinases (CaMK). It can be mediated in unique ways, for instance, by a 
pseudosubstrate sequence in the case of PKA[181], a juxtamembrane segment in the 
receptor tyrosine kinases that occupies the catalytic cleft[182], or a C-terminal 
autoinhibitory helix-loop-helix segment in the case of CaMKI[183]. A classic case 
was seen where serine phosphorylation in the catalytic or associated regulatory 
subunit of PI3K down-regulated the enzyme[180]. 
Indeed, relevant to the current study, PI-dependent autophosphorylation of 
PIP5KIȖ_i2 decreased its lipid kinase activity by ten-fold, indicating the possibility of 
PIP5K autophosphorylation inhibiting PIP2 synthesis in vivo[127]. Depolarisation-
dependent dephosphorylation of neuronal PIP5KIȖ in synaptosomes was accompanied 
by an increase in phosphoinositide turnover[165]. In addition, it has been known that 
the binding of talin to PIP5KIȖ_i2 activates the latter, probably by releasing 
autoinhibitory constraints in IȖ_i2’s C-terminal tail[184]. In other words, the talin-
binding site of IȖ (see Section 1.3.5) probably contributes to autoinhibitory 
interactions in the unactivated kinase. 
On the other hand, phosphorylation on other motifs of PIP5K may well enhance its 
activity. For instance, PIP5K was suggested to be up-regulated by WASP-Arp2/3-
mediated tyrosine phosphorylation[16], and focal adhesion kinase (FAK) 
phosohorylation on certain tyrosine residues of PIP5KIȖ led to increased lipid kinase 
activity[164], either directly or via altered interactions with talin[171] (more 
discussion in Section 1.3.5). 
 
 
29 
 
1.3.2.Localisation
When we investigate the detailed localisation of PIP5KIȖ_i3, it may be interesting to 
reflect on some insights given by its product PIP2 and its substrate PI4P (see Sections 
1.1.4 and 1.1.5 above). Logically, it would make sense for PIP5KIȖ to localise to 
where its substrate is most available, and hence where its product is abundant as a 
result. Besides the discussions above on the localisation of PIP5Ks in general (Section 
1.2.2), here we focus on the PIP5KIȖ_i3-specific perspectives. 
In situ hybridisation has shown that IȖ_v3 expression is confined to certain groups of 
neurons in the brain, such as the cortex, cerebellum and especially some major 
excitatory output neurons in the forebrain e.g.  hippocampus and olfactory bulb[167]. 
In situ signals were also detected in the pituitary, primarily in the anterior part 
(adenohypophysis) (unpublished), although this is somewhat puzzling since it is the 
posterior pituitary that has a more typical neuronal origin. Overall, this neuronal and 
even class-specific expression pattern is in contrast to the other two spliceoforms, 
especially IȖ_i2 which is much more widely expressed. This suggests possibly unique 
functions of IȖ_i3 in the brain. 
Since IȖ_i2 and IȖ_i3 share the same C-terminal 26 AA (i.e., the IȖ_i2 tail), an 
antibody raised against their common C-terminus would not produce specific staining. 
This adds complexity to the earlier literatures (prior to IȖ_i3 discovery) on 
endogenous IȖ_i2 distribution that were based on antibody-binding. Therefore, in the 
present study, I use overexpression of GFP- or FLAG-tagged vectors in HEK-293 and 
COS-7 cells to provide a way of specifically detecting the spliceoform of interest. 
Despite the obvious caveat that IȖ_i3 is naturally expressed in neurons, the data 
obtained can shine indirect but informative light on the endogenously expressed IȖ_i3. 
 
A fascinating finding was obtained in an earlier paper[179], from expression of the 
wild type IȖ_i3 and two different dominant negative (kinase-inactive) constructs. With 
both IȖ_i2 and IȖ_i3, the active enzyme was primarily at the PM. However, it was 
observed that the inactive IȖ_i3 was completely cytosolic, while the inactive IȖ_i2 
counterpart remained largely membrane-bound, more similar to its active wild type. In 
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terms of how IȖ_i3’s additional 26-AA insert might have produced this difference 
between inactive IȖ_i2 and IȖ_i3, one could imagine that the insert disrupts some 
important interaction required for membrane localisation (see next Section). However, 
even so, why this effect was uncovered only when the enzymes were inactive was not 
easily understood. The two inactivating mutations used, K188A and D316K, impaired 
the enzyme’s ability to bind ATP and transfer proton via weak base, respectively, both 
independently required for its kinase activity[98]. Therefore, it was unlikely that the 
common cytosolic presence observed was due to a non-specific disruption of protein 
structure. 
In addition, such different localisations also depended on the catalytic activity of the 
individual kinase molecule, instead of the overall intracellular PIP2 produced. In an 
elegant control using cotransfection of active and inactive IȖ_i3, the inactive IȖ_i3 
was still cytosolic as if transfected on its own[179]. In other words, the capability of 
active IȖ_i3 molecules to make PIP2 in the cell did not rescue the non-membrane 
localisation of inactive IȖ_i3. Importantly, neither K118A nor D316K should affect 
the binding of the enzyme to its lipid substrate, PI4P, and therefore the effects on 
localisation observed should be independent of PI4P-binding at the membrane and 
genuinely activity-dependent. 
 
 
1.3.3.Iɀ_i3ǦspecificInsert
Such activity- and insert-dependent differences in localisation required further 
investigation. What could the IȖ_i3-insert do that affects only the inactive IȖ_i3, but 
neither active IȖ_i3 nor active/inactive IȖ_i2, at least in its apparent membrane-
targeting? 
I thought that there might be a simple explanation for the difference. The 26-AA 
insert in IȖ_i3 may serve as a PIP2-binding site. Indeed, this is consistent with the fact 
that the insert actually has a run of four arginine residues (R648 – R651, shown in 
Figure 6c), whose positive charge may very well bind PIP2 and enhance PM-
association[185-188]. Such basic residues and consensus motifs were identified in 
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other phospholipid binding sequences such as PH, FYVE, PX and ENTH domains[9, 
189-195], and other PI(3,4,5)P3- and PIP2-binding proteins could be targeted to the 
PM by their characteristic polybasic clusters[196]. Therefore, suppose there is an 
added mechanism in IȖ_i3, where the insert is (or is part of) a PIP2-binding site which 
holds its own catalytic product in place once it is produced, and this conformational 
change in turn helps its localisation to the PM either directly or by interacting with 
other proteins. Inability to produce PIP2 will at this level impair the interaction, and 
therefore make inactive IȖ_i3 (but not IȖ_i2) cytosolic. 
As described later in this thesis, I generated a mutant “4R”, which has all the four 
arginine residues within the insert mutated into glutamate, i.e., 
RRRR(648,649,650,651)EEEE (Figure 6c) to address this issue. Also I used another 
mutant, “5P”, which has all five potential phosphorylation targets in the insert 
abolished, hence preventing any phosphorylation happening within this peptide insert 
of IȖ_i3. 
 
 
1.3.4.ActivationLoop
Type I and Type II PIP kinases (i.e., PIP5K and PIP4K) share sequence similarity 
clustered in the catalytic core, and little homology outside this region, potentially a 
mechanism allowing for distinct regulation. They also share 20–25 amino acids nearer 
to the C-terminus (Figure 5b), topologically corresponding to the activation loop in 
other kinases. The activation loops are highly conserved within the same PIP kinase 
subfamily, but are divergent between subfamilies (Figure 6a). Although the activation 
loop seems to be disordered in the crystal structure of IIȕ, it spans the active site of 
the kinase and therefore implies an important role in substrate recognition, phosphate 
coordination on the inositol ring, and, ultimately, second messenger generation[98]. 
Meanwhile, the loop is adjacent to critical membrane-interaction interfaces (Figure 
6b), potentially strategically positioned for subcellular targeting. 
Earlier studies from Anderson’s group showed that mutagenesis in the activation loop 
revealed crucial information regarding the localisation and substrate specificity of PIP 
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kinases. When the activation loop of PIP kinases Type Iȕ and IIȕ were swopped, the 
localisation appeared to correspond to the activation loop present, but not the 
remaining backbone of the enzyme[197]. Even more strikingly, a single amino acid 
substitution in the loop (A381E in IIȕ and the reciprocal E362A in Iȕ) changed the 
stero-specific substrate recognition[130]. It was suggested that Glu362 in the Iȕ 
activation loop conferred selectivity by preventing interaction with the D-5 phosphate 
on inositol, either through electrostatic repulsion, or interaction with a positively 
charged residue. In addition, Glu362 also helped to orient the substrate in the catalytic 
core for specific phosphotransfer to the correct hydroxyl, demonstrated by moderate 
PIP kinase-chimera activity (Vmax/Km) arising from the Type I activation loop[130]. 
Meanwhile, the entire activation loop consensus of PIP5K seemed to be both 
necessary and sufficient for targeting PIP4KIIȕ to the PM (when combined with the 
IIȕ backbone), and PIP5KIȕ with the IIȕ loop appeared cytosolic. In contrast, while Iȕ 
E362A was no longer membrane-bound, the reciprocal A381E point mutation above 
did not manage to target IIȕ to the PM, despite the same binding affinity to PI4P and 
kinase activity to produce PIP2 as that of the Iȕ loop. This portion of the loop was 
implicated in high-affinity substrate-binding, and these data imply that efficient 
substrate binding by the activation loop alone is necessary, but not sufficient, for 
anchoring PIP5K to the PM[197]. For instance, a conserved dilysine motif is present 
in the N-terminus of the Type I activation loop (KK in Figure 6a), whose positive 
charge is likely to contribute to PM localisation. In fact, the membrane-attachment 
interface on a PIP5K dimer is a highly basic, exceptionally flat (and large) surface that 
extends right across the dimer interface[98]. In order to realise total PIP5K functions, 
additional features outside the activation loop must also be required (e.g. [198]). 
These interesting roles of the activation loop raised one important question – 
previously, the absence of protein kinase activity in a lipid kinase-inactive PIP5KIȕ 
mutant suggested the same catalytic mechanism in both activities[127], so the above 
inactive mutants should also have impaired autophosphorylation activity. Was it 
possible that an impaired general catalytic mechanism led to the dislocation from the 
membrane, instead of the inability to produce PIP2? That is, the enzyme might require 
a conformational change upon binding ATP to expose further interaction sites[199], 
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or indeed undergo autophosphorylation (involving the general catalytic mechanism), 
which then brings it to the PM. As an alternative mechanism, binding to PI4P (and 
ARF) was shown to be able to enhance the Golgi-to-PM translocation of FAPP[92], 
potentially a mechanism for PM-targeting. To address this, Dr Luisa Giudici 
(unpublished) designed two rat PIP5KIȖ mutants based on the human PIP5KIȕ E362A 
in Kunz et al.[130], E410A and EH(410,411)AE, impairing the enzyme’s ability to 
bind its PI4P substrate, while leaving the ATP-binding and general base catalysis 
intact. 
Interestingly, preliminary studies by Giudici revealed a reduction in phosphorylation 
with EH(410,411)AE compared to E410A, and therefore, it was plausible that His411 
might be adjacent to some phosphorylation site. An obvious candidate was residue 
Thr412, right next to His411(Figure 6a), therefore mutations T412D and T412A will 
also be generated in this study to explore further the regulatory mechanisms (Section 
4.2). 
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a   Activation loop 
IIDILQSYRFVKKLEHSWKALVHDGDT-----VSVHRP  H. sapiens IĮ 
IIDILQSYRLMKKLEHSWKALVYDGDT-----VSVHRP  H. sapiens Iȕ 
IIDILQSYRFIKKLEHTWKALVHDGDT-----VSVHRP  H. sapiens IȖ 
IIDILQNYRLLKKMEHSWKAILHDGDT-----ISVHNP  C. elegans Type I 
IIDILQSYRLEKKLEHTFKSILYNGDT-----VSVCRP  D. melanogaster skittles 
IIDFLTSYSVMKKLETFWRSLRHDTKL-----VSAIPP  S. pombe MSS4 
IIDLLTKYSYVKRVEHLWKGINHSDSV-----ISAVPP  S. cerevisae MSS4 
 
IIDILTHYDAKKKAAHAAKTVKHGAGAE----ISTVNP  H. sapiens IIĮ 
IIDILTPYDAKKKAAHAAKTVKHGAGAE----ISTVNP  H. sapiens IIȕ 
LIDILTQYDAKKKAAHAAKTVKHGAGAE----ISTVHP  H. sapiens IIȖ 
IIDVLTQYGVKKQAAKAAKTVKYGSNVDG---ISTCDP  D. melanogaster Type II 
 
IIDFIRTFTWDKKLESWVKEKGLVGGASVIKQPTVVTP  S. cerevisiae Fab1 
IIDYIRTFTWDKKLEMVVKSTGILGGQGKM--PTVVSP  M. musculus PIKfyve 
IIDFMRQYTWDKHLETWVKASGILGGPKNAS-PTIVSP  A. thaliana Fab1 
IVDYMRTYTLDKKLESWVKIVAIPGAHL----PTILSP  C. elegans Fab1 
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b 
Activation loop 
DTVSVHRPGFYAERFQRFMCNTVFKKIP---LKP   M. musculus IĮ 
DTVSVHRPSFYADRFLKFMNSRVFKKIQA--LKA   M. musculus Iȕ 
DTVSVHRPSFYAERFFKFMSSTVFRKSSS--LKS   M. musculus IȖ 
DTVSVCRPSFYAKRFQDAMGKQVFKKTPTFPLKH   D. melanogaster 
DTISVHNPNFYASRFLTFMTEKVFKKGTA--LKQ   C. elegans 
KLVSAIPPRDYANRFYEFIEDSVDPLPQ---KKT   S. cerevisiae 
. :*.  *  **.**   : . *         * 
c 
…STDIYFFAHGRYWLFSPRRRRLRAVTPSHTGAPTDERSWVYSPLHYSARPASDGESDT 
631                           688 
Figure 6 Segments from PIP kinase peptide sequences, illustrating important features 
For an alignment of the complete peptide sequences of rat, mouse and human PIP5KIȖ, as 
well as different human PIP kinase homologues, refer to the Appendix. (a) Multiple 
alignment of PIP kinase peptide sequences around the activation loop. Sequences are obtained 
from GenBankTM, alignement generated by ClustalW. Identical and similar amino acids 
conserved in all PIP kinase subfamilies are shaded in gray. Conserved residues within the 
activation loop of Type I PIP kinase and close relatives are shaded in green. Glu410, His411 and 
Thr412 in IȖ_i3 are labelled by a box. (b) Site of Val443 in Type I and related PIP kinases, 
shown in red, just downstream of the activation loop. Dibasic residues are shaded in grey. The 
relevance of this site will be discussed in Section 3.1. (c) Amino acid sequence of the C-
terminal region of IȖ_i3, where the 26-AA insert specific to IȖ_i3 is underlined, followed by 
the 26-AA IȖ_i2 tail. Residue numbers (as in the rat version of IȖ_i3) are noted below the 
sequence. Note that the mouse numbering for residues in this C-terminal region is smaller by 
1 than for the rat, i.e., ending with Thr687. Within the insert, five putative phosphorylation 
sites are shaded in blue, and four adjacent arginine residues in red. SPLH domain in the tail is 
shaded in yellow, flanked by Tyr671 and Tyr676. 
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1.3.5.CǦterminaltail
The 26-AA C-terminus shared by IȖ_i2 and IȖ_i3 is also an interesting region (Figure 
6c). Research has shown that the SPLH domain is a talin-binding site, explaining why 
IȖ_i2 binds talin in an activity-independent fashion in focal adhesions[164, 171, 172] 
and IȖ_i1 does not, as it lacks IȖ_i2’s 26-AA tail. Moreover, overexpression of this C-
terminal tail results in loss of talin from focal contacts. This binding is competitive 
with the NPXY motif in ȕ-integrin, whose interaction with talin is disrupted by Src 
phosphorylation. Meanwhile, Src phosphorylation also phosphorylates IȖ on the 
Tyr644 (numbering based on mouse IȖ_i2, equivalent to Tyr671 of rat IȖ_i3 as in Figure 
6c) immediately preceding SPLH, enhancing its interaction with talin[164, 200]. 
Other tyrosine residues[201], e.g. the Tyr634[173] and Tyr649[184], have also been 
implicated, although they are perhaps less crucial. This provides a novel, non-NPXY-
based phosphotyrosine recognition mode that outcompetes integrin-binding to talin 
FERM domain[202] upon Src phosphorylation. Such a molecular switch serves to 
enrich PIP2 production for the regulation of focal adhesion assembly and integrin 
signalling. On the other hand, p35/Cdk5- and MAPK-mediated phosphorylation 
targets the Ser645 residue of the SPLH motif itself (mouse numbering, equivalent to 
Ser650 in humans), disrupting the PIP5KIȖ binding to talin at the synapse[203]. 
Importantly, the phosphorylations of Tyr644 and the adjacent Ser645 antagonise each 
other, forming a crosstalking point between two independent signalling pathways, 
which is potentially critical for the balance between cell adhesion and cell motility at 
the synapse. 
Interestingly, talin-binding activates IȖ_i2, probably by releasing autoinhibitory 
constraints due to the otherwise consititutively phosphorylated Ser645[184]. Therefore, 
the C-terminal talin-binding region may be implicated in autoinhibitory interactions in 
the unactivated kinase, presumably acting as a pseudosubstrate (also see Section 1.3.1 
above). 
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1.3.6.OtherFunctionalObservations
Besides the above-mentioned localisation differences, functionally IȖ_i3 is also 
dramatically different from its close relative IȖ_i2. Expression of both dominant 
negative (kinase-inactive) constructs independently produced a detrimental effect on 
cellular morphology of rat cerebellar granule cells, including greatly shortened 
processes and increased cell death[167]. Again, interestingly, this striking effect of 
inactive enzymes appeared spliceoform-specific to IȖ_i3, since the two corresponding 
kinase-inactive mutants of IȖ_i2 did not produce a similar effect[167]. It was therefore 
suggested that IȖ_i3 may be responsible for the synthesis of a separate pool of PIP2, 
required for the trafficking of cellular components, and hence essential in the 
maintenance of neuronal processes. 
 
 
1.4. Aim of This Study 
Despite the achievements described above, the regulation of IȖ_i3 and its differences 
compared to IȖ_i2 (and IȖ_i1) are still relatively poorly understood. This study builds 
upon the previous studies on PIP5KIȖ_i3, and some emphasis is given to its 26-AA 
insert (which supposedly causes the difference between IȖ_i3 and IȖ_i2). With a 
natural mutation that is discovered in our previously used IȖ_v3 constructs, I turn it 
into a useful tool for investigating the fine details of the enzymes’ various properties 
(Results I). 
Meanwhile, a series of mutageneses is performed in an attempt to identify the crucial 
sites implicated in a range of properties, such as substrate binding, kinase activity and 
membrane association. Using these tools, I endeavour to understand further the 
relationship between its localisation, phosphorylation state, lipid kinase activity and 
putative autophosphorylation (Results II). 
I also try to confirm the alternative splicing pattern of the PIP5KIȖ gene in various 
rodent tissues (Results III), and investigate for the first time whether these are also 
present in humans (Results IV). As we shall see, a novel IȖ splice variant was 
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discovered from these studies. This potentially completes our knowledge base of 
PIP5KIȖ’s alternative splicing profile, and shines useful light onto the alternative 
splicing in rodents and especially humans. 
An antibody developed against a IȖ_i3-specific peptide will be tested and optimised, 
as well as a co-immunoprecipitation protocol for PIP5K and Rac, which will become 
useful tools for further studies on the endogenous protein of the novel splice variant. 
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2.MaterialsandMethods
 
2.1. Plasmid Constructs 
FLAG-constructs were based on the expression vector pCMV-2B, where a FLAG 
epitope tag (DYKDDDDK) was expressed at the N-terminus. GFP-constructs were 
based on pEGFP-C1, where an EGFP gene was fused upstream to the gene of interest. 
Gene expression in both vectors was driven by a pCMV promoter. The initial 
constructs containing PIP5KIȖ were obtained as described in [167] and [179]. 
Both FLAG- and GFP-tagged vectors were selected by kanamycin resistance. 
Plasmids were amplified in XL10-Gold cells grown in Luria-Bertani (LB) Medium 
containing 50 ȝg/ml kanamycin. 
2.2. RNA Extraction and Purification 
Prior to the experiment, glass equipment was incubated in diethyl pyrocarbonate 
(DEPC) (Sigma) overnight at 37 °C, followed by autoclaving. Other non-disposal 
equipment was cleaned using RNaseZAP (Sigma). Fresh or frozen (in RNAlater RNA 
stabilization reagent, QIAGEN) tissues were homogenised in a Dounce homogeniser, 
using the RNeasy mini kit (QIAGEN). 
2.3. DNA/RNA Quantification 
The yield of nucleic acid was determined on a diode-array UV/vis spectrophotometer 
(S2000, WPA lightwave). The light path was 10 mm. dsDNA concentration (in ȝg/ml) 
= OD260 x 50. RNA concentration (in ȝg/ml) = OD260 x 44. 
2.4. Polymerase Chain Reaction 
Polymerase Chain Reaction (PCR) was performed using Taq DNA polymerase 
(Sigma) together with Pfu Turbo DNA polymerase (Stratagene), in a 4:1 molar ratio. 
For a 50 µl reaction, 1 µl (5 units) of enzyme was supplemented with 50 ng DNA 
template, 0.2 µM of each primer, 200µM each dNTPs and 1x reaction buffer (50 mM 
KCl, 10 mM Tris-HCl, 1.5 mM MgCl2, pH 8.3). A typical thermal cycle consisted of 
2 min at 95 °C, 25–30 cycles of 30 sec at 95 °C, 1 min at 55 °C and 1 min at 72 °C. 
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This was followed by 5 min at 72 °C, and 4 °C thereafter. Typical primer pairs were 
designed to be 18–22 bp in length, with a GC content of 50–60% and similar Tm, 
between 55–60 °C. 
The rat hippocampal cDNA library was a gift from Dr Hilmar Bading. For the 
amplification from human tissues, the templates were obtained commercially (First 
Strand cDNA of human tissues, OriGene). The custom primers (Sigma) used are 
listed in Table 8 and Table 9 in the Results. 
2.5. Reverse-transcription PCR 
Access RT-PCR system (Promega) was used, with specific primers, to amplify the 
region of interest from RNA. Basic PCR and RT-PCR were carried out in one thermal 
reaction to produce double-stranded DNA fragments. RNA templates were obtained 
either from tissue extraction (see above, in the cases of rat pituitary and AtT-20) or 
commercially (mouse total RNA, Ambion). Primers were designed to span the 
junctions of two adjacent exons of the target, where possible, in order to avoid any 
potential contamination from genomic DNA. The pair of primers are designed to have 
similar GC content (> 40%) and Tm (> 78 °C). For a list of custom primers (Sigma) 
used, see Table 8 in the Results. 
2.6. Site-directed Mutagenesis 
Mutations were generated in the FLAG- and GFP-tagged vectors, using the 
QuikChangeTM Site-Directed Mutagenesis kit (Stratagene). Typical PCR procedure 
included a 5 min hot start at 95 °C, followed by 16–18 cycles consisting of 30 sec 
denaturation at 95 °C, 1 min annealing at 55 °C, and 14 min elongation at 68 °C. 
Generally, primers were designed to anneal to the plasmid 10–15 bp on either side of 
the mutation site, with predicted Tm > 78 °C and GC content > 40%. For a list of 
custom primers (Sigma) used, refer to Table 3, Table 5, Table 6 and Figure 39 in the 
Results. 
Amplified product was analysed on 0.7% (w/v, g/ml) agarose gel containing 0.5 
ȝg/ml ethidium bromide, and the sample was digested for 1 hr in DpnI before 
proceeding to transformation. Vectors were selected to contain the desired mutation 
by sequencing of 2–3 single colonies on the transformation plates. 
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2.7. Agarose Gel Electrophoresis 
0.7–1 g of agarose was resuspended in 100 ml Tris-buffer saline (TBS, containing 50 
mM Tris, 140 mM NaCl, pH 7.5), heated to dissolve, topped up with 0.5 ȝg/ml 
ethidium bromide, and left to set in the gel tank at room temperature. DNA samples 
were loaded near the cathode in the loading dye (2.5% Ficoll-400, 11 mM EDTA, 3.3 
mM Tris-HCl, 0.017% SDS, 0.015% bromophenol blue, pH 8.0). A voltage of 
typically 80 V was applied till the blue front line of the dye ran out of the gel. The 
separation pattern of the DNA bands could then be visualised and digitalised under 
the UV light. 
2.8. Gel Extraction, Nucleotide Removal and PCR Purification  
Gel extraction, nucleotide removal and PCR purification were performed using the 
corresponding QIAquick kits (QIAGEN). 
2.9. Restriction Digestion and Ligation of DNA Vectors 
Commercially available restriction enzymes (NEB) were used to linearise circular 
plasmid vectors following their recommended protocol. In cases where a linear piece 
of DNA was to be inserted between the restriction sites, shrimp alkaline phosphatase 
(NEB) was used to treat the linearised vector, prior to ligation using the Rapid DNA 
Ligation Kit (Roche) containing T4 DNA ligase. 
2.10. Plasmid Purification 
Plasmid was harvested from bacteria growing in LB medium at 37 °C, 24 hr after 
transformation, using either the QIAprep miniprep kit or the EndoFree plasmid maxi 
kit (QIAGEN). The latter method was preferentially used for plasmids that were 
subsequently used for transfection. 
2.11. Competent Bacteria Preparation 
E. coli XL10-Gold strain was grown in starting LB culture at 37 °C overnight. 1% 
was inoculated into 250 ml SOB medium (20 g/l tryptone, 5 g/l yeast extract, 8.6 mM 
NaCl, 2.5 mM KCl, 10 mM MgCl2, pH7.0) plus 1% glycine, where the culture was 
left shaken at 18 °C until the OD600 reaches 0.5–0.6. Cells were washed twice with 
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ice-cold Transformation Buffer (10 mM PIPES, 55 mM MnCl2, 15 mM CaCl2, 250 
mM KCl, pH 6–7), harvested at 2500 g, and resuspended in 40:3 (v/v) Transformation 
Buffer/DMSO. Aliquots were snap-frozen in liquid nitrogen, and stored at -80 °C. 
2.12. Bacterial Transformation 
A 200 ȝl aliquot of XL10-Gold competent cells were taken from -80 °C to thaw on 
ice. Typically, 1 ȝl of plasmid (or, in the case of site-directed mutagenesis, the DpnI-
treated PCR product) was added to the cells, and allowed to sit on ice for 30 min. Heat 
shock was delivered as a 45 sec pulse at 42 °C. Cells were immediately put back on 
ice for 2 min, and then 500 ȝl of 37 °C SOC media was added (20 g/l tryptone, 5 g/l 
yeast extract, 8.6 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 20 mM glucose, pH7.0). 
Samples were shaken at 37 °C for 1 hr, before being spread onto LB/Agar selection 
plates containing 50 ȝg/ml kanamycin, and left overnight at 37 °C. Single colonies 
were amplified by growth in LB at 37 °C for another 24 hr, and plasmids extracted for 
analysis or transfection. 
2.13. Mammalian Cell Culture 
HEK-293, COS-7 and AtT-20 cells were maintained in Dulbecco’s Modified Eagles 
Medium (DMEM) (Invitrogen) containing 10% foetal bovine serum (Invitrogen), 50 
U/ml penicillin and 50 U/ml streptomycin at 37 °C, 5% CO2. When cells were 90–
95% confluent, they were washed once by phosphate-buffered saline (PBS, containing 
2.67 mM KCl, 1.47 mM KH2PO4, 137.93 mM NaCl, 8.06 mM Na2HPO4), 
resuspended by Trypsin/EDTA/PBS, and plated onto new flasks in fresh growth 
medium at an appropriate density. In order to maintain a consistent condition for 
overexpression, cells were split from Passage 6 up to 23. 
For subsequent transfection, the resuspended cells could be quantified on a 
haemocytometer, and seeded at an appropriate density, e.g. 3 x 106 per ml, onto either 
polystyrene cell culture dishes (Corning) for experiments involving protein extraction, 
or glass-bottom dishes (WillCo) for live confocal imaging. In the case of 
immunofluorescence staining, cells were seeded onto 1.5 cm diameter glass coverslips 
in 6 well dishes. Before seeding, dishes and glass coverslips were pre-coated with 
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0.07 mg/ml poly-D-lysine (Sigma) in 20 mM H3BO3/NaOH pH 8.4, washed with 
ddH2O, and left to dry. 
2.14. Mammalian Cell Stock Maintenance 
To use the HEK-293, COS-7 and AtT-20 stock, cells from -80 °C were warmed up at 
37 °C, pelleted at 1000 RPM, and resuspended in warm growth medium. Cells were 
immediately plated onto a poly-D-lysine-coated culture flask, and the medium was 
changed the next day. 
To make the stock, early passage cells were resuspended, pelleted at 1000 RPM, and 
supplemented with fresh growth medium and 10% sterile DMSO. Aliquots were left 
in -80 °C in an isopropanol-surrounded chamber, and transferred into liquid nitrogen 
the next day. 
2.15. Transfection 
Transient transfection of HEK-293 cells in 10 cm diameter polystyrene dishes for 
protein extraction was performed by the calcium phosphate precipitation technique. 
Growth medium was changed 3–4 hr before transfection. Meanwhile, for each 
transfection, 20 µg DNA and 36 µl of 2 M CaCl2 were made up to 300 µl in an 
Eppendorf tube. This was added slowly and dropwise to 300 µl 2x HBSS (Hank's 
Balanced Salt Solution, containing 274 mM NaCl, 10 mM KCl, 1.4 mM Na2HPO4, 15 
mM D-glucose, 42 mM HEPES, pH 7.07) while bubbling through another pipette in 
the solution. The calcium phosphate/DNA precipitate mixture was incubated at room 
temperature for 30 min, and was added to the cells. Cells were incubated overnight, 
followed by a glycerol shock (4 ml of 15% glycerol, 2 min) the next morning. Then 
the cells were washed with PBS and kept in fresh growth medium for another 24 hr. 
HEK-7 and COS-7 cells in 3 cm/6 cm diameter polystyrene dishes, 6-well plates and 
WillCo dishes were transiently transfected using FuGene6 transfection reagent (Roche 
Molecular Biochemicals), 24 hr before imaging, at 80–90% confluence. 
No discernible difference was observed in cellular morphology or expression level 
using the two methods above. 
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2.16. Protein Extraction 
After transfection, the lysates were made by freezing (over dry ice) and thawing the 
cells, scraped from their dishes in 1% (v/v) Triton X-100, 5 mM EDTA, 5 mM EGTA 
plus 1:200 protease inhibitor cocktail (Sigma). The homogenates were then passed 
three times through a 0.4 mm diameter needle (Terumo) and centrifuged at 14000 g 
for 10 min at 4 °C. The supernatants were stored at -80 °C. Lysates used for direct 
comparison in lipid kinase activity and autophosphorylation activity assays were 
frozen and thawed in parallel each time, in order to control for temperature-dependent 
protein denaturation, even if not all lysates from the same batch were used in one 
particular experiment. 
2.17. Protein Dephosphorylation 
Protein lysate was incubated with shrimp alkaline phosphatase (NEB) in its buffer. 
Typically, a 0.5–1 hr incubation at 30 °C was stopped by transferring samples to 4 °C, 
in order to minimise potential impairment of the native structure. 
2.18. SDS-PAGE 
The sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) running 
gel (6%, w/v, g/ml) was made up of 2.5 ml 30% acrylamide, 6.25 ml 0.75 M 
Tris/0.2% SDS pH 8.8, 45 ȝl ammonium persulphate (AMPS), 15 ȝl N, N, N', N'-
tetramethylethylenediamine (TEMED) in a total volume of 12.5 ml. For the 15% (w/v, 
g/ml) running gel, 6.25 ml acrylamide was added instead. After settling under a thin 
layer of tertiary alcohol, the upper surface of the running gel was rinsed by ddH2O, 
and 4% stacking gel was added on top and allowed to set (1 ml 30% acrylamide, 3.75 
ml 0.75 M Tris/0.2% SDS pH 8.8, 27 ȝl AMPS, 9 ȝl TEMEM in a total volume of 7.5 
ml).  Samples were made to contain 1x sample buffer (80 mM Tris-HCl pH 6.8, 10% 
glycerol, 2% SDS, 50 ȝg/ml bromophenol blue and 5% ȕ-mercaptoethanol) and 
boiled for 3 min immediately before loading. 
The running buffer contained 24.8 mM Tris, 19.2 mM glycine and 3.5 mM SDS. For 
experiments concerning the phosphorylation states, good separation was achieved by 
running samples (from cathode to anode) under 100 V through the stacking gel, and 
then 200 V until 5 min after the dye front ran out of the running gel. A gentler running 
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condition, e.g. 5 mA throughout, gave a flatter shape of the dye front, but sometimes a 
less clear separation between the phosphorylation states. 
Because only the enzyme of interest needed to be visualised on the gel, gels were 
Western blotted in order to detect the enzyme over a low background. 
2.19. Western Blotting 
Proteins separated by SDS-PAGE were transferred to nitrocellulose membranes 
(Schleicher & Schuell) at 4 °C, under either 20 V overnight, or 1 A for 1 hr. Blotting 
buffer contained 25 mM Tris, 190 mM glycine and 20% methanol. Blots were 
blocked at room temperature with 5% (w/v, g/ml) non-fat dried milk and 0.05% (v/v) 
Tween-20, and then probed with the primary antibody (diluted in the blocking buffer). 
Blots were washed 5 times within 30 min by TBS containing 0.05% (v/v) Tween-20, 
and then incubated in the secondary antibody (diluted in the blocking buffer) for 1 hr. 
After another 5 washes in TBS/Tween-20 as above, blots were washed once in TBS 
and visualised by SuperSignal West Femto chemiluminescent substrate (Pierce). 
Images were then either developed using high performance chemiluminescence film 
(GE Healthcare), or acquired digitally. In the latter case, acquisition was done by 
GeneSnap (SynGene), and subsequent analysis was performed in the GeneTool 
(SynGene) software. 
Where the primary antibody was mouse anti-FLAG monoclonal antibody (1:10000 
from 1 mg/ml, Strategene) or mouse anti-Rac monoclonal antibody (1:1000 from 0.25 
mg/ml, BD Transduction), the secondary used was horseradish peroxidase (HRP)-
linked goat anti-mouse (1:2500 from 10 ȝg/ml, Pierce) or, in the case of Rac-detection, 
HRP-linked goat anti-mouse-heavy-chain (1:7500, Pierce). Where the primary 
antibody was rabbit E2139 (1:7500), HRP-linked goat anti-rabbit antibody was used 
as the secondary (1:1000 from 10 ȝg/ml, Pierce). 
2.20. Immunoprecipitation 
The FLAG-tagged enzymes were immunoprecipitated by incubation of the cell lysate 
with the monoclonal M2 anti-FLAG antibody (4 ȝg/ml) in 500 ȝl PBS overnight at 4 
°C, and subsequent incubation with 25 ȝl Protein G-Sepharose beads (Amersham 
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Biosciences) for 3 hr at 4 °C. The immunoprecipitates were washed twice in TBS and 
then resuspended in the PIP kinase assay buffer (80 mM KCl, 10 mM MgCl2 , 2 mM 
EGTA, 50 mM Tris-HCl, pH 7.4) at 4 °C. 
2.21. Lipid Kinase Assay 
The lipid kinase assay was performed on immunoprecipitates obtained from HEK-293 
cells, transiently transfected with FLAG-tagged PIP kinases by the calcium phosphate 
precipitation technique described above. 
The lipid kinase activity was assayed in a final volume of 100 ȝl at 30 °C in PIP 
kinase assay buffer, by using 10 ȝM ATP (plus 50 ȝCi/ml [Ȗ-32P]ATP) and the 
liposome mixture (or lipid micelle) as substrates. The lipid micelle contained 9.57 
mg/l PI4P and 7.25 mg/l PA. The liposome mixture contained 3.44 mg/l PIP2, 3.2 
mg/l PI4P, 0.027 mg/ml PI, 0.11 mg/ml PE, 0.44 mg/ml PC, 0.126 mg/ml PS and 2.4 
mg/l PA. The lipid mix was ultrasonicated for 10 min (Decon F5 Minor). 
Recombinant PIP4KIIĮ was run alongside as a control for identifying the [32P]PIP2 
product, using PI5P as the substrate instead of PI4P. The linearity of the lipid kinase 
assay for each PIP kinase was determined by allowing the reaction to proceed for 
variable time courses (see individual figures). 
The reaction was stopped by transferring the samples to 4 °C. 500 ȝl of 
chloroform/methanol (1:1, v/v) and subsequently 125 ȝl of 2.4 M HCl were added. 
After spinning at 10000 g and removal of the upper phase, the lower phase was 
washed once with 490 ȝl of chloroform/methanol/1 M HCl (3:47:49, by volume) and 
then dried down in vacuum. Lipids were separated by thin-layer chromatography 
(TLC) on silica-gel plates (Merck) impregnated with 1% potassium oxalate and 
containing 4 mM EGTA, and pre-conditioned at 110 °C for 1 hr. The lipids extracted 
from each sample were dissolved in chloroform/methanol/water (2:1:0.01, by volume), 
loaded on to plates and separated by ethanol/chloroform/water/saturated ammonium 
hydroxide solution (40:28:10:6, by volume). The plates were dried and exposed to an 
imaging plate (Fujifilm) at room temperature for 24 hr. The imaging plate was read by 
a phosphoimager, and PIP2 was identified by comparison with a radioactive standard 
(see above) run on the same plate. 
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The relative activity of the PIP kinases was measured on immunoprecipitates 
containing similar amounts of recombinant enzyme. This was carefully determined by 
prior analysis of the immunoprecipitates with SDS-PAGE and Western blotting. A 
serial dilution of [Ȗ-32P]ATP was also included on the TLC plate, to ensure that the 
phosphoimager readings were within the linear range. 
During image analysis, regions of interest were selected containing the PIP2 produced. 
The mean pixel intensity was measured for each sample, and plotted against its 
reaction time. The non-linear curve for each PIP kinase construct was fitted by the 
equation y = A x (1 - e-kx). The lipid kinase activity was then taken as the initial slope 
of the reaction profile at time 0, for relative comparison within the same set of 
experiments. 
2.22. Autophosphorylation Assay 
The autophosphorylation assay was performed on immunoprecipitates obtained from 
HEK-293 cells, transiently transfected with FLAG-tagged PIP kinases by the calcium 
phosphate precipitation technique described above. 
The assay mixture contained 50 ȝM PI, 10 ȝM ATP, and 10 ȝCi of [Ȗ-32P]ATP (3000 
Ci/mmol, 10 mCi/ml as of the delivery date, Perkin Elmer) per sample in the PIP 
kinase assay buffer. If the assay was to be visualised by Western blot to see the 
overall phosphorylation pattern (instead of the 32P incorporation), 200 ȝM non-
radiolabelled ATP was added instead. The protein kinase activity was assayed by 
adding 80 ȝl assay mixture to the enzyme at 30 °C for 3 hr. The samples were mixed 
repeatedly during the incubation. 
The reaction was stopped by transferring the samples to 4 °C . Samples were 
centrifuged at 13000 g for 1 min, and washed with ice-cold TBS for 6–7 times. This 
was to remove the majority of remaining [Ȗ-32P]ATP that would otherwise contribute 
to the background noise and preclude detection of the phosphorylated protein. 
25 ȝl of 2x protein loading buffer was added to each sample, and 6% SDS-PAGE was 
performed. Attention was given to ensure the dye front to run out, so that little [Ȗ-
32P]ATP remained trapped in the gel. The gel was overlaid on top of a filter paper, 
wrapped by parafilm and dried over vacuum suction. When dry, the gel was then 
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exposed to an imaging plate (Fujifilm) at room temperature for 24 hr, and the imaging 
plate was read by a phosphoimager. 
The relative activity of the PIP kinases was measured on immunoprecipitates 
containing similar amounts of recombinant enzyme. This was carefully determined by 
prior analysis of the immunoprecipitates with SDS-PAGE and Western blotting. 
During analysis, regions of interest on the gel image were selected containing the 
phosphorylated PIP kinase of interest. The mean pixel intensity was measured for 
each sample, for relative comparison within the same set of experiments. 
2.23. Live Confocal Imaging 
Immediately prior to the experiment, HEK-293 cells transfected with GFP-tagged 
constructs were incubated for 1 min at room temperature, in 1 ml of DMEM 
supplemented with 25 mM D-glucose, 4 mM L-glutamine and 25 mM HEPES 
(Invitrogen), with or without 0.5 ȝl Cellmask (Molecular Probes). Experiments were 
then conducted in fresh DMEM, either at room temperature or 37 °C. No temperature-
dependent effects were observed on subcellular localisation. 
Images were acquired using a Leica CTR6500 confocal microscope and Leica 
Application Suite software (2.4.1 build 6384). An Argon laser at 28 mW and a HeNe 
543 laser provided the sources of illumination at 488 and 543 nm, respectively. A 40x, 
1.25 NA oil-immersion objective was used. GFP-fused kinases were visualised 
through a 495–535 nm filter, and the Cellmask signal was filtered between 586–617 
nm. Images were collected in 1024 x 1024 pixels, each line as an average of 4 
consecutive scans, sampling bidirectionally at 1400 Hz. Experimental results with 
each construct were saved as LIF files for offline analysis. 
2.24. Quantification of Plasma Membrane Fraction 
Single confocal sections (in the form of LIF files) were analysed in ImageJ. The 
original brightness and contrast were unaltered during quantitative measurement. For 
each cell imaged, five regions of interest were randomly selected in the cytosol (while 
care was taken to exclude the nucleus). The average of their fluorescent signal 
intensity, minus the extracellular background, served as the cytosolic reference. Five 
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other regions were randomly taken within the plasma membrane (labelled by the 
Cellmask) to give the membrane fluorescent intensity (after subtracting the 
extracellular background). The ratio of the membrane signal over the cytosolic 
reference gave the membrane fraction index. For each construct examined, typically 6 
cells were imaged, producing 30 raw data points. Unpaired t-test was performed 
between two comparable constructs to determine the statistical significance, where p 
< 0.05 and p < 0.001 were denoted * and **, respectively, in corresponding figures. 
2.25. Fluorescence Recovery after Photobleaching 
Fluorescence Recovery after Photobleaching (FRAP) was performed using a Leica 
CTR6500 confocal microscope and Leica Application Suite software (2.4.1 build 
6384). A 40x, 1.25 NA oil-immersion objective was used. Illumination was provided 
by an Argon laser at 28 mW, filtered at 488 nm. The GFP signal was visualised 
through a 495–535 nm filter, frames sampled every 0.366 sec on average. The 
photobleach was performed by turning the 488 nm illumination to 100% intensity 
(280mW) for 100 msec, with the pinhole open. Typically, 15 frames were collected 
before the photobleach, and 300 frames afterwards. Bleach spot intensity (minus the 
background) was plotted, after compensating for the time-dependent, non-specific 
decrease in the whole cell signal throughout the observation. 
Data were only used where the initial bleach was more than 70% and the recovering 
signal stabilised to a plateau. 
2.26. Immunocytochemistry 
Paraformaldehyde was heated to 60–70 °C and depolymerised with 1-2 drops of 
NaOH, allowed to cool, and dissolved 4% (w/v, g/ml) in 0.1 M NaH2PO4 buffer (pH 
7.4) to make the fixative solution. Cells on glass coverslips were washed with 
PBS/0.9 mM CaCl2/0.52 mM MgCl2/0.16 mM MgSO4, and incubated in fixative at 4 
°C for 1 hr. All subsequent steps were performed at room temperature. The cells were 
washed 5 times in PBS, permeabilised with 0.1% (v/v) Triton X-100 in PBS for 5 min 
at room temperature, and washed again 4 times with PBS. Cells were then blocked 
with 4% fish skin gelatin (Sigma)/2% normal goat serum (Sigma) in PBS for 1 hr. 
The glass coverslips were incubated on parafilm for 1 hr with 100 ȝl blocking buffer 
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containing mouse monoclonal M2 anti-FLAG antibody (1:500 from 1 mg/ml, 
Stratagene), mouse monoclonal anti-GFP (1:250 from 0.2 mg/ml, Molecular Probes), 
or E2139 at a 1:750 dilution. Cells were washed 4 times in PBS over 15 min, and re-
blocked with gelatine/serum for 15 min. Immunofluorescence detection was made 
possible by incubation for 30 min in the dark with the secondary antibody (goat anti-
mouse or anti-rabbit) conjugated to Alexa Fluor dyes (1:100 from 2 mg/ml, 
Invitrogen), usually 555 nm (red) or 548 nm (green). Stained and PBS-washed 
coverslips were mounted in the Prolong antifade reagent (Molecular Probes). For 
long-term storage, coverslips were sealed with adhesive polymers (e.g. resin) 
dissolved in acetone and stored at 4 °C. Images were acquired with a Leica CTR6500 
confocal microscope and Leica Application Suite software (2.4.1 build 6384), through 
appropriate filters corresponding to the staining. 
2.27. Immunohistochemistry 
Sagittal mouse brain slices (perfused animal, 4% paraformaldehyde-fixed, 10% 
sucrose-impregnated, cryostat-sectioned and mounted on glass slides, frozen at -80 °C) 
were obtained by courtesy of Dr Jon Clarke[204]. The slide was incubated in NaBH4 
(26 mM fresh in PBS) at room temperature for 10 min and repeated 2–3 times. It was 
washed 3 times in PBS for 5 min each and blocked at room temperature for 2 hr (or 
overnight at 4 °C) in PBS with 0.3% Triton X-100 and 1% fish gelatine, followed by 
primary incubation with E2139. Longer incubations were generally performed in a 
humidified chamber. After 3 times of 10 min washes in PBS, the slide was incubated 
for 4 hr at room temperature with secondary antibodies. The donkey anti-rabbit 
antibody (conjugated to 555 nm Alexa Fluor, 1 mg/ml, Invitrogen) was used at a 
1:1000 dilution. Meanwhile, NeuroTrace 535 nm Nissl stain (Invitrogen) was added 
where necessary at a dilution of 1:3000. Stained and PBS-washed slides were 
mounted in the Prolong antifade reagent (Molecular Probes). For long-term storage, 
coverslips were sealed with adhesive polymers (e.g. resin) dissolved in acetone and 
stored at 4 °C. High magnification images were acquired with a Leica CTR6500 
confocal microscope and Leica Application Suite software (2.4.1 build 6384), through 
appropriate filters corresponding to the staining. Low magnification images of the 535 
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nm NeuroTrace green signal were acquired on a fluorescence microscope with 488 
nm illumination. 
2.28. Generation of IȖ_i6-specific Antibody, E2139 
The custom polyclonal rabbit antibody E2139 was produced by NeoMPS (San Diego, 
USA), > 96% pure by high-performance liquid chromatography (HPLC). It was 
against the 16 amino acids on the C-terminus of the unique 26-AA peptide of IȖ_i3/6. 
The epitope sequence was CRRRRLRAVTPSHTGA. 
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3.ResultsI–BehaviourofIɀ_i3ComparedtoIɀ_i1and
Iɀ_i2
 
3.1. V443A Found in IȖ_i3 Clones Previously Used 
At the beginning of this study, relevant plasmid constructs from Dr Giudici’s previous 
studies were sequenced, covering the full length of IȖ_v3. The linker/multiple cutting 
site sequences flanking the fusion protein within both the pEGFP-C1 and pCMV-2B 
vectors were determined, and integrated into corresponding plasmid maps (Figure 7a 
and b). 
A mutation of thymidine-1328 into cytosine was found to have occurred since the 
initial cloning of IȖ_v3 from the rat hippocampal cDNA library in our lab[167], which 
corresponded to a non-synonymous conversion from valine-443 into alanine after 
translation (Figure 7c). This T1328C (i.e. V443A) mutation has accumulated in all 
subsequent IȖ_v3 constructs generated by site-directed mutagenesis. 
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Figure 7 Discovery of the T1328C mutation in IȖ_v3 construct previously used 
Plasmid map and sequencing scheme of IȖ_v3 in the (a) pCMV-2B (FLAG) plasmid and (b) 
pEGFP-C1 plasmid. (c) T1328C discovered in IȖ_v3 constructs used, compared to wild type 
IȖ_v2. 
 
 
In comparison, the IȖ_v1 and IȖ_v2 constructs both had the correct, wild type 
thymidine-1328 within Exon 11 (Figure 6b), as expected from the Ensembl database 
of the rat genome. 
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In the PIP5KIȖ entry of the Ensembl database (Table 1), this mutation did not show 
up as a naturally occurring genetic variation. In fact, 90% of the natural variations 
listed were single-nucleotide polymorphism (SNP), which could be either 
synonymous (where specific point mutations of DNA did not alter the amino acid it 
coded for, due to the degeneracy of the codon table), or non-synonymous. 
This means that the non-SNP mutation observed in our IȖ_v3(A) construct was not 
likely to be frequent enough to be considered physiologically representative, despite 
the fact that it may have been a genuine, natural mutation from the particular 
mRNA/cDNA template during the initial cloning, which was amplified and preserved 
in all subsequent PCR steps. 
In this thesis, IȖ_v3 with V443A is hereafter referred to as IȖ_v3(A), while the true 
wide type IȖ_v3 containing Val443 is denoted IȖ_v3(V). Such a convention is also 
applied to other splice variants, with (V) representing the wild type and (A) for the 
mutant with V443A in place. 
Since Val443 is in proximity to a crucial dibasic motif implicated in membrane 
targeting, and just downstream of the activation loop that is central to lipid substrate 
binding and catalysis (Figure 6b, see Introduction), its mutation into alanine could 
potentially have an effect on many aspects of the enzyme property, including its 
subcellular localisation, phosphorylation state and kinase activity. 
Some of the previous studies (e.g. [167, 179]) used constructs based on IȖ_i1(V), 
IȖ_i2(V) and IȖ_i3(A). Therefore, some of the special characteristics attributed to 
IȖ_i3 could have been partially due to the intrinsic presence of V443A in Ȗ_i3, but not 
Ȗ_i1 or Ȗ_i2. In other words, previous comparisons between Ȗ_i1, Ȗ_i2 and Ȗ_i3 may 
not have been strictly valid. 
Therefore, IȖ_v3(A) “wild type” and mutants generated earlier were mutated back 
into the IȖ_v3(V) version, with Val443 in place. Meanwhile, the IȖ_v2(V) wild type 
and some of its mutants were also purposely mutated to generate the corresponding 
IȖ_v2(A) enzyme, i.e., to include V443A (Table 3). 
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Primer Note Sequence 
For sequencing the plasmid 
E3 to sequence downstream of EGFP CAAAGACCCCAACGAGAAG 
E5 to sequence upstream of EGFP TGAACTTGTGGCCGTTTAC 
G5 to sequence downstream of the shared 
middle part of PIP5KIȖ 
TGAACCTCAACCAGAACC 
P3 to sequence downstream of CMV-IE 
promoter 
CGGTGGGAGGTCTATATAAG 
PE to sequence downstream of the middle of 
CMV-IE promoter 
CAGTACATCAATGGGCG 
PI to sequence downstream of the shared 
middle part of PIP5KIȖ 
GAGACAGATGACACGATGG 
PR to sequence upstream of the shared middle 
part of PIP5KIȖ 
GGTCAATGTTGTGCACACC 
T3 to sequence downstream into the FLAG tag ATTAACCCTCACTAAAGGGA 
T7 to sequence upstream into the inserted gene 
in pCMV-2B 
TAATACGACTCACTATAGGG 
For correction of T1328C (V443A) from IȖ_v3 
TCback_f SDM forward GAGCAGCACGG T CTTCCGGAAGAGTTCC 
TCback_r SDM reverse CTTCCGGAAG A CCGTGCTGCTCATGAAC 
For introduction of T1328C (V443A) into IȖ_v1 and IȖ_v2 
V443A_f SDM forward GTTCATGAGCAGCACGG C CTTCCGGAAGAG 
V443A_r SDM reverse GGAACTCTTCCGGAAG G CCGTGCTGCTC 
Table 3 Primers designed for plasmid sequencing and mutagenesis regarding V443A 
The nucleotides in the underlined and Italic font refer to the mismatching region with the 
template, i.e., the sequence desired after site-directed mutagenesis. 
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This would allow for direct comparison between equivalent IȖ_v2 and IȖ_v3 
constructs, and hence more accurately deduce the role of the 26-AA insert itself in 
IȖ_i3. 
 
 
3.2. Revisiting Genuine Behavioural Differences Between IȖ_i3 and 
Other Spliceoforms 
We now re-examine some of the previously observed differences between IȖ_i3 and 
IȖ_i2/1, as well as a range of their mutant counterparts. This is to correct for any 
effect potentially attributable to V443A, and therefore deduce the remaining, genuine 
behavioural differences between PIP5KIȖ_i3 and its splicing relatives, IȖ_i2 and IȖ_i1. 
Therefore, when observing the behaviours of Ȗ_i3(V), we shall bear in mind two 
important dimensions in this Chapter: (1) Val443 vs. Ala443; (2) IȖ_i3 vs. IȖ_i2/1. 
 
 
3.2.1.InVivoPhosphorylation
In a Western blot, overexpressed PIP5KIȖ could typically be observed as several 
bands, as opposed to a singlet. The slower mobility in SDS-PAGE of the additional 
upper band(s) likely resulted from post-translational modifications such as protein 
phosphorylation, compared to the unphosphorylated molecules. When treated with 
alkaline phosphatase in vitro, the upper band completely collaspsed into the lower 
band (Figure 8a), confirming that the upper and lower bands indeed corresponded to 
the phosphorylated and unphosphorylated versions of the same PIP5KIȖ protein, 
respectively. This provided us with a convenient way of observing the enzyme’s 
phosphorylation pattern in vivo. In this thesis, typical phosphorylation patterns of 
various constructs from many experiments are shown below, in which a wild type 
enzyme was always included as a control (as well as, often, a kinase-inactive mutant). 
When aligned, the relative intensities of the major bands could be assessed and 
compared between different constructs. 
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It had been previously observed that IȖ_i3(A) was less phosphorylated than IȖ_i2(V). 
In re-examining this, I observed that with the wild type Val443, both IȖ_i2 and IȖ_i3 
were in fact phosphorylated to a comparable extent (Figure 8b). Interestingly, when 
V443A was introduced into IȖ_i2, it also became less phosphorylated (Figure 8b). 
Therefore, the V443A mutation itself appeared to be mostly responsible for shifting 
the equilibrium towards unphosphorylated PIP5KIȖ. 
D316K, the kinase-inactive mutation, dramatically decreased phosphosphorylation 
(compare Figure 8b and c). However, while the previously reported IȖ_i3(A) D316K 
was completely unphosphorylated, IȖ_i3(V) D316K was now partially phosphorylated 
(Figure 8c). A similar reduction in phosphorylation by V443A was observed with 
IȖ_i2(V) D316K compared with its V443A mutant (Figure 8c). Consequently, the 
presence of the double mutation V443A/D316K was able to completely abolish 
phosphorylation in vivo, for both IȖ_i3 and IȖ_i2 (Figure 8c). 
 
 
 
Figure 8 Phosphorylation patterns of IȖ_i3 and IȖ_i2 
Lysate from HEK-293 cells overexpressing each FLAG-tagged enzyme was extracted, and 
subjected to SDS-PAGE. The phosphorylation pattern in vivo was visualised by anti-FLAG 
staining of the Western blot. (a) Alkaline phosphatase treatment in vitro collapsed the upper 
band of IȖ_i3 into the lower one completely, indicating that the upper band consisted of 
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phosphorylated molecules. (b) Comparison of IȖ_i2 and IȖ_i3, adjusting for V443A. (c) 
Comparison of the kinase-inactive D316K constructs of IȖ_i2 and IȖ_i3, adjusting for V443A. 
(d) Phosphorylation profiles of IȖ_i3(A) and IȖ_i3(A) T412A, illustrating the isolation of a 
putative “middle band”. The middle band may be a partially phosphorylated band, compared 
to the upmost phosphorylated band. Bottom arrow indicates the direction of SDS-PAGE. 
 
 
The apparently discrete bands of phosphorylated states (as opposed to a smear of 
differentially phosphorylated proteins at various residues) do not necessarily suggest a 
singular, all-or-none phosphorylation event of the protein molecule. It is equally likely 
that multiple residues can be the target of regulated phosphorylation pathways, and 
that phosphorylation could indeed occur in a cooperative fashion. In agreement with 
this, IȖ_i3 seemed to have at least one extra phosphorylated state, in addition to 
IȖ_i2’s “completely” phosphorylated state and the unphosphorylated state (Figure 8b). 
A more quantitative comparison between the profiles of IȖ_i3(A) and its T412A 
mutant, for instance, confirmed this possibility (Figure 8d). 
Such a difference suggests that the additional peptide of IȖ_i3, the 26-AA insert near 
its C-terminus, may be an additional target of phosphorylation in vivo. This 
phenomenon is more thoroughly addressed later in Section 3.3. 
 
 
3.2.2.SubcellularLocalisation
The subcellular localisation of PIP5K IȖ variants was visualised by fluorescence 
confocal microscopy, in which the plasma membrane-bound fraction (as labelled by 
Cellmask in a simultaneously recorded channel) was compared to the cytosol. Care 
was taken not to include the nucleus in the cytosolic measurement. The higher the PM 
/ cytosol ratio, the more PM-targeted the kinase. A PM / cytosol ratio of 1 corresponds 
to a non-membrane-enriched localisation, as indicated by an orange, dashed line in the 
quantification panel in relevant figures. 
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Wild type IȖ_i3(V) and IȖ_i2(V) were to a large extent localised to the PM, with a PM 
/ cytosol ratio around 9–10 (Figure 9a and c). When V443A was introduced, IȖ_i3(A) 
and IȖ_i2(A) were clearly less PM-associated (Figure 9b and d). This reduction was 
greater with IȖ_i3. Similarly, direct comparisons using other mutant constructs of 
IȖ_i2 and IȖ_i3 followed the same pattern, i.e., V443A tended to decrease the PM-
association and make the enzyme more cytosolic, all else being equal (e.g. D316K in 
Figure 10 and T412D in Figure 11)1. 
In terms of its contribution to the enzyme’s localisation to the membrane, Val443 
seemed to be a factor independent of other motifs containing mutations. This was also 
seen in T412D, because it worked in conjunction with T412D to further reduce its 
already lowered PM localisation from the wild type (Figure 11b). This was paralleled 
by a similar reduction in PM-association in IȖ_i2, causing IȖ_i3(A) T412D and 
IȖ_i2(A) T412D to be completely cytosolic(Figure 11b and d). 
I deduced that the reason why V443A tended to decrease PM-association was caused 
by the relative hydrophobicity of these AA residues. The Val443 in the wild type was 
more hydrophobic than alanine (4.2 versus 1.8), and could therefore bind better with 
the lipid substrates on the PM, as well as associating through hydrophobic interactions 
with the phospholipid bilayer itself. This impact of the V443A mutation can now be 
seen to partially explain the previous observation that IȖ_i3(A) tended to be more 
cytosolic than IȖ_i2(V)[179]. 
 
 
 
1 The specific behavioural characteristics and significance of D316K and T412D are beyond the scope of the 
current chapter, and will be discussed in detail later in Chapter 4. 
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Figure 9 Subcellular localisation of wild type IȖ_i2/3, adjusting for V443A 
Typical subcellular localisation of overexpressed GFP-tagged constructs in HEK-293 cells 
(scale bar = 10 ȝm). Panel on the right indicates quantified ratio of PM / cytosol fraction. 
Orange dotted line indicates a cytosolic (non-membrane-enriched) localisation (n = 30, * p < 
0.05, ** p < 0.001). 
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Figure 10 Subcellular localisation of D316K mutants of IȖ_i2/3, adjusting for V443A 
Typical subcellular localisation of overexpressed GFP-tagged D316K constructs in HEK-293 
cells (scale bar = 10 ȝm). Panel on the right indicates quantified ratio of PM / cytosol fraction. 
Orange dotted line indicates a cytosolic (non-membrane-enriched) localisation (n = 30, * p < 
0.05, ** p < 0.001). 
 
 
 
Figure 11 Subcellular localisation of T412D mutants of IȖ_i2/3, adjusting for V443A 
Typical subcellular localisation of overexpressed GFP-tagged T412D constructs in HEK-293 
cells (scale bar = 10 ȝm). Panel on the right indicates quantified ratio of PM / cytosol fraction. 
Orange dotted line indicates a cytosolic (non-membrane-enriched) localisation (n = 30, ** p < 
0.001). 
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However, there are still genuine behavioural differences between equivalent IȖ_i2 and 
IȖ_i3 constructs, all else being equal. For example, although the kinase-inactive 
D316K mutants generally exhibited considerably less PM-association (Figure 10a – c), 
and IȖ_i3(A) D316K was completely cytosolic, IȖ_i2(A) D316K was not different 
from the active IȖ_i2(A) in its localisation (Figure 10d). That is, rendering the enzyme 
catalytically inactive had little effect on IȖ_i2, but a profound effect on IȖ_i3. This is 
examined further in the next Chapter. 
 
 
3.2.3.FluorescenceRecoveryafterPhotobleaching
Fluorescence recovery after photobleaching (FRAP) is an optical technique capable of 
quantifying the apparent mobility of a fluorescently labelled molecular probe. In 
earlier studies, IȖ_i3 (now known to contain the V443A mutation) demonstrated a 
notably large immobile fraction and slower recovery dynamics when compared to 
IȖ_i1 and IȖ_i2[179]. The reason for this apparent immobility had not been adressed, 
but was possibly due to association with unidentified cytoskeleton-related binding 
partners, which restricted the diffusion of the kinase in vivo. 
In this study (as well as in [179]), the FRAP method adopted from Brough et al.[205] 
is used to introduce a pulse bleach to the plasma membrane and measure the recovery 
of the fluorescent protein signal in that region, potentially by means of lateral 
diffusion within the two dimensional PM surface and/or exchange with adjacent 
cytosolic compartments. With sophisticated experimental protocols, it is possible to 
tease apart these two sources of recovery[47], which would be interesting but beyond 
the scope of the present study. Therefore, only the final level of fluorescence recovery 
is measured in this study, and used as a general measure of the mobility of membrane-
associated PIP5KIȖ. As we shall see, some empirical differences exist among different 
splice variants and mutants of IȖ, which provide informative insight into the behaviour 
of these constructs (also see more in the Discussions). 
Figure 12 shows a typical FRAP analysis using GFP-tagged PIP5KIȖ_i2 
overexpressed in HEK-293 cells. 
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Figure 12 Illustration of the procedure and quantification of FRAP 
(a) A typical procedure of FRAP, using GFP-tagged PIP5KIȖ_i2 overexpressed in HEK-293 
cells. Each image is 64.58 ȝm across, and the time from the start is indicated at the bottom 
right corner of each frame (in seconds). The lightening arrow in the second frame indicates 
the spot photobleach at 4 s. (b) After adjusting for the background and non-specific loss of 
signal through time (see Methods), the mobile fraction is calculated as b / a x 100%. 
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Previous studies[179] showed that when the plasma membrane was bleached by a 
laser spot, and FRAP was measured as an indication of mobility of the GFP-tagged 
PIP5Ks, IȖ_i1(V) and IȖ_i2(V) were largely mobile (recovering towards the original 
baseline over time), whereas IȖ_i3(A) was considerably immobile. When the mutation 
V443A was corrected back, IȖ_i3(V) was still partially immobile in FRAP, recovering 
to over 55% under the standard test condition (Figure 13a). This indicated that 
although the FRAP difference was initially discovered with the V443A mutation, 
there is still a genuine difference in mobility between IȖ_i3 and its related splice 
variants once the V443A mutation is corrected. 
It is worth notice that the final FRAP recovery observed also depended on the initial 
extent of bleaching. With a more thorough initial bleach (e.g. Figure 13b), the 
recovery of each isoform was generally lower, and the reverse was true for a weaker 
bleach (Figure 13c), illustrating how it is important to use a consistent extent of 
bleaching when comparing different constructs. In this context, the mobility of IȖ_i3 
was consistently lower than that of, for instance, IȖ_i1. 
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Figure 13 Fluorescence Recovery after Photobleaching of IȖ_i3 
GFP-tagged constructs were overexpressed in HEK-293 cells. (a) IȖ_i3(V) recovered to 55% 
of the original level, indicating the presence of an immobile fraction, in agreement with the 
previous data published by Giudici, 2006. The mobility of IȖ_i3 was consistently lower than 
that of IȖ_i1 in relative terms, when the initial bleach was deliberately made stronger (b) or 
weaker (c). Mean fluorescence intensity is plotted for (a) and (b) (n = 10), and is used to 
generate the line of best fit for (c) (n = 5). 
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3.2.4.LipidKinaseActivity
The lipid kinase activity of various IȖ_i3 constructs was assayed in vitro. Using PI4P 
as the substrate (see Methods), the lipids produced were separated by thin-layer 
chromatography (TLC), and the [32P]PIP2 produced (identified using a [32P]PIP2 
standard run on the same plate) were measured and compared between different 
constructs, as an indication of their lipid kinase activity. Where the apparent activity 
slowed down with a longer reaction time, a non-linear fit was applied to the reaction 
profile, with the equation y = A x (1 - e-kx). The initial rate of reaction was taken for 
the purpose of comparison. When x = 0, the gradient of the curve dy / dx = A x k. 
Somewhat surprisingly, the V443A mutation attenuated the IȖ_i3 activity by about 
55% (Figure 14). I reasoned that the V443A mutation might make such a difference to 
the apparent lipid kinase activity in vitro was because the interaction with lipid was 
facilitated by the more hydrophobic Val443. 
 
 
 
Figure 14 Lipid kinase activity of IȖ_i3(A) was lower than that of IȖ_i3(V) 
PI4P micelle was used as the substrate of PIP5KIȖ in the lipid kinase assay, with time courses 
of 2, 5 and 10 minutes. Lipid products were separated by TLC and the [32P]PIP2 level 
(identified using a radioactive standard, leftmost lane) was measured and compared between 
constructs (n = 2). 
67 
 
To explore this lipid interaction further, I constructed a more physiological way of 
presenting the lipid substrates in these in vitro assays, to mimic better the membrane 
environment where the PIP5K enzyme normally sees its substrate. I used a mixture of 
lipids (PIP2, PI4P, PI, PE, PC, PS and PA, see Methods) in the form of liposomes. 
 
 
 
Figure 15 Lipid kinase activity of IȖ_i2/3 using micelle and liposome substrates 
In both cases, PI4P was used as the substrate with PA as the activator, for the lipid kinase 
assay, with time courses 2, 10 and 30 minutes. They were either applied at 10 ȝM each on 
their own (micelles, “m”), or at 3.3 ȝM each with a lipid mixture mimicking the physiological 
composition of inner cell membrane (liposomes, “l”). The enzymes used were (a) IȖ_i2(V) 
and (b) IȖ_i3(V). Lipid products were separated by TLC and the [32P]PIP2 level was measured 
and compared. 
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As shown in Figure 15, the liposome presentation of substrates caused a much higher 
lipid kinase activity than with the micelle, even though both used PI4P as the substrate 
and PA as the activator (and note that the PI4P concentration was in fact higher in the 
micelle composition). This suggests that the PIP5K enzyme has adapted through 
evolution to function in its physiological environment, e.g. in this case sampling lipids 
anchored in the cell membrane. Therefore, it is important to supply the kinase with a 
lipid composition as close as possible to that in the cell, in order to interpret 
meaningfully the enzyme’s activity measured in the in vitro assay. I therefore adopted 
the liposome method for all subsequent experiments on the lipid kinase activity. 
In order to compare the lipid kinase activity of Ȗ_i3 with that of the other splice 
variants, I set out to perform assays in parallel, using the lysates of HEK-293 
overexpressing the FLAG-tagged enzymes (Figure 16). The relative quantity of 
enzymes present was assessed by Western blot of the immunoprecipitates, in parallel 
to those subjected to the kinase assay. 
These experiments revealed that IȖ_i3 and IȖ_i2 exhibited the same level of lipid 
kinase activity in vitro, after compensating for the relative quantity of enzymes used. 
This suggests that the alternative splicing near the C-terminus of PIP5KIȖ does not 
affect the overall structure of the enzyme, or the enzyme’s catalytic ability as a lipid 
kinase. 
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Figure 16 IȖ_i2 and IȖ_i3 exhibited a similar level of lipid kinase activity in vitro 
The relative quantity of enzymes present was assessed by Western blot of the equivalent 
immunoprecipitates, in parallel to those subjected to the kinase assay. Wild type IȖ_i2 and 
IȖ_i3 were assayed in parallel, with time courses 2, 10 and 35 minutes in duplicate. The 
quantity ratio was 1.2 : 1 from the Western blot. Analyses confirmed that both splice variants 
of PIP5KIȖ exhibited a similar level of lipid kinase activity in vitro. 
 
 
3.2.5.ProteinKinaseActivity(Autophosphorylation)
Since PIP5K was also documented to possess protein kinase activity, most likely for 
autophosphorylation (see Introduction), I also investigated how this might have been 
changed by the V443A mutation in Ȗ_i3. In vitro, the IȖ_i3(A) was only 60% as active 
as IȖ_i3(V), as a protein kinase (Figure 17a). 
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I also investigated how the protein kinase activity would be changed by the presence 
or absence of the 26-AA peptide near the enzyme’s C-terminus, that is, how Ȗ_i2 and 
Ȗ_i3 differed from each other in this aspect. 
The lysate containing overexpressed enzyme was first quantified by Western blot 
(Figure 17b), and then volume-adjusted, in an attempt to use the same amount of 
enzyme for the kinase assay (Figure 17c). A protein kinase assay was carried out and 
the 32P incorporation into the enzyme was measured. The IȖ_i3 protein exhibited a 1.5 
fold higher autophosphorylation compared to IȖ_i2 (Figure 17d). 
 
 
 
Figure 17 Protein kinase activity of IȖ_i2 and IȖ_i3, adjusting for V443A 
(a) 32P incorporation into the enzymes in the autophosphorylation assay, visualised by 
autoradiography of the dried polyacrylamide gel. (b) Western blot of the whole HEK-293 
lysate overexpressing the FLAG-tagged enzyme. Quantity ratio of IȖ_i3 : IȖ_i2 = 3 : 2. (c) 
Western blot of the equivalent immunoprecipitates subjected to the kinase assay, successfully 
titrating the quantity ratio to 1: 1. (d) Typical 32P incorporation into the enzymes in the 
autophosphorylation assay, visualised by autoradiography of the dried polyacrylamide gel. 
IȖ_i3 exhibited a 1.5 fold higher protein kinase activity compared to IȖ_i2, as measured by 32P 
incorporation (n = 2). 
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The interpretation of this observation was not immediately clear, given that the two 
spliceoforms varied only in the C-terminus and the general catalytic ability (at least 
when measured as lipid kinase activity) was expected to be unchanged. The increased 
autophosphorylation in IȖ_i3 in the presence of the additional 26-AA insert may 
suggest that either the insert peptide is a further target of autophosphorylation, or it 
may serve to interact with other segments within the structure, which would otherwise 
inhibit autophosphorylation. This would uncover an apparent protein kinase activity 
of the enzyme by disinhibition. 
 
 
3.2.6.AReviewoftheV443AMutation
The mutation V443A discovered in our original IȖ_i3 constructs, as well as the 
several corresponding IȖ_i3(V), IȖ_i2(V) and IȖ_i2(A) constructs generated, has given 
me significant insight into the regulation of PIP5KIȖ localisation and activity. It seems 
that the previously reported profound differences between IȖ_i2 and IȖ_i3[179] were 
partly due to this V443A mutation in the IȖ_i3 construct used. For example, the 
IȖ_i3(V) D316K mutant was not completely cytosolic, but remains partly associated 
with the PM, unlike the cytosolic IȖ_i3(A) D316K mutant reported before (Figure 10a 
and b). 
In general, a PIP5KIȖ with Ala443 had a more cytosolic (i.e., less PM-bound) 
localisation than its Val443 counterpart. Interestingly, within the range of mutations 
tested, each of which disrupted different domains of the enzyme, the moderate effect 
caused by V443A substitution seemed to be similar. That is, V443A substitution 
seemed to exert an independent influence, leading to a general reduction of PM-
association. Many of such changes may be explained by the fact that valine, as one of 
the most hydrophobic amino acid residues (hydropathy index 4.2), has a much higher 
hydrophobicity than alanine (hydropathy index 1.8). Therefore, the affinity of 
IȖ_i3/2(V) to the lipid compositions in the PM was higher than the corresponding 
IȖ_i3/2(A). 
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This “off-membrane” effect is particularly intriguing in light of our earlier discussions 
on multiple, low-affinity membrane-interactions (Section 1.2.2). It may be viewed 
that when the wild type Val443 is present, it increases (albeit minutely) the affinity of 
the enzyme towards the membrane, and this incremental change is big enough to 
make certain mutants to go to the membrane, while remaining subthreshold for the 
others. So, in our hands this V443A mutation turned into a helpful tool to dissect out 
some of the intrinsic, yet otherwise non-apparent, differences in the PIP5K 
background. 
Moreover, a closer look at AA residue 443 reveals that there may be additional factors. 
The Val/Ala443 site is C-terminal to the activation loop, and is also immediately 
upstream of a conserved dibasic motif (RK in Figure 6b). The latter motif of two basic 
residues is important for the PM-localisation and function of IȖ, as revealed by a 
series of mutagenesis experiments[198]. My results are also consistent with earlier 
findings identifying residues that were crucial to the activity of PIP5KIȕ, homologous 
to Ser440 – Ser447 of IȖ[108] (Figure 6b). A truncated Iȕ protein ending C-terminally 
with Ile399 retained 100% activity as well as the ability to reorganise actin, whereas Iȕ 
ending with Asn392 (lacking the Val443-homologue and dibasic motif mentioned above) 
was < 5% active, and was unable to reorganise actin. Therefore, I have further 
established the importance of this region immediately C-terminal to the kinase 
homology domain in contributions to IȖ’s PM-localisation, and have revealed that 
residue Val443 near the dibasic motif may also be crucially implicated in the necessary 
interactions with the hydrophobic substrate. Therefore, although the Type I activation 
loop consensus is necessary for correct PM-targeting (see Introduction), other motifs 
in the rest of the kinase body, such as this one containing Val443, are also required. 
To assess whether or not Ala443 induced a distortion to the general structure rather 
than to a specific binding or catalytic site, I compared the lipid kinase activity of 
IȖ_i3(V) and IȖ_i3(A). IȖ_i3(A) retained only 40% activity compared with IȖ_i3(V) 
(Figure 14). This result may be explained by the fact that alanine, being considerably 
less hydrophobic than valine, reduces the efficiency of IȖ_i3’s interaction with its 
lipid substrate, PI4P, near the activation loop. However, the autophosphorylation 
activity of IȖ_i3(A) was also considerably reduced, to 60% of that of IȖ_i3(V) (Figure 
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17a). Many more experiments would be required to establish if the lipid and protein 
kinase changes are significantly different from each other. However, a preliminery 
argument can be advanced that the protein kinase activity of IȖ_i3 may be impaired by 
V443A to a lesser extent than the lipid kinase activity because of the location of the 
Val443 residue close to the lipid-binding activation loop. The overall behaviour is not 
explained by previous findings that phosphorylation of the PIP kinase may in some 
cases be negatively correlated with lipid kinase activity[127, 129]. 
In conclusion, in addition to weakening lipid-association, V443A may interfere 
slightly with the general catalytic mechanism of IȖ_i3 as well as its in vivo 
phosphorylation (discussed below), possibly through a non-specific structural 
disruption. Nonetheless, as we shall see in Chapter 4, I demonstrate that the V443A 
mutation can be exploited as a helpful (albeit accidental!) tool in exaggerating the 
effect of certain mutations, and therefore it can shine useful light onto how the 
physiological functions of PIP5KIȖ are performed and regulated. 
 
 
3.3. Role of the 26-AA Insert of IȖ_i3 
As described above, after correcting back the V443A mutation, there were still several 
genuine functional and behavioural differences between IȖ_i3 and its related 
spliceoforms, IȖ_i1 and IȖ_i2. These unique characters must be caused by a structural 
difference between these splice variants, and this must reside in the 26-AA peptide 
inserted into IȖ_i3 between Exon 16 (the IȖ_i1 “tail”) and Exon 18 (the IȖ_i2 “tail”), 
as illustrated in the Introduction (Figure 5). 
Based on experimental evidence and reasoning, I formulated several possible roles of 
this IȖ_i3-specific insert. This thesis would now address these possibilities in turn. 
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3.3.1.PotentialPIP2ǦbindingSite–the4RMutant
It was observed earlier, and this was particularly obvious with the Ala443 in place, that 
the kinase-inactive D316K mutants of both Ȗ_i3 and Ȗ_i2 were completely 
dephosphorylated (Figure 8c). However, while the IȖ_i3(A) D316K was cytosolic 
(Figure 10b), IȖ_i2(A) D316K remained appreciably localised on the plasma 
membrane (Figure 10d). This difference could underlie earlier data indicating that 
IȖ_i3(A) D316K caused a great reduction in neuronal proliferation, while IȖ_i2(V) 
D316K did not[179]. Moreover, these data seemed to suggest a unique, specific 
activity-dependency of IȖ_i3’s PM-association, which was not shown by other splice 
variants. 
Since the Asp316 position was part of the weak base catalytic mechanism, specifically 
underlying the enzyme’s catalytic capability (as a lipid or protein kinase), the D316K 
mutation only impaired the kinase activity and spared the lipid binding domains. In 
other words, the interaction of the D316K mutant with its PI4P substrate should be 
normal. This effectively ruled out the possibility that the different localisation of 
D316K was due to its disrupted binding with membrane-associated PI4P. 
Clearly, for IȖ_i3 the loss of membrane localisation appears to be associated with a 
loss of activity in D316K. One possibility was that the enzyme IȖ_i3 needs sufficient 
PIP2 present on the cell membrane before it could be targeted to and stay on the PM 
(either directly or via binding PIP2) and that only the active version synthesises 
enough PIP2 near the enzyme. In order to test this idea, the ideal experiment would be 
to maintain the apparently normal PIP2 level in the relevant cellular compartments, 
and observe if the IȖ_i3(A) D316K stayed on the PM. Such a scenario was in fact 
already tested in an earlier study by Giudici[179], where the Ȗ_i3(A) D316K mutant 
was co-transfected with active Ȗ_i3 or Ȗ_i2, differentially tagged by GFP and FLAG. 
Interestingly, the kinase-inactive molecules remained cytosolic, whereas the active 
enzymes still localised normally to the PM, as if there was no cross-talking. This 
suggested that it was not the overall PIP2 abundance that dictated the enzyme’s 
localisation, but more likely it was the activity specific to each enzyme molecule that 
determined its own targeting. 
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I therefore reasoned that the Ȗ_i3’s peptide insert could serve as (or as part of) a PIP2-
binding site, which binds to the lipid kinase product whenever a PI4P is turned into 
PIP2 by the same enzyme molecule. Conceivably, the PIP2 produced may be 
transferred from the catalytic site immediately to this putative binding pocket (formed 
by the 26-AA peptide), and then expose an interaction site with potential binding 
partners and turn the enzyme into a conformation that was ready to localise to the PM. 
The converse of this idea is that when the insert has no PIP2 bound, it changes the 
structure of the enzyme, hence the inactive Ȗ_i3 does not go to the PM as readily as 
the inactive Ȗ_i2. This would give the Ȗ_i3 splice variant an activity-dependency 
specific to each molecule, which was not seen in Ȗ_i2 or Ȗ_i1. 
The hypothesis of a PIP2 binding site in the 26 AA itself was encouraged by the 
presence of four adjacent arginine residues in the insert (Figure 6c). To test this 
hypothesis, I engineered a mutant by site-directed mutagenesis, changing all four 
residues (Arg648 to Arg651) into negatively charged glutamate, denoted mutant 4R. The 
making of the 4R constructs is summarised later along with other mutageneses in 
Section 4.1. 
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Figure 18 Major characters of the 4R mutants 
(a) – (c) Typical subcellular localisation of overexpressed GFP-tagged 4R constructs in HEK-
293 cells (scale bar = 10 ȝm). Panel on the right indicates quantified ratio of PM / cytosol 
fraction. Orange dotted line indicates a cytosolic (non-membrane-enriched) localisation (n = 
30, ** p < 0.001). (d) FRAP behaviour of 4R constructs, mean fluorescence intensity plotted 
(n = 20). 
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When introduced alongside D316K, 4R did not make any difference to the cytosolic 
localisation of Ȗ_i3 (Figure 18c), as expected from the activity-dependency of the 
PIP2-binding hypothesis above. However, in the active enzyme, the 4R mutation also 
did not change the original localisation of Ȗ_i3(V) (Figure 18a). In case there was a 
“ceiling effect” because Ȗ_i3(V) was already maximally PM-bound, I also tested 4R 
on Ȗ_i3(A), which was localised on the PM to a lower extent. Again, the PM-
association was unchanged (Figure 18b). In other words, when the putative PIP2-
binding site could no longer bind the PIP2 product, the localisation of Ȗ_i3 was not 
altered. Nonetheless, the 4R mutation increased the degree of mobility of the enzyme 
to a greater degree in the presence of Val443 (Figure 18d). This would make sense, if 
the four positively charged arginine residues normally interact and associate with 
other protein and lipid partners, either specifically (e.g. PIP2 as in my hypothesis) or 
in a general, electrostatic fashion. However, in the absence of an effect on localisation, 
the interpretation of these data was not immediately clear. Presumably, it still remains 
a remote chance that the 4R mutation did not impair the PIP2-binding as we expected. 
Nevertheless, the above preliminary results seem to suggest that the PIP2-binding 
hypothesis is probably incorrect. 
 
 
3.3.2.PotentialPhosphorylationTarget–the5PMutant
As mentioned in the last Section (3.2), the apparently discrete phosphorylated states 
of PIP5KIȖ_i3 in vivo do not suggest a singular, all-or-none phosphorylation of the 
protein molecule. It is more likely that multiple residues may be the target of 
regulated phosphorylation pathways. Indeed, Ȗ_i3 seemed to have at least one extra 
phosphorylated state, between the “completely” phosphorylated state and the 
unphosphorylated state (Figure 8d). Furthermore, the autophosphorylation activity of 
Ȗ_i3 seemed to be higher than that of Ȗ_i2 (Figure 17c and d), which might suggest 
that the additional peptide of Ȗ_i3, the 26-AA insert near its C-terminus, could be a 
target of phosphorylation in vivo. Conceivably, the insert itself may contain additional 
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phosphorylation sites that, together with the sites in common with IȖ_i2, give the 
larger separation of the “completely phosphorylated” band in IȖ_i3 (Figure 8d). 
Various bioinformatics tools were used in an attempt to narrow down the search for 
potential phosphorylation sites, producing a theoretical prediction of the target S, T 
and Y residues in the Ȗ_i3 peptide (e.g. NetPhos in Figure 19a). In particular, within 
the 26-AA insert (AAs 637–662), Ser646, Thr656 and Ser658 were predicted with a 
superthreshold score above 0.50 (0.990, 0.934 and 0.879, respectively), labelled as 
highly probable by the program. This result was confirmed by a related, kinase-
specific program, NetPhosK[206]. 
Therefore, although the phosphorylation state observed provides us with some useful 
information and intriguing correlations with the rest of IȖ_i3 behaviour, the overall 
phosphosphorylation should not be taken as an entity, and we need to bear in mind the 
possibility of different combination of residues producing indistinguishable patterns 
on Western blot.  
I sought to address this possibility experimentally by extracting and purifying the 
overexpressed enzyme from mammalian cells, treating some of it with alkaline 
phosphatase in vitro (which removes all phosphorylation as shown in Figure 8a), and 
then subjecting both the native (retaining the original phosphorylation pattern) and 
dephosphorylated protein to mass spectroscopy.  This comparison should enable the 
identification of key AA residues implicated in the phosphorylation in vivo. With the 
use of smaller peptide fragments generated by proteases, we could then dissect out 
which residues within this 26-AA insert is a genuine phosphorylation target. This 
would enable us to obtain the fine print of the overall phosphorylation state observed, 
to distinguish between autophosphorylation and phosphorylation by other proteins, 
and to determine whether phosphorylation at a certain site is necessary or sufficient 
for other enzyme behaviours, e.g. PM-targeting (see next Chapter). 
Protocols were developed and the purification was proven to be possible, either by 
immunoprecipitation using the anti-FLAG antibody, or by competition using the 
3xFLAG peptide. The exact conditions for these protocols to work required a 
considerable amount of optimisation. For example, with the immunoprecipitation 
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method, trials were carried out with 3, 6, 10 and 15 washes. When the washes were 
too few, it was difficult to get rid of the non-specific background; when too many, less 
and less tagged protein remained on the beads. It was discovered that 6–10 washes 
produced the best signal to background ratio (Figure 19b). However, after several 
preliminery trials, it proved difficult to obtain the overexpressed FLAG-tagged 
PIP5KIȖ_i3 at a high enough purity to proceed with. 
 
 
 
Figure 19 Prediction of phosphorylation sites and IȖ_i3 purification for mass 
spectroscopy 
(a) Theoretical prediction of target residues on the Ȗ_i3 peptide by NetPhos, the bottom 
numbers corresponding to AA numbers in the Ȗ_i3 peptide, and the height of the bars 
indicating the likelihood of being a phosphorylation site. (b) Picture of dried down SDS-
PAGE gels, stained with Coomassie blue; arrows indicate the FLAG-tagged Ȗ_i3 band. The 
enzyme was purified by immunoprecipitation using the anti-FLAG antibody (with 10 washes). 
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Due to the significant time and resources required by this mass spectroscopy project, 
and considering the amount of information and analysis involved once the numerous 
phosphorylation targets were identified, it seemed unrealistic, given the timescale, for 
the present study to proceed in this direction. Instead, we conceived a simpler way of 
at least confirming whether or not the 26-AA insert of Ȗ_i3 was a physiological target 
of phosphorylation. 
This method is based on the fact that only certain amino acids could possibly undergo 
phosphorylation, i.e., serine, threonine and tyrosine. There were five such residues 
within the 26-AA insert, namely, Tyr642, Ser646, Thr656, Ser658 and Thr660. As a proof-
of-principle experiment, I mutated all five residues into alanine, denoted mutant 5P. 
The making of the 5P constructs is summarised later along with other mutageneses in 
Section 4.1. 
 
 
81 
 
 
Figure 20 Major characters of the 5P mutants 
(a) Phosphorylation pattern of 5P constructs. (b) – (e) Typical subcellular localisation of 
overexpressed GFP-tagged 5P constructs in HEK-293 cells (scale bar = 10 ȝm). Panel on the 
right indicates quantified ratio of PM / cytosol fraction. Orange dotted line indicates a 
cytosolic (non-membrane-enriched) localisation (n = 30, * p < 0.05, ** p < 0.001). (f) Lipid 
kinase activity of IȖ_i3(V) 5P, with time courses of 5 and 10 minutes. Lipid products were 
separated by TLC and [32P]PIP2 was measured and compared between constructs (n = 2). (g) 
FRAP mobility of IȖ_i3(V) 5P, mean fluorescence intensity plotted (n = 20). 
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If any of the five residues were physiological phosphorylation sites, we reasoned that 
the 5P mutant should eliminate such modification, and consequently the protein 
should show up as having a smaller separation between the phosphorylated and 
unphosphorylated bands in SDS-PAGE. In the 5P mutants tested, the separation of the 
“completely phosphorylated” band from the presumed dephosphorylated band did not 
decrease (Figure 20a). Furthermore, a hint of the middle band, although fainter, could 
still be detected. 
Interestingly, it was the overall ratio of phosphorylated to unphosphorylated 
molecules that was reduced. It meant that the insert was not likely to be a direct 
phosphorylation target in vivo, but might cause indirect changes in the enzyme’s 
structure or accessibility to kinases (including its own catalytic core) that would lead 
to further phosphorylation on the rest of the protein. This alternative theory could 
explain the fact that 5P slightly reduced the enzyme’s efficiency as a lipid kinase, 
slowing it down even if the overall capacity of catalysis remained comparable to the 
wild type (Figure 20f). The different kinetics in Figure 20f require confirmation and 
then more detailed examination before any interpretation can be put on them. 
The mutant’s mobility was unaffected, measured by FRAP (Figure 20g), while the 
PM-association of IȖ_i3 constructs appeared to be significantly reduced by 5P, 
whether the enzyme was active (Figure 20b and c) or inactive (Figure 20d). In fact, 
such a correlation between PM-association and in vivo phosphorylation was 
frequently observed for PIP5KIȖ (see next Chapter), so whether the lower PM-
association of 5P was the cause or the result of its reduced phosphorylation is not 
clear from these data. This topic will be addressed in the next Chapter, when the 
relationship between different aspects of the enzyme’s behaviour is more thoroughly 
studied. 
 
 
3.3.3.TheCǦterminusonItsOwn
As a quick experiment to find out whether there was any discernible difference 
between the C-terminal peptides of Ȗ_i3 and Ȗ_i2 on themselves, i.e., without 
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potential combinatorial influence from the sophisticated regulatory motifs in the 
whole protein, we devised a “C12” construct for both splice variants. The C12 
constructs consisted of the C-terminal portion of the enzyme, starting from Exon 12 
(downstream of the activation loop). Perhaps not surprisingly, these constructs failed 
to be targeted to any compartments and filled the cytosol as a consequence, since the 
peptides made had no protein backbones to fold onto and therefore were likely 
unstructured (Figure 21c and d). 
 
 
 
Figure 21 Subcellular localisation of the C-terminal constructs of IȖ_i3/2 
Typical immunocytochemical staining of overexpressed FLAG-tagged constructs in HEK-293 
cells. 
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Taken together, the above data most likely indicated that the 26-AA insert of IȖ_i3 
was probably not a direct phosphorylation target, nor a PIP2-binding site. A 
hypothesis for the above data is that the 26-AA insert could impose a structural 
influence on IȖ_i3, potentially exposing additional AA targets for 
autophosphorylation. Only when such autophosphorylation takes place could IȖ_i3 be 
recognised by certain partners, which might then bring the molecule onto the PM. 
Conversely, in the absence of the insert (i.e., IȖ_i2 and IȖ_i1), the enzyme may have a 
conformation that is readily accessible by these partners. Such a theory could also 
explain the observation that the PM-association of IȖ_i3 required the enzyme being 
active, while on the other hand it was not necessary for the localisation of IȖ_i2. 
Without detailed knowledge of the phosphorylation sites, it was far from straight 
forward to start testing this hypothesis. Nonetheless, we may be able to gain some 
insight from in silico screening of available protein databases. Meanwhile, one further 
possibility is proposed in the Discussions (Section 7.3.3). 
 
 
3.3.4.StructuralInsights
A preliminary search in the Pfam database[207] identified several features of the 
peptide insert, which could underlie its interaction with other parts of the protein. For 
example, part of the insert peptide was matched to a hinged ȕ-pleated sheet in 
hemopexin, a serum glycoprotein that binds and transports haem. This might imply 
potential interactions with other peptide motifs, enabling the functions as 
hypothesised above. 
Except for the above finding, however, there were in fact very few hits the online 
screening produced for the insert peptide on itself, based on sequence homology. This 
was initially puzzling, until I considered the possibility that the insert may be a 
“purposely” unstructured peptide through evolution. This refers to protein segments 
(potentially with certain characteristics) that fail to self-fold into a fixed 3-
dimensional structure, sometimes in their native state[208, 209]. The significance of 
such peptides is only being increasingly understood recently, more frequently 
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encountered in the eukaryotes[210, 211], primarily as a way of introducing structural 
disturbance and flexibility to a protein, whereby it gains or loses salient functions. 
According to the “Protein Trinity Hypothesis”, a given native protein can be in any of 
the ordered, partially ordered or extended forms, and functions can arise from any one 
of the three forms or from transitions between them[211]. A particularly intriguing 
example is MARCKS, whose basic effector domain is unstructured, yet binds PIP2 
with very high affinity on the lipid bilayer[50]. This is only explained by the fact that 
the unstructured effector domain binds several (probably three) PIP2 molecules to 
form an electroneutral complex, greatly enhancing its affinity for the PC/PIP2 
membrane, whereas a small basic hydrophilic peptide cannot typically form 
complexes with more than one PIP2[212, 213]. In other cases, the structurally 
disordered peptide domain may form a regulatory sensor, a folding inhibitor, a 
flexible linker, an entropic spring, or a loose loop prone to protease cleavage, upon 
which it alters conformation and is able to bind other partners and assume novel 
functions[208]. 
86 
 
4.ResultsII–LocalisationandRegulationofIɀ_i3
 
4.1. Mutagesis and Subcloning of Constructs 
This study designed and generated quite a few mutants, either by site-directed 
mutagenesis or by subcloning (using restriction digestion followed by ligation). As so 
many constructs are mentioned in the previous Chapter as well as this, it may be 
helpful to summarise them here. 
4.1.1.SummaryofMutantsUsedinThisStudy
A summary of all relevant mutants in the present study is shown in Table 4. 
Mutation Original Mutated Note 
V443A Val443 Ala443 Random mutation discovered in our IȖ_i3 
constructs, accumulated from the initial cloning 
into all subsequent mutants made* 
D316K Asp316 Lys316 Mutation in the weak base catalytic mechanism of 
the conserved kinase domain, making the enzyme 
inactive for both lipid and protein catalysis* 
K188A Lys188 Ala188 Mutation in the ATP-binding site of the 
conserved kinase domain, an alternative way to 
D316K of making the enzyme catalytically 
inactive 
E410A Glu410 Ala410 Mutation in the activation loop, significantly 
reducing Type I lipid kinase activity, and giving 
rise to considerable Type II activity[130] 
T412A Thr412 Ala412 Mutation in the activation loop, where 
substitution of threonine into alanine prevents 
phosphorylation on this residue 
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T412D Thr412 Asp412 Mutation in the activation loop, where 
substitution of threonine into aspartate mimics the 
effect of constitutive phosphorylation on this 
residue by negative charge* 
5P Tyr642, 
Ser646, 
Thr656, 
Ser658,  
Thr660 
Ala642, 
Ala646, 
Ala656, 
Ala658,  
Ala660 
Mutation prevents phosphorylation at all five 
putative phosphorylation targets within the IȖ_i3-
specific 26-AA insert* 
4R Arg648, 
Arg649, 
Arg650, 
Arg651 
Ala648, 
Ala649, 
Ala650,  
Ala651 
Mutation eliminates the positive charges on the 
basic motif within the IȖ_i3-specific 26-AA 
insert* 
E111L Glu111 Leu111 Mutation homologous to E61L in rat PIP kinase 
Iȕ, where interaction with Rac is abrogated[138]. 
Rac is a small monomeric G-protein and a 
member of the Rho family GTPases, required for 
plasma membrane-association of Type I PIP 
kinases 
PM Met1… Met1Gly2 
Cys3Ile4 
Lys5Ser6 
Lys7Arg8 
Lys9Asp10… 
Mutation adds a 9-AA N-terminal tag from Lyn 
kinase, responsible for the posttranslational 
modifications palmitoylation and myristoylation, 
attaching lipid on the protein and thereby 
inserting it into the plasma membrane 
C12 full length Exons 12–19 Mutation keeps only the C-terminal portion of the 
enzyme, without the catalytic core or activation 
loop* 
Table 4 Summary of all mutants used in the present study 
* indicates mutations that already appeared in the previous Chapter (Results I). 
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4.1.2.GenerationofMutantsbySiteǦdirectedMutagenesis
Typically, the point mutations introduced involved a single amino acid substitution. 
This was achieved with the help of appropriately designed primer pairs that annealed 
to both sides of the target site of mutagenesis, flanking the desired sequence to be 
introduced (Table 5). In the case of multiple amino acid substitutions, e.g. the 4R and 
the 5P mutants, several rounds of site-directed mutagenesis were performed 
sequentially, to change the residues in smaller, manageable groups. This was because 
a larger region of mismatch may lead to non-specific or particularly weak binding 
between the primers and the template. For instance, with the 4R mutants, I originally 
attempted to mutate all four Arg residues simultaneously. However, the result was 
negative, prompting me to achieve this by dividing it into two sequential steps, as 
described above. 
 
 
Purpose SDM forward SDM reverse 
A443V GAGCAGCACGG T 
CTTCCGGAAGAGTTCC 
CTTCCGGAAG A 
CCGTGCTGCTCATGAAC 
V443A GTTCATGAGCAGCACGG C 
CTTCCGGAAGAG 
GGAACTCTTCCGGAAG G 
CCGTGCTGCTC 
D316K GAGCTTCAAGATAATG AAG 
TACAGCCTGC 
CCAGCAGCAGGCTGTA CTT 
CATTATCTTG 
5P (1–2) CGCCCACGGGAGA GC 
CTGGCTTTTC G CTCCCCGTCG 
CGGCGACGACGGGGAG C 
GAAAAGCCAG GC TCTCCCG 
5P (3–5) CGCCGACTGCGGGCCGTG G 
CACCA GC CCAC G 
CAGGCGCTCC 
CGTCGGTGGGAGCGCCTG C GTGG 
GC TGGTG C CACGGCCCGC 
4R GGCTTTTCTCTCCC 
GAAGAAGAAGAA CTGCGGGC 
CCCGCAG TTCTTCTTCTTC 
GGGAGAGAAAAGCCAG 
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4R (1–2) CTTTTCTCTCCC GAAGAA 
CGCCGACTGCG 
CAGTCGGCG TTCTTC 
GGGAGAGAAAAGCC 
4R (3–4) CTCTCCCGAAGAA GAAGA 
ACTGCGGGCCG 
CACGGCCCGCAGT TCTTC 
TTCTTCGGGAG 
E410A GTTCATCAAGAAGTTAG C 
ACACACCTGG 
GGGCCTTCCAGGTGTGT G 
CTAACTTCTTG 
T412D CATCAAGAAGTTAGAACAC GA 
CTGGAAGGCCC 
GGACGAGGGCCTTCCAG TC 
GTGTTCTAAC 
T412A CAAGAAGTTAGAACAC G 
CCTGGAAGGCCC 
GGACGAGGGCCTTCCAGG C 
GTGTTCTAAC 
E111L GACTTCTATGTGGTG CTG 
AGCATCTTCTTTCCCAG 
GAAAGAAGATGCT CAG 
CACCACATAGAAGTCCTGC 
PM (see next section 4.1.3) 
Table 5 Primers for the generation of mutants by site-directed mutagenesis 
The nucleotides in underlined and Italic font refer to the mismatching region with the 
template, i.e., the sequence desired after site-directed mutagenesis. 
 
 
The site-directed mutagenesis typically generated a linear band of double-stranded 
fragment after PCR, theoretically with a background of the circular plasmid template 
which may not always be discernible on the gel due to its low concentration. This 
product was treated in vitro with the restriction enzyme DpnI to remove the 
contamination by the methylated DNA of the original plasmid (Figure 22). The 
remaining product should all contain the desired target sequence, dictated by the 
primers added. The resultant DNA was transformed into competent bacteria to 
amplify, and circular plasmids were extracted at the end. 
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Figure 22 Typical DpnI digestion in a site-directed mutagenesis 
 
 
4.1.3.TheGenerationofthePMMutants
I shall later discuss the important significance of the PM construct. Its generation 
involved the addition of nine amino acids (GCIKRKGKD) from the Lyn kinase onto 
the N-terminus of the fusion gene (just after the starting methionine). This was quite 
difficult to achieve, in that the insertion (~ 30 bp) was neither short enough to be 
achieved by a simple site-directed mutagenesis reaction, nor long enough to be readily 
ligated as an insertion fragment into the multiple cutting site at the N-terminus of the 
fusion gene. 
Since it was important to ensure that the PM tag only inserted in the correct direction, 
I decided to utilise two different restriction sites on either side of the potential PM 
insertion. Based on the existing multiple cutting site within the pEFGP-C1 and 
pCMV-2B (FLAG) vectors, I chose to introduce SalI and EcoRV, which were both 
novel and hence unique in the plasmids. This was important in the plasmid digestion 
steps later to produce a single backbone. Correspondingly, the SalI and EcoRV sites 
were also introduced as the flanking sequences on the primers used for the 
amplication of the PM-tag, to be digested into the double-cut configuration after PCR 
purification (Figure 23a). 
Unfortunately, the entire fragment of PM-tag (including the flanking restriction sites) 
was below 40 bp, too short to be amplified by PCR. After a few unsuccessful attempts, 
an alternative method of making the double-cut PM fragment was tried. I decided to 
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make two DNA oligomers (as I would do for making ordinary site-directed 
mutagenesis and sequencing primers), both complementary over the PM sequence and 
each protruding at one end. When both strands were allowed to denature and remix in 
an aqueous solution, they should anneal with each other into double-stranded 
fragments, with both ends in a configuration exactly as if it was cut by the SalI and 
EcoRV restriction enzymes (Figure 23b). This new strategy was successful. 
The next step was to introduce the same SalI and EcoRV sites into the PIP5KIȖ-
containing plasmids, just before the start codon. Using appropriate primers for site-
directed mutagenesis on both plasmids, I managed to obtain the plasmids with the 
desired restriction sites in place. I then proceeded to double digest the plasmids 
containing the FLAG- or GFP-tagged PIP5KIȖ, so that the N-terminus of the fusion 
gene could accept the PM insert (Figure 23c). The digestion was successful, 
producing linear backbones of the correct size (Figure 24a and b). 
Since the ligation was unidirectional (using two different restriction sites) and hence 
the cut vector could not reanneal on itself, the phosphatase treatment was optional in 
this scenario (Figure 23c). The concentration of both the cut backbone and “cut” 
insert was measured, and titrated in search of an optimised molar ratio (e.g. Figure 
24c). However, after several attempts, the ligation was not successful, presumably 
because, again, the insert was too small and consequently the stoichiometric ratio was 
too extreme to be optimised. 
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Figure 23 The subcloning scheme of PM-tagged constructs 
(a) Introducing restriction sites into both end of the PM-tag while cloning it out of an existing 
vector using normal PCR. This double-stranded fragment may then be cut by corresponding 
restriction enzymes. (b) Two oligonucleotides annealing together to form the double-stranded, 
cut configuration of the PM-tag. (c) Subcloning procedure, making the gene-containing vector 
available for ligation with the PM insert. 
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Figure 24 Subcloning of PM-tagged constructs 
(a) Circular GFP (pEGFP-C1) and FLAG (pCMV-2B) plasmids containing the PIP5KIȖ_v3 
before digestion. Appropriate restriction sites already introduced into the N-terminus of the 
fusion gene. (b) The same plasmids linearised after restriction digestion. (c) Titration of 
optimal conditions for the ligation of PM insert and plasmid backbones. Top rows indicate the 
equivalent molar ratio of vector to insert. Values are volumes in ȝl. 
 
 
I therefore sought after a different approach to make the PM constructs, by sequential 
site-directed mutagenesis, as I did for the 4R and 5P mutants. A first trial of two site-
directed mutagenesis steps on IȖ_v3(V), each with a relatively lengthy mismatching 
fragment, proved to work (Table 6). I then obtained the other PM constructs by 
introducing e.g. the V443A and D316K mutations into this PM/GFP- or PM/FLAG-
tagged IȖ_v3(V) construct.  
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Purpose Mutagenesis (forward) Mutagenesis (reverse) 
PM (1/2) for pEFGP-C1 CGGTCGCCACC 
ATGGGATGTATTAAA 
GTGAGCAAGGG 
CCCTTGCTCAC 
TTTAATACATCCCAT 
GGTGGCGACCGGTAG 
PM (2/2) for pEFGP-C1 CACCATGGGATGTATTAAA 
TCAAAAAGGAAAGAC 
GTGAGCAAGGG 
CTCGCCCTTGCTCAC 
GTCTTTCCTTTTTGA 
TTTAATACATCCCAT 
PM (1/2) for pCMV-2B CGGCCGCCACC 
ATGGGATGTATTAAA 
GATTACAAGG 
CATCCTTGTAATC 
TTTAATACATCCCAT 
GGTGGCGGCC 
PM (2/2) for pCMV-2B GCCACCATGGGATGTATTAAA 
TCAAAAAGGAAAGAC 
GATTACAAGG 
CGTCATCCTTGTAATC 
GTCTTTCCTTTTTGA 
TTTAATACATCCCATGG 
Table 6 Primers for the generation of PM mutants by site-directed mutagenesis 
The nucleotides in underlined and Italic font refer to the mismatching region with the 
template, i.e., the sequence desired after site-directed mutagenesis. 
 
 
4.2. Relationship between Kinase Activities and Membrane 
Localisation 
4.2.1.RequirementforActivationLoopMutants
As described and extensively used in earlier studies[167, 179] as well as the previous 
Chapter, the IȖ_i3(A) D316K mutant was completely cytosolic, and IȖ_i3(V) D316K 
mutant was also significantly less PM-bound than the wild type IȖ_i3(V) (Figure 10). 
The D316K mutation was a widely accepted way of making a dominant negative 
PIP5KIȖ. Asp316 is a weak base involved in the general catalytic mechanism, therefore 
D316K should impair both the lipid kinase and protein kinase activities[127]. 
Moreover, D316K was unlikely to have caused undesired, non-specific structural 
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changes to the rest of the enzyme, since K188A, a non-ATP-binding mutant, had 
independently produced similar effects on cerebellar granular cells in earlier 
experiments (e.g. [179], see Introduction). From these data, one obvious possibility is 
that lipid kinase activity is required for PM-localisation. However, it was equally 
likely that autophosphorylation was necessary for PM-targeting, instead of the ability 
of producing PIP2 itself. In the D316K mutant, the impairment to these two kinase 
activities was coupled and therefore non-separable. 
In order specifically to impair the enzyme’s ability to perform lipid catalysis, while 
leaving the protein kinase activity intact, the E410A, T412D and T412A mutants were 
designed, generated and tested. These mutations are all in the activation loop. 
 
 
4.2.2.CharacterisationoftheT412AandT412DMutants
As described in the Introduction (Section 1.3.4), since preliminary results by Giudici 
on the EH(410,411)AE showed reduced phosphorylation compared to E410A, the 
immediately adjacent Thr412 residue came to our attention. This Thr/Ser residue is 
completely conserved in the Type I PIP kinase family, which are generally PM-
associated. This led us to wonder whether it could be a conserved Thr/Ser 
phosphorylation site implicated in IȖ_i3’s regulation. Two mutants were generated, 
T412D and T412A, in an attempt to constitute the effect of phosphorylation and 
dephosphorylation, respectively. Despite certain caveats related to the electrostatic 
property (see below), this is a well documented and widely adopted method of 
mimicking amino acid phosphorylation states. 
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Figure 25 Characterisation of the T412D mutants 
(a) – (d) Typical subcellular localisation of overexpressed GFP-tagged T412D constructs in 
HEK-293 cells (scale bar = 10 ȝm). Panel on the right indicates quantified ratio of PM / 
cytosol fraction. Orange dotted line indicates a cytosolic localisation (n = 30, ** p < 0.001). (e) 
Prior in vitro phosphatase treatment of IȖ_i3 did not change their autophosphorylation activity, 
measured by incorporation of 32P. (f) Prior in vitro phosphatase treatment of IȖ_i3 decreased 
its extent of phosphorylation as detected by Western blot. This pattern was only partially 
restored by subsequent autophosphorylation. (g) In vivo phosphorylation pattern of the T412D 
mutants. (h) Protein kinase activity of T412D, measured by autoradiography. (i) Lipid kinase 
activity of the T412D mutant (n = 2), substrate presented as liposomes. (j) Lipid kinase 
activity of the T412D mutant, substrate presented as micelles (n = 2). For both (i) and (j), time 
courses of 10, 30 and 60 minutes were performed. Lipid products were separated by TLC and 
[32P]PIP2 was measured and compared between constructs. 
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Thus, T412D was expected to mimic the effect of phosphorylation on the Thr412 
residue by its negative charge. The T412D mutation significantly reduced the PM-
association in IȖ_i3, and these effects were paralleled by similar reductions in PM-
association in IȖ_i2, leading to, in the extreme cases, both the IȖ_i3(A) T412D and 
IȖ_i2(A) T412D being completely cytosolic (Figure 25a – d). Meanwhile, T412D also 
reduced phosphorylation of both IȖ_i3(V) and (A), to an extent that IȖ_i3(A) T412D 
was completely dephosphorylated (Figure 25g). 
We tested the effect on general dephosphorylation (by phosphatase treatment in vitro) 
on the autophosphorylation activity and the 32P incorporation did not seem to be 
greatly altered (Figure 25e). Autophosphorylation with non-radioactive ATP had only 
a minor reversing effect of the dephosphorylation shift on a Western blot (Figure 25f). 
Importantly, when IȖ_i3(V) T412D was assessed for its autophosphorylation, it was 
phosphorylated to a comparable extent (after background subtraction) to the wild type 
(Figure 25h), indicating the integrity of the general kinase structure. In contrast, the 
lipid kinase activity was specifically impaired by as much as 94%, using the liposome 
substrate (Figure 25i). Interestingly, when the PI4P substrate was presented in the 
form of micelles, the lipid kinase activity was much weaker in the wild type and then 
impaired only slightly in the T412D mutant (Figure 25j), again, illustrating the 
importance of presenting the substrate in a form better resembling a membrane. 
This was encouraging so far, in that all these data are consistent with the idea that 
Thr412 could be a target of phosphorylation, which in turn would regulate its 
behaviour. The fact that parallel effects of T412D were observed in IȖ_i3 and IȖ_i2 
was particularly interesting. It suggested that phosphorylation of the conversed 
Thr/Ser residue in the activation loop may indeed represent a universal mechanism of 
regulation of Type I PIP kinases, and also this is the first mutation I introduced that 
appeared to affect IȖ_i2 and IȖ_i3 identically. Potentially, we could even extend our 
investigation into PIP5KIĮ and Iȕ in the near future to consolidate this finding. To 
exhaust our knowledge about this potential phosphorylation site, I generated and 
studied its complementary mutation, T412A. 
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Figure 26 Characterisation of the T412A mutants 
(a) – (b) Typical subcellular localisation of overexpressed GFP-tagged T412A constructs in 
HEK-293 cells (scale bar = 10 ȝm). Panel on the right indicates quantified ratio of PM / 
cytosol fraction. Orange dotted line indicates a cytosolic (non-membrane-enriched) 
localisation (n = 30, ** p < 0.001). (c) In vivo phosphorylation pattern of the T412A mutants. 
 
 
While the lipid kinase activity was similar to the wild type (about 115% from 
Giudici’s unpublished observation), the overall in vivo phosphorylation was generally 
increased, as well as its PM-association. In contrast to T412D, IȖ_i3(A) T412A was 
more PM-associated than IȖ_i3(A) (perhaps due to alanine being more hydrophobic 
than threonine) (Figure 26a). Meanwhile, IȖ_i3(V) T412A was similar to IȖ_i3(V) in 
its localisation (Figure 26b), although this might have been a “ceiling effect” in that 
IȖ_i3(V) wild type was already near maximally PM-localised, as could be measured 
using our method. T412A also increased the phosphorylation of both IȖ_i3 constructs, 
with the most striking effect on the Val443 construct, where the mutant was completely 
phosphorylated (Figure 26c). 
However, these data raised another question. The crucial difference between the 
overall phosphorylation profiles of IȖ_i3 and IȖ_i2 (Figure 8) should be recalled. 
Compared to IȖ_i2, which had one major “fully” phosphorylated band, IȖ_i3 had at 
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least one additional phosphorylated state, and its “fully” phosphorylated band 
appeared to have a larger separation from the dephosphorylated band than that of 
IȖ_i2. With T412A, the putative “partially phosphorylated” band was obviously 
weakened (Figure 8d), but without a general absence of phosphorylation (indeed, the 
overall phosphorylation actually increased), indicating that Thr412 residue does not 
itself account for the major phosphorylated bands observed, and suggesting that any 
phosphorylation on the Thr412 residue is a small part of the overall phosphorylation 
pattern. 
Therefore, the effects observed using T412D and T412A could have been indirectly 
related to phosphorylation, e.g. a general, electrostatic effect due to the acidity or 
hydrophobicity, respectively, of the substituted residue. The decrease in PM-
association with T412D may be due to the negative charge on the aspartate residue 
compared to threonine, decreasing the affinity for the PM. Conversely, the higher 
hydrophobicity on alanine could have led to the opposite effect of T412A. Similarly, 
these could produce the observed effects on the lipid kinase activity, given the 
affinities of the substituted residues to the negatively charged and hydrophobic lipid 
substrate. Once targeted to the PM, the protein could then be phosphorylated by other 
kinases on (or near) the membrane, achieving its full phosphorylation pattern in vivo 
at equilibrium (see more studies in Section 4.3). 
 
 
4.2.3.CharacterisationoftheE410AMutant
As described in the Introduction, Glu410 is an extremely important residue implicated 
in the Type I specificity of PIP5KIȖ. Its substitution into alanine should impair the 
PI4P 5-kinase activity of Ȗ_i3 selectively, while sparing the general structure of the 
enzyme[130]. 
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Figure 27 Characterisation of the E410A mutants 
(a) – (b) Typical subcellular localisation of overexpressed GFP-tagged E410A constructs in 
HEK-293 cells (scale bar = 10 ȝm). Panel on the right indicates quantified ratio of PM / 
cytosol fraction. Orange dotted line indicates a cytosolic (non-membrane-enriched) 
localisation (n = 30, ** p < 0.001). (c) In vivo phosphorylation pattern of the E410A mutants. 
(d) FRAP behaviour of the E410A mutant, mean fluorescence intensity plotted (n = 30). (e) 
Western blot of raw HEK-293 lysate overexpressing the FLAG-tagged constructs. (f) Western 
blot of the lysate in (f) after volume titration and immunoprecipitation using the anti-FLAG 
antibody. (g) Lipid kinase activity of the E410A mutant (n = 2). (h) Lipid kinase activity of 
the D316K mutant. For both (g) and (h), time courses of 1, 2.5 and 5 minutes were performed. 
Lipid products were separated by TLC and [32P]PIP2 was measured and compared between 
constructs. 
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In order to compare the degree of impairment of E410A as a kinase-inactive mutant, 
and to see if it truly reached the lowest activity detectable using the current protocol, 
the E410A mutant was assayed alongside the wild type and the well established 
kinase-inactive mutant, D316K. Total lysates were Western blotted in order to 
determine the relative concentration of the enzyme (Figure 27e), and added in 
different volumes so the amount of enzyme in the assay was the same across the 
samples. This was verified by Western blot using the post-immunoprecipitation 
samples, treated in parallel as the samples submitted to the actual kinase assay (Figure 
27f). 
The lipid kinase activity of E410A was severely reduced, retaining only a trace 
amount of residual activity (Figure 27g). This was comparable to the activity of 
D316K (Figure 27h), confirming that the enzyme was indeed made essentially 
inactive as a PI4P 5-kinase. This result was consistent with Kunz et al., where the 
equivalent single AA substitution in Iȕ partially impaired the PI4P-binding specificity 
(and thus made it cytosolic) and also its Type I PIP kinase activity, while giving rise 
to Type II activity[130]. 
Strikingly, the localisation of E410A mutants were not significantly different from 
that of the wild type IȖ_i3 (Figure 27a and b), and they were also phosphorylated to a 
similar extent (Figure 27c). In addition, the FRAP mobility was indistinguishable 
from the wild type (Figure 27d). 
This collection of observations is potentially interesting. The mutant enzyme is 
indistinguishable from the wild type in many behavioural aspects (such as in vivo 
phosphorylation, membrane localisation, cytoskeletal association and mobility), but 
has specifically abolished lipid kinase (PI4P 5-kinase) activity. Given the low levels 
of PI5P relative to PI4P in vivo[95], the Type II (PI5P 4-kinase) activity that it 
possesses can be regarded as leading to negligible PIP2 synthesis. As we shall see later 
in the next section, this mutant has proven to be a key that helped us to exclude 
several alternative hypotheses regarding the regulation of the enzyme. 
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To verify whether the E410A mutant had indeed become a Type II, PI5P 4-kinase 
despite its dramatically reduced Type I activity, I tested its catalytic efficiency by the 
lipid kinase assay using PI5P as the substrate (instead of PI4P). 
 
 
 
Figure 28 Co-immunoprecipitation of Type II PIP kinase activity with immunopulldown 
of PIP5KIȖ 
(a) Lysates of overexpressed FLAG-tagged IȖ_i3 and its E410A mutant titrated to the same 
concentration after anti-FLAG immunoprecipitation. (b) Lipid kinase assay of IȖ_i3 and the 
E410A mutant, each using PI4P and PI5P as the substrate, and PIP2 product measured by 
autoradiography. (c) Western blot using anti-PIP4KIIĮ antibody, after immunoprecipitation 
for FLAG-tagged PIP5KIȖ and its E410A mutant. 
 
 
Using the same quantity of enzymes (Figure 28a), the E410A mutant exhibited an 
almost negligible Type I activity, exactly as described before (Figure 27g). However, 
in the PIP4K assay (using PI5P as the substrate), both the wild type and mutant 
enzyme showed the same amount of Type II activity, which was very high even 
compared to the Type I activity. This was puzzling at first sight, given that although 
E410A might be expected to assume some PIP4K activity, the wild type PIP5KIȖ had 
always been known as a strictly Type I enzyme. 
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I reasoned that this could be due to an artefact caused by contaminating Type II 
enzymes in the immunoprecipitation preparation, since the enzymes were 
overexpressed in HEK-293, a mammalian strain which could endogenously express 
PIP4Ks. Indeed, when I Western blotted the PIP5KIȖ immunoprecipitate for the 
presence of PIP4KIIĮ, the most active[110, 111] and usually predominant isoform of 
PIP4Ks, both IȖ_i3 and IȖ_i3 E410A pulled down a significant amount of PIP4KIIĮ 
(Figure 28c). This co-immunoprecipitation was in agreement with previous findings, 
where Type I and Type II PIP kinases were observed to associate with each other both 
in vivo and in vitro[105]. Therefore, a more appropriate way of detecting the Type II 
activity of Type I PIP kinases, or vice versa, would be to overexpress the protein in a 
bacterial system, where there was no contamination from other endogenous enzymes, 
as done in Kunz et al.[130]. 
The fact that wild type and the E410A mutant of IȖ_i3 pulled down the same amount 
of PIP4KIIĮ is consistent with the above discussion. It suggests that Type I and II 
interaction is mediated by interfaces independent of the activation loop, and at the 
same time confirms that E410A caused minimal disturbance to the general structure 
of the IȖ_i3 enzyme. 
 
 
4.2.4.SynopticConsiderationsfortheRelationshipbetweenKinase
ActivitiesandMembraneLocalisation
The quantified kinase activities, as individually determined above, are collectively 
presented in Table 7. 
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Lipid Kinase Activity Protein Kinase Activity  
IȖ_i3(V) IȖ_i3(A) IȖ_i3(V) IȖ_i3(A) 
Wild type 100 45 
100 
100 60 
100 
D316K 4 <1 * ND ND 
T412D 6 15 * 80 ND 
T412A ND 115 * ND ND 
E410A 5 5 * ND ND 
Table 7 Summary of lipid and protein kinase activities of the activation loop mutants 
Calculations were based on the raw data shown in the previous figures. Activities of mutants 
were calculated as a percentage of either IȖ_i3(V) activity (in blue), or IȖ_i3(A) (in red) (n no 
smaller than 2). Ratios above 10% were approximated to the nearest 5%, for the ease of 
communication. ND = not determined. * indicates data from previous work (by Giudici, 
unpublished), from which raw data was not included in the present study. 
 
 
Putting the T412D and T412A data together suggests that the changes in their lipid 
kinase activity may have been a direct result of a change in the electrostatic charges of 
the activation loop. For example, the T412D mutation introduced a negative charge to 
the activation loop, and this may have imposed electrostatic repulsion and steric 
hindrance on its substrate-binding, hence lowering the lipid kinase activity. T412A, 
on the other hand, made the residue slightly more hydrophobic and gave easy access 
of its lipid substrate to the activation loop. So it could be that the effects on lipid 
kinase activity were caused by the same factors that altered its PM-association (and 
overall phosphorylation). 
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However, the fact that E410A mutants had greatly impaired lipid kinase activity but 
largely unchanged PM-localisation, phosphorylation and FRAP mobility from the 
wild type tells us the PM-localisation is not a simple consequence of the lipid kinase 
activity, nor of the interaction with the hydrophobic substrate. It is important to note 
here that our observations are consistent with the PIP5KIȕ data of Anderson’s 
group[130].  
While E410A showed that the PM-association was not necessarily dependent on the 
lipid kinase activity of IȖ_i3, I showed in the previous Chapter that the localisation of 
IȖ_i3(A) required its kinase activity in general, as highlighted by the differences 
between the D316K constructs of IȖ_i3 and IȖ_i2. Given these two findings, the most 
parsimonious explanation to fit both observations would be: it is the protein kinase 
activity that is implicated at the initial stage of IȖ_i3’s membrane localisation. That is, 
a IȖ_i3 molecule needs to phosphorylate itself (or potentially other protein partners), 
before it could be targeted to the plasma membrane. 
Experimentally, it is difficult, if not impossible, to generate a mutant that specifically 
impairs the protein kinase activity of the PIP5KIȖ, while leaving the lipid kinase 
activity unaffected. Given that both activities share the same catalytic core underlying 
the general phosphate-transferring mechanism, it would only be by identifying the 
amino acid residues that are autophosphorylated and mutating them that this could be 
achieved. Without the knowledge of target AA residues to mutate, the 
autophosphorylation of the protein cannot be manipulated in a specific fashion. 
However, using the mutants affecting either the general kinase activity (D316K) or 
the lipid-binding site in the activation loop (E410A), I was able to dissect out the 
differences, and arrive at conclusion that the protein kinase activity was most likely 
essential for the initial targeting to the PM. 
The above conclusion leads to another key question: does membrane localisation lead 
directly to the rest of the phosphorylation events in vivo, as observed by Western blot 
(e.g. Figure 8)? This will be addressed in detail now in the next section. 
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4.3. Relationship between Membrane Localisation and 
Phosphorylation 
4.3.1.AMeaningfulCausalRelationship?
From the wide range of mutants tested above, an intriguing correlation seemed to 
have emerged, between their in vivo phosphorylation state and PM-association. A 
general pattern could be observed, that the higher the overall phosphorylation, such as 
in the case of T412A, the more PM-localised the enzyme. The converse cases were 
observed e.g. with the V443A, D316K and T412D mutants. 
This, of course, is not a quantitatively precise correlation, and is likely to involve 
multiple mechanisms of phosphorylation and PM-targeting. For example, IȖ_i3(A) 
and IȖ_i3(V) D316K had apparently the same PM-bound fraction (Figure 9b and 
Figure 10a), but slightly different phosphorylation profiles (Figure 8b and c). 
Is this apparent correlation a causal relationship? In other words, does 
phosphorylation help a PIP5KIȖ molecule to associate with the PM, or does 
membrane-associaion lead to its phosphorylation instead? If so, is this causal 
relationship necessary or sufficient? These were the questions that we were potentially 
interested in, and to break this cyclic argument, I needed to specifically interfere with 
one factor and observe its effect on the other. 
As discussed in the previous Chapter, without comprehensive knowledge of the target 
residues implicated in the in vivo phosphorylation, it would be difficult to interfere 
with the phosphorylation pattern per se. On the other hand, if I had certain ways of 
forcing an originally cytosolic enzyme to attach to the membrane, or making an 
otherwise normal enzyme cytosolic, I would be able to gain insight into the role of 
membrane localisation in the full phosphorylation of the protein. These experiments 
were made possible by my PM and E111L mutants, as discussed below. 
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4.3.2.ForcingaCytosolicPIP5KIɀontotheMembrane–thePM
Mutant
Whether PM-association is sufficient on its own to lead to phosphorylation was an 
unanswered question, and to address this I used the ten amino acids at the N-terminal 
motif from the human Lyn kinase (MGCIKRKGKD), which lead to palmitoylation 
and myristoylation (“PM”) in vivo that forces the attachment of the fusion protein 
onto the membrane, regardless of the protein’s original localisation[214]. 
 
 
 
Figure 29 Major characters of the PM mutants 
(a) and (b) Typical subcellular localisation of overexpressed PM- and GFP-tagged constructs 
in HEK-293 cells (scale bar = 10 ȝm). Panel on the right indicates quantified ratio of PM / 
cytosol fraction. Orange dotted line indicates a cytosolic (non-membrane-enriched) 
localisation (n = 30, ** p < 0.001). (c) In vivo phosphorylation pattern of the PM mutants. (d) 
FRAP mobility of the PM mutants, mean fluorescence intensity plotted (n = 10). 
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The PM constructs unfailingly localised to the plasma membrane, as expected (Figure 
29). In particular, the normally completely cytosolic IȖ_i3(A) D316K mutant was 
targeted to the membrane by the PM-tag to an extent comparable to the wild type 
enzyme on itself. This confirmed that the PM-tag could override other potential 
regulatory mechanisms and anchor the fusion protein to the plasma membrane as a 
useful molecular tool, without the need of altering the property of the rest of the 
protein. 
Perhaps not surprisingly, the PM constructs exhibited a lower mobile fraction and 
slower recovery relative to the enzyme on itself (Figure 29d). This would be due to 
the fact that the PM-tag was irreversibly attached to the membrane, and therefore the 
fusion protein could be constricted in its range of diffusion by various lipid 
compartments, compared to a freely diffusible protein according to the fluid mosaic 
model. The rate of diffusion was most likely limited by the collision and transient 
binding of the PM-tag to other components in the lipid bilayer, which should 
inevitably slow the diffusion down. Moreover, the overexpressed fluorescent enzyme 
was entirely membrane-bound in this case, therefore the source of recovery was 
limited to lateral diffusion, with no input from exchanges with the cytosolic 
proteins[47]. 
Strikingly, the PM-tagged constructs were all phosphorylated, regardless of their 
original phosphorylated pattern before PM-targeting (Figure 29c). The most 
persuasive example was the PM-tagged IȖ_i3(A) D316K, which enabled the protein to 
be fully phosphorylated, when the IȖ_i3(A) D316K on itself was completely 
unphosphorylated (Figure 8c). This evidence suggested strongly that the protein 
kinases that phosphorylate IȖ_i3 in vivo are very likely situated on or close to the 
plasma membrane. 
Having stated the above, the membrane association aided by the PM-tag may still be 
different from that occurring physiologically. For example, the PIP5KIȖ may 
normally be binding to specific proteins (e.g. Rac, as discussed in the next section) or 
to particular lipids on the membrane, instead of anchoring itself randomly in the 
phospholipid bilayer. The PM-tag may have a different preference for the lipid 
composition with which it associates, and therefore it could become inserted into a 
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different compartment or raft (see Introduction). Also, the physiological association of 
IȖ with the membrane is likely reversible and dynamic, where the equilibrium is 
determined by the on/off constants of its binding with partners. In contrast, the PM-
tag becomes palmitoylated and myristoylated, which in turn leads to irreversible 
anchoring at the plasma membrane[47]. Nevertheless, given the results above, the 
membrane localisation was proven to be sufficient for achieving the phosphorylation 
of IȖ_i3. 
 
 
4.3.3.ForcingaMembranePIP5KIɀintotheCytosol–theE111L
Mutant
Whether or not the membrane localisation is necessary for IȖ_i3 phosphorylation was 
a different question. To address this, I needed to bring a wild type enzyme off the 
membrane and, without changing anything else, observe its phosphorylation pattern. 
It has been documented that a particular glutamate residue (Glu61) before the 
conserved kinase domain in PIP kinase Iȕ was crucially implicated in the association 
with the monomeric G-protein Rac (a member of the Rho family GTPases)[138]. 
Extensive data from Halstead et al. using mutagenesis, microscopy and co-
immunoprecipitation demonstrated conclusively that this glutamate was essential for 
the binding of PIP5KIȕ with Rac. This interaction was abolished when this glutamate 
was mutated into leucine, and consequently there was no PM-association[138]. 
Following on from these observations, I therefore generated the equivalent mutant in 
IȖ_i3, E111L. 
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Figure 30 Major characters of the E111L mutants 
(a) – (b) Typical subcellular localisation of overexpressed GFP-tagged E111L constructs in 
HEK-293 cells (scale bar = 10 ȝm). Orange dotted line indicates a cytosolic (non-membrane-
enriched) localisation (n = 30, ** p < 0.001). (c) Overlay of GFP (IȖ_i3) and Cellmask 
channels, where yellow indicated superposition of the green and red signals. (d) In vivo 
phosphorylation pattern of the E111L mutants and the PM & E111L double mutants, on a 
wild type, V443A or D316K enzyme. (e) Lipid kinase activity of the E111L mutant, with time 
courses of 1, 2.5 and 5 minutes. Lipid products were separated by TLC and [32P]PIP2 was 
measured and compared between constructs (n = 2). (f) Alkaline phosphatase treatment and 
control incubation at 30 °C did not affect the apparent lipid kinase activity in vitro. 
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The E111L mutants turned out to be indeed cytosolic (Figure 30a and b), suggesting 
that this mutation could prove to be a useful tool to impair the membrane association 
of IȖ_i3 without altering its other functional motifs. 
However, a more detailed examination of the confocal images revealed an important 
difference between these two constructs. The IȖ_i3(V) D316K & E111L double 
mutant was cytosolic in the real sense, in that it did not colocalise with any portion of 
the cell membrane, highlighted by the red Cellmask label. In contrast, the IȖ_i3(V) 
E111L construct was still partially present at the membrane, shown by the yellow 
superposition with the Cellmask signal. It simply did not enrich at the membrane, 
giving the general impression that it was cytosolic (Figure 30c). Evidently, this fine 
difference was not picked up by our plasma membrane / cytosol ratio analysis, 
probably because of the limited resolution of the region-of-interest intensity 
measurement. 
This E111L mutant was nevertheless totally unphosphorylated, similar to D316K, as 
was the D316K & E111L double mutant (Figure 30d). However, when then tagged 
with a PM-tag, even the most cytosolic IȖ_i3(A) D316K & E111L became fully 
phosphorylated (in complete agreement with earlier data, Figure 29), again pointing to 
plasma membrane association as being the main driver of IȖ phosphorylation. 
 
On a separate note, I tested the E111L mutant as a lipid kinase, and found that its 
activity was reduced to about 1/3 (Figure 30e). This was unexpected, since the E111L 
mutation was not supposed to cause disruption to the general structure or any 
catalysis-related domains of the enzyme. As a control, I investigated whether the 
overall phosphorylation per se (which is abolished in this mutant) could be a cause of 
the reduction in the lipid kinase activity. It appeared not to be the case, since 
incubation with alkaline phosphatase in vitro (which removed all phosphorylation, see 
Figure 8a) prior to immunoprecipitation did not alter the activity measured; neither 
did the pre-incubation temperature have a descernible effect (Figure 30f). It led me to 
reason that it must be an intrinsic property of E111L, e.g. the inability to bind Rac, 
that caused this reduction. Indeed, Rac has long been identified as an activator in 
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many phosphoinositide-related pathways, including not only the Type I PIP5K[136], 
but also e.g. the Type II PI4K[75], PI 4,5-kinase, PI 3-kinase and PI 5-kinase[143]. 
This also indirectly supported the proposed effect of the E111L mutation as to abolish 
Rac-binding of the kinase. 
 
 
4.3.4.RacandIɀInteraction–AssessedbyCoǦimmunoprecipitation
I tried to see whether the wild type IȖ_i3 and Rac associated in vivo and could be co-
immunoprecipitated together, and thereby demonstrate that the E111L mutation 
indeed obliterated (or reduced) such binding. 
I first attempted to immunoprecipitate the FLAG-tagged enzymes with anti-FLAG, 
and detect whether Rac co-immunoprecipitated with various IȖ_i3 constructs. Rac has 
a molecular weight of 21 kDa. Unfortunately, the light chain of the mouse IgG1 used 
as the immunoprecipitating antibody (hence remaining in the sample) had a MW of 22 
kDa, running at exactly the distance of interest and hence contaminating the Rac 
signal (Figure 31a). The heavy chain should run at 43.3–55 kDa, and protein G 
(linked to the sepharose beads for immunoprecipitation) at around 31–34 kDa 
(apparent in the SDS-PAGE, as reported by the manufacturer, despite its calculated 
MW of 21.6 kDa). Therefore, the unfortunate recognition of the light chain of the 
immunoprecipitate/primary antibody imposed a real problem to the studies. 
I reasoned that it would be possible to overcome this problem, if the secondary 
antibody for Western blot only recognised the heavy chain of IgG1, instead of both 
chains (Figure 31b). I therefore managed to find a secondary antibody against the 
mouse heavy chain, denoted anti-mouse-IgG1-HC. Using this antibody, the problem 
above was indeed overcome. The light chain was no longer detected, shown by the 
anti-FLAG antibody control, and the protein G was not in the way of Rac detection 
either. This, along with the use of 15% polyacrylamide running gels, was developed 
into a standard tool for all the future experiments where I was interested in detecting 
Rac from an immunoprecipitation. 
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However, even though the immunoprecipitation of Ȗ_i3 constructs worked fine 
(Figure 31c), the Rac signal itself was not detected in the range of samples tested, 
including even the wild type IȖ_i3(V) (Figure 31d). The thin band ubiquitiously 
present in all samples at around 20 kDa was not Rac, as the genuine endogenous Rac 
signal was controlled for in the total lysate sample running alongside, producing a 
higher band at exactly 21 kDa, as expected. 
This co-immunoprecipitation experiment was repeated for another 4–5 times using the 
same mild conditions of detergent extraction and minimal number of washes during 
immunoprecipitation, producing the same negative results on Rac, in spite of normal 
Ȗ_i3 pull-down. It seemed that the putative association between PIP5KIȖ_i3 and 
E111L may not be strong or long enough for me to detect using the above protocol. 
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Figure 31 Rac did not co-immunoprecipitate with PIP5KIȖ_i3 using the E2139 antibody 
FLAG-tagged IȖ_i3 constructs were overexpressed in HEK-293 cells and extracted. (a) Rac 
signal had the same apparent MW on the Western blot as the antibody light chain. (b) 
Schematic illustration of the IgG1 structure. (c) Immunoprecipitation of overexpressed IȖ_i3 
constructs. (d) Western blot using anti-mouse-IgG1-HC, detecting the heavy chain, but not 
the light chain, of IgG1. Overexpressed IȖ_i3 constructs were compared with controls (shown 
in red), such as the immunoprecipitating anti-FLAG, protein G, as well as total HEK-293 
lysate (as a Rac standard). 
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Potentially, one possibility for such difficulty was that Rac interacted with the N-
terminal domains of PIP5KIȖ (e.g. the motif containing E111L falling back onto its N-
terminus in 3D). This would compete with the binding of anti-FLAG antibody to the 
Ȗ_i3 during the immunoprecipitation. Once the antibody pulls the enzyme down, Rac 
binding would be lost. As an alternative means of demonstrating this association, I 
decided to go about it from another direction, immunoprecipitating for the Rac and 
detecting the FLAG signal on the Ȗ_i3. 
The commercial Rac antibody had only been used for Western blot previously, and I 
had no knowledge whether or how readily it would immunoprecipitate. As a first step, 
the immunoprecipitation protocol using the anti-Rac antibody was optimised. It 
appeared that the antibody indeed pulled down Rac. For the following experiments, 1 
µl of anti-Rac (in 500 µl PBS, diluted from 0.25 mg/ml, BD Transduction) was used 
with a standard immunoprecipitation protocol. 
 
 
 
Figure 32 PIP5KIȖ_i3 co-immunoprecipitated with Rac using the anti-Rac antibody 
Co-immunoprecipitation of IȖ_i3 constructs with Rac, using anti-Rac antibody. FLAG-tagged 
IȖ_i3 constructs were overexpressed in HEK-293 cells and extracted. 
 
 
The endogenous Rac was again confirmed to be pulled down by this antibody, in a 
variety of Ȗ_i3 overexpression lysates tested (Figure 32). When blotted with the anti-
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FLAG antibody, the IȖ_i3 signals were successfully detected (Figure 32). The relative 
position and pattern of phosphorylation were exactly those expected of these 
constructs, as addressed earlier. Note that with the same amount of overexpression 
(titrated by volume before the immunoprecipitation), the Ȗ_i3 was most readily 
immunoprecipitated. The PM construct was immunoprecipitated to a less extent, 
presumably because the artificial anchoring to specific lipid compartments by the PM-
tag hindered the enzyme’s interaction with Rac. Moreover, the PM-tag was at the very 
N-terminus of the fusion protein and hence, if our earlier theory of Rac binding with 
N-terminus of PIP5KIȖ was correct, it could hinder the interaction with Rac in vivo. 
More interestingly, the IȖ_i3(A) D316K mutant was pulled down (although at a lower 
quantity). This may be because the enzyme was completely cytosolic in vivo, and 
therefore had not much opportunity to sample the membrane-bound Rac, while during 
the extraction and immunoprecipitation procedure, it came in contact with Rac, and 
became bound to Rac since its Glu111 motif was intact. The crucial E111L mutant 
exhibited greatly impaired binding to Rac, exactly consistent with Halstead et al.[138]. 
 
I should note that this co-immunoprecipitation was relatively difficult to reproduce 
and did not work every time I repeated this experiment. Presumably, the binding of 
Ȗ_i3 and Rac was relatively weak and transient after all, and the association was only 
clearly revealed when multiple factors in the co-immunoprecipitation were optimal, 
such as the overexpression level, lysate quality, extraction severity and incubation 
conditions. In fact, in the original Halstead study, although it was stated that all 
isoforms of Type I PIP kinase (including IȖ) were confirmed to associate and co-
immunoprecipitate with Rac, they only showed data using microscopy, mutagenesis, 
Rac immunoprecipitation followed by lipid kinase activity assay (as an indication of 
the presence of the kinase), or co-immunoprecipitation using the more reliable 
biotin/streptavidin system in the initial immunoprecipitation[138]. Perhaps strikingly 
in retrospect, similar types of data were shown in earlier studies showing PIP5K 
association with Rac too[139, 141, 143]. In contrast, co-immunoprecipitation using an 
anti-Rac antibody, followed by direct detection of PIP5KI on Western blot (as I tried 
to achieve), was never directly demonstrated. Such difficulty in co-
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immunoprecipitation was confirmed by the authors (Divecha, personal 
communications). This interesting case also reiterates the point that genuine molecular 
interactions in vivo, especially via weak and transient interactions on multiple 
domains, do not necessarily last strongly or long enough for their association to be 
reliably detected in vitro, which may be required to last e.g. longer than 5 
seconds[215]. 
Nevertheless, here I successfully demonstrated the co-immunoprecipitation of 
membrane-bound PIP5KIȖ with endogenous Rac, as well as the greatly reduced 
binding of the E111L mutant, in a direct and less arbitrary fashion (Figure 32). This is 
helpful when interpreting the behavioural data of the E111L mutants (Figure 30), 
which is exactly consistent with this Rac-binding theory. 
 
 
4.3.5.SynopticConsiderationsfortheRelationshipbetween
MembraneLocalisationandPhosphorylation
In summary, I have managed to break the cyclic argument and tease apart the apparent 
correlation between the observed phosphorylation pattern and the enzyme’s 
membrane localisation. Taken together, these data have demonstrated that the 
membrane localisation is not only sufficient, but also necessary for the 
phosphorylation of IȖ_i3 in vivo, independent of the enzyme’s catalytic (lipid or 
protein kinase) activity. In the previous section (4.2), I showed that the membrane-
dependent full phosphorylation in vivo is likely a downstream process of the protein’s 
initial autophosphorylation (which may be the main arbiter of whether IȖ_i3 
associates with the membrane). Once it associates with the membrane, IȖ_i3 becomes 
further phosphorylated by other protein kinases at or near the membrane. When the 
protein is unable to associate with the membrane, no discernible phosphorylation 
takes place, in spite of unaltered functions in all other aspects of the protein. 
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5.ResultsIII–DiscoveryandCharacterisationofANovel
PIP5KIɀSpliceVariant,Iɀ_i6
 
5.1. Discovery of IȖ_v6 
In an attempt originally set up to establish a more comprehensive distribution pattern 
of PIP5KIȖ_v3 in vivo and to find a mammalian cell line which potentially expressed 
IȖ_v3 endogenously, I investigated mRNA libraries of different mouse tissues. 
Previously, in situ hybridisation had shown that IȖ_i3 expression is confined to certain 
groups of neurons in the brain, such as the cortex, cerebellum, hippocampus, olfactory 
bulb[167] and the pituitary (primarily in the anterior part, unpublished by Giudici). A 
mouse cell line available in the Department, AtT-20, is also derived from the anterior 
pituitary of mice, and could potentially be used as a cell line that expresses 
endogenous IȖ_v3, if I could confirm the expression in the anterior pituitary. 
Therefore, the pituitary was my first target in which to look for IȖ_v3. The tissue was 
dissected, frozen in the RNAlater reagent and extracted for mRNA. 
In order to show IȖ_v3 exclusively, i.e., to avoid the products from amplification of 
IȖ_v1 and IȖ_v2 (which would have resulted from PCR with primers against common 
sequences of all these spliceoforms), two pairs of primers were designed to 
specifically pick up IȖ_v3 (A1 and A2 in Figure 33). 
Reaction A1 confirmed the existence of Ȗ_v3 in this tissue, with a 353 bp fragment 
produced as expected. Apparently, using the primer pair against Exons 16 and 19, 
reaction AC preferentially used Ȗ_v1 as the template over Ȗ_v2 and Ȗ_3 (as could be 
told from the predicted fragment length), though this did not necessarily indicate a 
quantitative difference among these splice variants. 
The A2 result was more interesting. Besides the predicted band of 319 bp with Ȗ_v3, 
there was a background smear potentially containing other PCR fragments. This was 
not expected, since no other mRNA was expected to contain both Exons 16 and 17, 
except for that of IȖ_v3. The identity of the lowest band just below 300 bp was 
subjected to sequencing. 
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a 
 
b 
 
c 
 
Figure 33 RT-PCR for IȖ_v3 from rat anterior pituitary mRNA 
(a) PCR scheme. A1: forward primer anneals to Exons 13/14, reverse primer against 17/18 
(Ȗ_v3 specific), IȖ_v3 product expected at 353 bp. A2: forward primer anneals to Exons 16/17 
(Ȗ_v3 specific), reverse primer against Exon 19 3’ UTR, IȖ_v3 product expected at 319 bp. 
AC: forward primer anneals to Exon 16, reverse primer against Exon 19 3’ UTR, IȖ_v3 
product expected at 493 bp, but also IȖ_v2 at 415 bp, and IȖ_v1 at 337 bp. +: actin control 
expected at 323 bp. (b) RT-PCR product after agarose gel electrophoresis. A1 and + band 
sizes were as expected, the main product of AC corresponded to the preferential amplification 
of Ȗ_v1, and the A2 product consisted of smaller bands besides that expected from IȖ_v3. The 
lower band was subjected to sequencing and confirmed to be a novel spliceoform, named 
PIP5KIȖ_v6. (c) Splicing scheme of the new splice variant, IȖ_v6. 
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This unexpected band was found to be a novel splice variant of PIP5KIȖ. It included 
Exons 1–16 as all other spliceoforms, followed by the 78-nt Exon 17 (as in Ȗ_v3) and, 
instead of having Exon 18 (which Ȗ_v2 and Ȗ_v3 have in common), was ligated 
directly onto Exon 19, the beginning of which is the stop codon TAA. In other words, 
this novel protein could be described as a truncated version of PIP5KIȖ_i3, ending 
with the 26 AAs that constitute the unique peptide insert of Ȗ_i3. 
We named this new spliceform PIP5KIȖ_v6, according to the convention that Schill 
and Anderson suggested[170]. It is interesting that since Exon 17 and Exon 18 (and 
hence the peptide that they code for) have the same length, IȖ_i6 should have the 
same molecular weight as IȖ_i2 (around 90 kDa). 
It should be noted here that the actin reaction (Lane + in Figure 33b) controlled for the 
optimisation of the PCR protocol. During subsequent PCR experiments, this positive 
control was included whenever it was necessary to trouble-shoot a reaction where no 
amplification product was observed (data not shown). However, in a typical set of 
reactions using the same condition and mix composition in parallel, the experiments 
were already internally controlled for, because some reactions showed positive results 
demonstrating not only the optimisation of the general conditions, but also the 
availability of PIP5KIȖ templates and the specific accessibility by their PIP5KIȖ 
primers. 
 
 
5.2. IȖ Spliceform Expression Profile in Specific Tissues 
Since the IȖ_v2 and IȖ_v6 would produce fragments of the same size in a general 
PIP5K PCR (e.g. AC primers in Figure 33), it left open to other interpretations 
previous estimates of IȖ variants using similar primers (e.g. [167, 170]). Moreover, to 
study IȖ_v6 further, it was necessary to be able to distinguish between each splice 
variant unambiguously. I further developed this PCR strategy into a more targeted 
way of distinguishing between different splice variants, by using primers that 
annealed to particular spliceoform-specific junctions of exons. This way, I was able to 
detect the existence of a particular splice variant exclusively. 
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Figure 34 shows the PCR for specific IȖ splice variants in the anterior and posterior 
parts of the rat pituitary, as well as AtT-20, the mouse anterior pituitary derived cell 
line. 
 
 
a 
 
b 
 
Figure 34 PCR for specific IȖ splice variants in the pituitary and AtT-20 cell line 
(a) PCR scheme. A, E, I: forward primer anneals to Exons 16/18, reverse against 19, Ȗ_v2 
product expected = 243 (rat) or 234 (mouse) bp. B, F, J: forward 16/17, reverse 19/18, Ȗ_v3 
product expected = 184 (rat) or 191 (mouse) bp. C, G, K: forward 16/17, reverse 19, Ȗ_v6 
product expected = 241 bp, Ȗ_v3 product = 319 bp. D, H: forward 13/14, reverse 19/16, Ȗ_v1 
product expected = 294 bp. L: forward 15/16, reverse 19, Ȗ_v1 product = 286 bp, Ȗ_v2/6 
product = 364 bp, Ȗ_v3 product = 442 bp. (b) PCR product. mRNA template added: A – D: 
anterior pituitary (rat), E – H: posterior pituitary (rat), and I – L: AtT-20 (mouse anterior 
pituitary). 
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Relevant bands were sequenced after gel extraction. It was confirmed that Ȗ_v3 was 
indeed expressed in all of the three sources, i.e., anterior pituitary, posterior pituitary 
and AtT-20. In addition to the Ȗ_v6 found in the pituitary as described in the previous 
section, its expression was also confirmed in AtT-20 (band extracted and sequenced). 
 
I extended the search further onto the hippocampus, where IȖ_v3 expression was 
previously demonstrated[167]. Using specific primers for each splice variant, the 
existence of each template was verified (Figure 35). IȖ_v1, IȖ_v2 and IȖ_v3 were all 
confirmed to be present in the rat hippocampal cDNA library. However, The lower 
band in Lane B corresponded to IȖ_v3 (319 bp), while the upper band was confirmed 
to be a non PIP kinase product by sequencing. By these criteria, IȖ_v6 is apparently 
absent from the hippocampus. 
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Figure 35 PCR for specific IȖ spliceoforms from rat hippocampus 
(a) PCR scheme from rat hippocampal cDNA library. Primer pairs used were: A: 16/18 and 
19, B: 16/17 and 19, C: 16/17 and 19/18, D: 13/14 and 19/16. Expected fragments were 243, 
319/241, 184, 294 bp, respectively. (b) PCR result. A, C and D fragments were of the lengths 
expected. The lower band in Lane B corresponded to IȖ_v3 (319 bp), while the upper band 
was a non PIP kinase product. The band expected using the IȖ_v6 template (241 bp) was 
absent. 
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5.3. Tissue Distribution of PIP5KIȖ Spliceoforms in Mice – the 
Updated Picture 
In an attempt to repeat Giudici’s initial cloning of IȖ_v3 from total mRNA of various 
tissues of Swiss Webster mice, and to confirm its expression pattern across different 
tissues, RT-PCR was repeated with the same protocol as in Giudici et al. (2004)[167]. 
With the forward primer spanning the junctions of Exons 15 and 16 (in common of all 
known IȖ spliceoforms) and the reverse primer complementary to the 3’ UTR in Exon 
19, the experiment was designed to amplify all PIP5KIȖ splice variants. 
Reassuringly, the expression pattern observed was identical to the one published by 
Guidici et al.[167] (Figure 36b). 
 
 
125 
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b 
 
Figure 36 RT-PCR result for general amplification of PIP5KIȖ from mouse tissue total 
mRNA. 
(a) PCR scheme, forward against Exons 15/16, reverse against Exon 19. (b) PCR results 
consistent with Giudici (2004). IȖ_v3 products were the subsidiary bands just above the IȖ_v2 
products, though less obvious due to lower intensity. The very high band in the tescicle lane 
was confirmed to be a non-PIP5K product. It is worth noting that the middle band was 
originally considered as the PCR product from IȖ_v2 exclusively. Now we know that the 
template could have been both IȖ_v2 and IȖ_v6, the novel splice variant discovered in this 
study. 
 
 
As mentioned above, this adds complexity to the interpretation of existing evidence 
on the tissue distribution of IȖ splice variants. For example, in the original RT-PCR 
experiment[167], the middle lane corresponding to 364 bp had always been 
considered a segment resulting from the amplification of Ȗ_v2. Now we know that 
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with this choice of primers, the middle lane may well have been the result of the 
amplification of a mixture of both Ȗ_v2 and Ȗ_ v6, both giving PCR products of the 
same length. The identity of this middle lane is therefore no longer specific for a 
particular splice variant. 
Therefore, I focussed on the tissue distribution of each splice variant in turn, and 
performed RT-PCR from the total mRNA of mouse tissues (Figure 37), using specific 
primers for each splice variant, as described in the previous section. 
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Figure 37 RT-PCR for specific splice variants in mouse tissues 
(a) PCR scheme, using primers (A) 16/18 and 19 for Ȗ_v2 (234 bp), (B) 16/17 and 19/18 for 
Ȗ_v3 (191 bp), (C) 16/17 and 19 for Ȗ_v6 (241 bp) and Ȗ_v3 (319 bp), and (D) 15/16 and 19 
for Ȗ_v1 (286 bp), Ȗ_v2/6 (364 bp) and Ȗ_v3 (442 bp). (b) PCR result from the total mRNA of 
mouse tissues. Note that the IȖ_v3 bands in B and C resembled each other, although it seemed 
less favourable to be used as the template in reaction D, compared to other splice variants. 
 
 
It is apparent that the various IȖ splice variants produced fragments at the expected 
sizes, indicating their presence. IȖ_v2 was present largely ubiquitously throughout 
different tissues. The pattern of IȖ_v3 expression was similar in Panels B and C, 
which both resembled that in Giudici et al. (2004)[167]. The band separation was 
probably not clear enough for each product to reflect the original abundance of the 
mRNA of each spliceoform naturally present, and this PCR protocol is largely 
qualitative. 
I therefore resorted to one more PCR screening (with a larger separation in gel 
electropheresis). Besides the same paradigm as Panel C in Figure 37, another pair of 
primers was also designed to specifically detect IȖ_v6, annealing to Exons 15/16 and 
19/17, respectively. 
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b 
 
Figure 38 RT-PCR of IȖ_v3 and IȖ_v6 in the mouse tissues 
(a) PCR scheme using primers (A) 16/17 and 19 for Ȗ_v3/6 (318/240 bp), and (B) 15/16 and 
19/17 for Ȗ_v6 (239 bp). (b) PCR result from the total mRNA of mouse tissues. 
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It appeared that the Ȗ_v3 expression pattern was highest in the brain, as found before. 
The 239-bp band from the amplification of Ȗ_v6 in Panel B seemed to be present 
across different tissue types. In order to verify its identity, the bands from the heart, 
liver, spleen and kidney were extracted, purified and sequenced. In all these samples 
tested, the presence of the Ȗ_v6 splice variant was confirmed unambiguously. These 
data revealed a low but ubiquitous expression of IȖ_v6 across tissues included in the 
library. The upper bands in Figure 38b (B) did not correspond to any of the other 
splice variants, and probably resulted from misbinding of primers to other non-
PIP5KIȖ templates. 
 
 
5.4. List of Primers Used for Rodent Templates 
Below is a list of primers used above, to amplify PIP5KIȖ from the rat and the mouse 
(Table 8). 
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Organism Exon(s) Sequence 
mouse 15/16 forward GGAGGAGGGTGCAGG AGTGGAGGTC 
mouse 16/17 forward CCCTCTACAGACATCTATTTT TTCGCCCATGG 
mouse 19/18 reverse CTGCATAGAAGTTA TGTGTCGCTCTCGCCG 
mouse 19/17 reverse GGGGACTGCATAGAAGTTA AGTGCCTGTGTGG 
rat 13/14 forward GGTACAG GCGGCGTACGCAGTCTTC 
rat 15/16 forward GCAGGGTGCAGG AGTGGAGGTTCC 
rat 16 forward  
rat 16/17 forward GACATCTATTTT TTCGCCCACGGGAGATAC 
rat 18/19 forward GACTGCATAGAAGTTA TGTGTCGCTCTCGCC 
rat 18/17 reverse GGTGGG AGCGCCTGTGTGGCTTG 
rat/mouse 16/18 forward CAGACATCTATTTT CCCACCGACGAGAGG 
rat/mouse 19/16 reverse CAGATTGGGGACTGCATAGAAGTTA AAAATAGATGTCTG 
rat/mouse 19 reverse CCGTCAGTGGGAGGGAGAGAACAAG 
Table 8 List of primers used for the amplification of PIP5KIȖ from the rodents 
The space within sequences illustrates the exon junction. 
 
 
5.5. Generation of Mammalian Expression Vectors Containing IȖ_i6 
and Its Mutants 
Having validated that IȖ_i6 was naturally expressed in the cells, I went on to subclone 
IȖ_i6 that is N-terminally tagged with GFP and FLAG, under the mammalian 
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promoter pCMV. This would allow me to overexpress IȖ_i6 in e.g. HEK-293 and 
COS-7 cells, and study its features extensively in comparison with the other splice 
variants. 
Usually, a de novo cloning project would require us to amplify the IȖ_v6 gene out of a 
cDNA/mRNA library, clone it into a bacterial expression vector, and then subclone it 
into a mammalian vector (such as the pCMV-2B and pEGFP-C1 used above). 
However, an alternative approach was adopted. Since IȖ_i6 only differed from IȖ_i3 
by a 26-AA peptide at the very C-terminus of the latter (i.e. the IȖ_i2 “tail”), I decided 
to introduce a stop codon into the spectrum of IȖ_i3 constructs, in order to generate 
the corresponding IȖ_i6 mutants (Figure 39a). 
 
 
 
Figure 39 Generation of the IȖ_i6 construct for overrexpression 
(a) Primers used to introduce by site-directed mutagenesis a stop codon (immediately after 
Exon 17), illustrated by the underlined and Italic font refer to the mismatching region with 
the template, i.e., the desired sequence. (b) Overexpressed FLAG-tagged IȖ_i6 in HEK-293 
cells, lysate detected by anti-FLAG antibody in Western blot. The protein band appeared at 
the correct molecular weight expected for the full length IȖ_i6. 
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When detected by anti-FLAG antibody in Western blot, the IȖ_i6 band appeared at the 
correct molecular weight expected of the full length protein, 26 amino acids shorter 
than IȖ_i3 (Figure 39b). 
 
 
5.6. Live Imaging of Overexpressed IȖ_i6 
The GFP-tagged PIP5KIȖ_i6 was overexpressed in COS-7 cells. Like its other 
spliceoforms, the enzyme seemed to localise primarily to the plasma membrane 
(Figure 40). Using alternative methods, the localisation of IȖ_i6 is investigated in 
more detail in later sections. 
 
 
Figure 40 GFP-tagged IȖ_i6 localised to the plasma membrane 
Typical subcellular localisation of overexpressed GFP-tagged IȖ_i6 constructs in COS-7 cells 
(scale bar = 10 ȝm). 
 
 
5.7. FRAP Behaviour of IȖ_i6 
When assessed by FRAP, IȖ_i6 recovered towards a lower equilibrium level 
compared to IȖ_i1 and 2, partially resembling IȖ_i3 (Figure 41). This seemed to 
suggest that the 26-AA insert was at least partially responsible for the observed 
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immobile fraction of IȖ_i3. These data also suggest that the immobility of IȖ_i3 was 
not a simple consequence of its larger molecular size compared to IȖ_i2. 
 
 
 
Figure 41 The mobility of IȖ_i6 partially resembled that of IȖ_i3 
FRAP behaviour of different splice variants of PIP5KIȖ, mean fluorescence intensity plotted 
(n = 10). 
 
 
5.8. Subcellular Localisation of IȖ Splice Variants in COS-7 Cells –
Assessed by Immunocytochemistry 
The subcellular localisation of overexpressed IȖ_i6 was compared between that of the 
other IȖ splice variants in COS-7 cells. Proteins were N-terminally tagged with either 
GFP or FLAG, and the tag visualised by immunocytochemistry. 
As shown in the previous section (Figure 46) and earlier studies[179], all splice 
variants of PIP5KIȖ displayed similar localisation to the plasma membrane when 
overexpressed in HEK-293 cells. In contrast, when overexpressed in COS-7 cells, 
IȖ_i3 was shown to be more internalised than IȖ_i1 and IȖ_i2[179]. However, the 
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IȖ_i3 construct used is now known to contain the V443A mutation (see Results I); 
when this was corrected back, the difference between the wild type (Val443) of each 
splice variant was much less obvious, all constructs now primarily localising to the 
plasma membrane (Figure 42). Nonetheless, it was interesting to see how IȖ_i6 
behaved, since it had the same size (in terms of the primary sequence) as Ȗ_i2, yet 
possessed the peptide insert of Ȗ_i3, which made Ȗ_i3/6 different from IȖ_i2. In an 
immunocytochemical staining on COS-7 cells, Ȗ_i6 was shown to have a localisation 
that was largely membrane-bound, quite similar to the other splice variants (Figure 
42). 
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Figure 42 All wild type IȖ splice variants localised similarly in COS-7 cells 
Typical subcellular localisation of overexpressed GFP-tagged constructs in COS-7 cells (scale 
bar = 10 ȝm). All constructs used contained the wild type Val443. 
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5.9. Development of Specific Antibody Against IȖ_i6 
In order to be able to detect the endogenous IȖ_i6 at the protein level and perform 
Western blot, immunocytochemical staining and/or immunoprecipitation, I sought to 
generate a primary antibody that was raised against the C-terminus of IȖ_i6. This was 
of course also the unique 26-AA peptide present in IȖ_i3. A rabbit polyclonal 
antibody, E2139, was developed by our lab (outsourced to NeoMPS), against the C-
terminal 16 amino acids on the IȖ_i3/6 peptide insert. The epitope sequence was 
CRRRRLRAVTPSHTGA. 
 
 
5.10. Optimisation and Specificity of E2139 for Western Blot 
This primary antibody was first tested for Western blot application. Starting from the 
standard Western blot protocol (see Materials and Methods 2.19), optimisation was 
carried out testing a range of E2139 concentrations, while keeping the goat anti-rabbit 
secondary antibody at an established working concentration. 
Within the dilution range of 1:20000 – 1:1000 from the stock, the E2139 antibody 
appeared to work in a concentration-dependent fashion (Figure 43). 
 
 
 
Figure 43 Optimisation of the E2139 antibody 
Samples were equal volumes of HEK-293 lysate, overexpressing PIP5KIȖ_i6. 
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In this study, all subsequent Western blots using E2139 were performed according to 
this optimised protocol, with a 1 hr incubation of E2139 (1:7500, or 1:2500 from the 
1:1 glycerol-diluted stock), followed by a 1 hr incubation of HRP-conjugated goat 
anti-rabbit antibody (1:1000). 
There was, however, another concern. The epitope sequence (against which E2139 
was raised) was present not only in IȖ_i6, but also in IȖ_i3. The difference was that 
this peptide was at the very C-terminus of IȖ_i6, while in IȖ_i3 it was followed by the 
26-AA tail of IȖ_i2 (compare Figure 33a and c). 
I therefore tested the recognition efficacy of IȖ_i3 and IȖ_i6 by E2139 (Figure 44), 
and found that a stronger signal was generated by the same quantity (assessed by 
FLAG) of IȖ_i6 versus IȖ_i3. 
 
 
 
Figure 44 Recognition specificity of E2139 to IȖ_i3 and IȖ_i6 
Equal amounts of IȖ_i3 and IȖ_i6 were loaded, as assessed by Western blot using the anti-
FLAG antibody. 
 
 
This result was not very surprising, given the frequent observation that antibodies 
typically recognise the C-terminus of the antigen much better than an epitope that is 
more hindered within the peptide sequence (e.g. [216]). 
Such specificity of E2139 to IȖ_i6 was encouraging, because with a PIP5KIȖ signal 
recognised by E2139 as the primary antibody, we could interpret it as Ȗ_i6, but not 
Ȗ_i3, with reasonable confidence. 
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5.11. Optimisation and Specificity of E2139 for 
Immunocytochemistry 
With the antibody E2139 established to recognise IȖ_i6 specifically in Western blot, I 
moved on to test where it could be used for the same purpose in 
immunocytochemistry. 
The immunocytochemistry typically uses antibody at a much higher concentration 
(e.g. 5x) than that for Western blot. A preliminary staining revealed that using a 
dilution factor of 1:1000 – 1:100 for primary incubation produced successful staining 
with a good signal-to-background ratio (Figure 45). 
 
 
 
Figure 45 Optimisation of E2139 for immunocytochemistry 
Typical immunocytochemical staining of overexpressed FLAG-tagged IȖ_i6 constructs in 
HEK-293 cells (scale bar = 10 ȝm), using E2139 as the primary antibody. Ratios indicate 
dilution factor of the primary antibody incubation. 
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All subsequent immunocytochemical staining using E2139 was diluted at the optimal 
ratio of 1:750, to ensure good signal quality. 
Since there was not any spliceoform-specific antibody available for PIP5KIȖ, this was 
the first time that it was possible to detect the protein of a IȖ spliceoform directly, 
without the requirement for a peptide tag. Therefore, I first set out to investigate the 
reliability of our previously used immunocytochemistry protocols using anti-FLAG 
staining, and how it overlapped with the E2139 signal (Figure 46). 
 
As essential controls, Figure 46a and b showed that there was no bleed-through of 
Alexa 555 into the green channel, or the Alexa 488 into the red channel. c and d 
showed that there was no cross-talk between the mouse anti-FLAG primary and the 
anti-rabbit secondary, or the rabbit E2139 primary and the anti-mouse secondary 
antibodies. As an internal control, the negative staining in Panel c also showed that 
the anti-rabbit secondary by itself did not give rise to any non-specific background. 
Figure 46e and f established that the subcellular localisation pattern of overexpressed, 
FLAG-tagged IȖ_i6 was consistent, whether stained with anti-FLAG or E2139 
(against the enzyme’s C-terminus itself). This was demonstrated by the yellow 
overlapping signals in Panels k and l. 
In the mean time, I intended to verify that when used for immunocytochemistry, 
E2139 was still specific for IȖ_i6, as opposed to other IȖ spliceoforms. Figure 46g and 
h showed that FLAG-tagged IȖ_i1 and IȖ_i2 gave no signal when stained with E2139. 
However, Panels i and j seemed to suggest that there was some binding of E2139 to 
IȖ_i3, though the affinity (as shown by green intensity) was much less than that of 
IȖ_i6 (probably for the same reasons discussed above). 
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Figure 46 Comparison between E2139 and anti-FLAG staining 
Typical confocal images of fixed, permeabilised and stained HEK-293 cells overexpressing 
PIP5KIȖ constructs. Primary antibodies: anti-FLAG was made from the mouse and E2139 
from the rabbit. Secondary antibodies (from goat): the anti-mouse antibody was conjugated to 
Alexa 555 (red) and anti-rabbit conjugated to Alexa 488 (green). Cells overexpressed 
different constructs and were incubated with different antibody combinations, as indicated on 
the right hand side of each image. (a) – (j): left (red) channel = 550–580 nm, right (green) 
channel = 500–540 nm, excited using a 543 nm laser and an Argon laser filtered at 488 nm, 
respectively. (k) and (l) were superimposed images of (e) and (f), respectively. Image 
dimensions: 15.4 x 15.4 ȝm, except (c) 38.2 x 38.2 ȝm. 
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5.12. Detection of Endogenous IȖ_i6 Protein by 
Immunohistochemistry 
As described above, IȖ_v6 mRNA was confirmed in both the pituitary and the AtT-20 
cell line (Sections 5.1 and 5.2). I would therefore like to validate the presence of IȖ_i6 
in the pituitary (or other tissues) directly at the protein level. 
Using fixed sagittal slices from the mouse brain, I performed immunohistochemistry, 
in an attempt to detect endogenous IȖ_i6. After several trials, the protocol was 
optimised, and the E2139 signal could be detected against a relatively low background. 
Meanwhile, a NeuroTrace marker was included, which highlighted the Nissl body 
present only in the soma of neurons and hence served as a general neuron label. 
Different parts of the brain displayed different levels of staining with E2139. In 
particular, the signal appeared abundant in certain subclasses of neurons in the 
cerebral cortex, olfactory bulb, hypothalamus, limbic system and the cerebellum. It 
was reassuring that the signal was not ubiquitous for all neurons present in the same 
region (e.g. pons, olfactory bulb and prefrontal cortex), suggesting that the staining 
was epitope-specific. 
14
3 
 
144 
 
Figure 47 Immunohistochemical staining of the brain using E2139 
Images from different regions of the brain (red = E2139 + donkey anti-rabbit secondary, 555 
nm; green = NeuroTrace green, 535 nm), mapped onto the sagittal slice. Whole picture was 
acquired in smaller, overlapping pieces under low magnification fluorescence microscope 
(visualising the NeuroTrace signal) and joined together afterwards in silico. Hpc = 
hippocampus, DG = dentate gyrus, CB = cerebellum. Scale bar (bottom left) = 1 mm. 
 
 
However, the positive E2139 signal in various areas of the hippocampus was puzzling. 
As we saw earlier (Figure 35), the IȖ_v6 is apparently absent in the hippocampus at 
the mRNA level. This discrepancy could only be explained by the fact that IȖ_i3 was 
also detected by the E2139 antibody, albeit at a lower efficacy (see above, Figure 44). 
This means that ultimately, although we have good reasons to assume E2139 detects 
IȖ_i6 best, due to its uniquely exposed C-terminal epitope, it is impossible to rule out 
the possibility that some of the signal may also originate from binding with IȖ_i3 in a 
less specific manner. This preliminary immunohistochemistry work therefore needs 
careful interpretation at the splice variant level. Nevertheless, it is the first direct 
demonstration that IȖ_i6 and/or IȖ_i3 is indeed present endogenously at the protein 
level. 
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6.ResultsIV–ConfirmationofIɀ_i3andIɀ_i6Expression
inHumans
 
6.1. Theoretical Examination of the Human Genome Sequence 
The spliceoform IȖ_v3 was discovered by Giudici in our lab from the amplification of 
a rat hippocampal cDNA library[167], after Ishihara’s initial discovery of IȖ_v1 and 
IȖ_v2 in the rodents[108]. The 26-AA insert near the C-terminus is analogous on the 
peptide level (but not the DNA level) to an in silico translated segment of the human 
IȖ gene, and therefore it was long assumed that IȖ_v3 should very likely exist in 
human too, though its expression had never been directly demonstrated. Having 
characterised the IȖ_i3 and IȖ_i6 constructs from the rodents, I thought it would be 
interesting and important to investigate whether these two splice variants also existed 
in humans. This question became especially pertinent in the light of a detailed study 
on IȖ splicing in humans. 
Schill and Anderson[170] performed 3’ RACE on the purified mRNA from the 
mammary epithelial cell line MCF10A, with the forward primer annealing to Exon 16, 
which all the known PIP5KIȖ spliceoforms had in common. These experiments 
identified bands unexpected by their apparent molecular weight. Subsequent 
sequencing revealed two novel C-terminal splice variants of IȖ, both sharing the PIP 
kinase core spanning Exons 1–16, but rejoined onto different, novel downstream 
exons with unique stop codons within their own 3’ UTR. Schill and Anderson named 
them IȖ_v4 and IȖ_v5, and the novel human exons 16b and 16c, to distinguish them 
from the original Exon 16 (which they then called 16a). 
These novel exons (16b and 16c) were in an exceptionally lengthy region between 
human Exons 16a and 17 (which exactly corresponded to Exons 16 and 18 in the 
rodent, see Figure 5, though this interval was much shorter in rodents compared to the 
human). Therefore, it was impossible to find the counterparts in the mouse genome, 
homologous to human 16b and 16c. However, theoretical translation of this inter-
exonic region in the human Ensembl database and alignment by ClustalW revealed 
that part of the predicted peptide sequence was highly homologous to the 26-AA 
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insert of rodent IȖ_v3 (Figure 48a). In fact, a comparison (Figure 48a) revealed that 
this is exactly the first 26 amino acids of the human Exon 16c! 
 
 
 
Figure 48 In silico translation of Exon 16c of human PIP5KIȖ_i5 and other IȖ 
orthologues 
(a) ClustalW alignment of theoretically translated peptide sequences from the Ensembl 
genomic database, showing downstream of human Exon 16c. Red line indicates the initial 26 
AA, homologous to the rodent Exon 17. (b) An illustration of the underlying nucleotide 
sequence in human Exon 16c. Arrow indicates putative 3’ splice site, alternative to that used 
by PIP5KIȖ_i5. (c) Example of 5’ splice site consensus, size of nucleotide indicating 
occurance frequency, modified from Ast (2004)[217]. 
 
 
This observation begged the question of whether the DNA sequence underlying the 
26-AA peptide insert of the putative human IȖ_v3 might exist as an individual exon, 
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and also whether the IȖ_v3 splicing configuration actually occurrs in the human. It is 
plausible, because the sequence at the 3’ junction of this putative exon (i.e., the 5’ 
splice site with regard to the next intron), GTAAGT, appears to be a well documented, 
perfect 5’ splice site consensus (Figure 48c)[217, 218]. This site would enable the 
PIP5KIȖ gene to produce the IȖ_v3 splice variant (directly demonstrated at least in the 
rodents), and this site also appears to be highly conserved across the species, even in 
the humans, at both the DNA and peptide levels (motif VSD in Figure 48b). 
The possibility that the putative human exon in question existed (alongside 16b and 
16c) is fascinating, because it means that on the one hand, Exon 16c could be spliced 
as it is in IȖ_v4 and IȖ_v5, while on the other hand its initial 78 bp could be spliced 
out as an individual exon, and ligated to the next exon(s) much further downstream to 
form IȖ_v3. This would be a case of internal splicing, i.e. alternative splicing within 
one exon to produce another smaller, overlapping exon, depending on a different 
choice of the 5’ splice site (named with regard to the intron). 
In this chapter, I refer to all the exons by their numbering as in the rodent, unless only 
relevant to the human (Figure 49). That is, I consistently refer to the rodent Exons 18 
and 19 as in the above mentioned system, despite the confusing fact that Schill and 
Anderson[170] named them 17 and 18 instead, respectively. 
Figure 49a shows a schematic aligment of all hypothetical PIP5KIȖ splice variants 
that may be present in humans. The putative human Exon 17 (as should exist in IȖ_v3 
and IȖ_v6) is depicted in yellow, which exactly corresponds to the beginning 78 bp of 
Exon 16c, as illustrated in Figure 49b. 
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Figure 49 Illustration of the human genomic sequence between Exons 16 and 18 
(a) Updated alternative splicing scheme of human PIP5KIȖ, including the putative splice 
variants IȖ_v3 and IȖ_v6. The proposed Exon 17 is shown in yellow, with the rest of the 3’ 
tails of IȖ_v4 and IȖ_v5 in green, 3’ UTR in white, and other exons in blue. (b) Detailed 
genomic sequence of the human, emphasising the C-terminal sequence of IȖ. Exons are 
shown in blue, with introns (in the omitted form) in green, alternative stop codons highlighted 
in red and, again, putative Exon 17 in yellow. 
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Even though alternative 5’ splice sites are known to exist in human and other 
mammalian genomes[219], the feasibility of the above scenario was not certain and 
needed to be addressed experimentally. 
 
 
6.2. Detection of PIP5KIȖ_v3 in the Human Brain 
Based on our knowledge of IȖ_v3 and IȖ_v6 expression in the rodent brain, as 
described in the previous chapter as well as previous publications[167], I first 
investigated a cDNA library of the human brain. PCR was performed to amplify each 
splice variant of PIP5KIȖ, using primers that specifically annealed to the exon 
junctions, based on the human PIP5KIȖ gene sequence (Figure 50). The “Exon 17” 
counterpart in the human was assumed to be the initial 78 bp of the human Exon 16c 
(Figure 49b). 
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Figure 50 PCR for each IȖ splice variant in the human brain 
(a) PCR scheme. Primers used were: A: 14/15 and 19 for IȖ_v1/2/3/6 (404/482/560/482 bp), 
B: 16/17 and 19/18 for IȖ_v3 (199 bp), C: 14/15 and 19/16 for IȖ_v1 (268 bp), D: 14/15 and 
19/18 for IȖ_v2/3 (354/432 bp), E: 16/17 and 19 for IȖ_3/6 (327/249 bp), F: 14/15 and 18/17 
for IȖ_v3 (343 bp). (b) PCR result from the human brain cDNA library. 
 
 
The PCR products from Figure 50 were extracted, purified and sequenced. The 482-
bp band in A and 354-bp band in D were confirmed to be fragments of IȖ_v2. 
Importantly, the 199-bp band in B and 327-bp in E were confirmed to be fragments of 
IȖ_v3. This means that the initial 78 bp of human Exon 16c is indeed an exon in its 
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own right, and in at least certain tissues (e.g. the brain) it could be spliced out in the 
same fashion as the rodent Exon 17. This exon, ligated between Exons 16 and 18, 
forms the human version of IȖ_v3. In other words, IȖ_i3 was demonstrated to be 
expressed in the human. 
 
 
6.3. Detection of PIP5KIȖ_v6 in the Human Brain 
In Figure 50, the lower, 249-bp band in Lane E corresponded to the molecular weight 
of the PCR product from IȖ_v6, but the gel extract was not pure enough to be 
sequenced unambiguously. I therefore repeated this PCR, and sequenced the 249 bp 
product (Figure 51). 
 
 
 
Figure 51 Amplification of IȖ_v3 and IȖ_v6 in the human brain 
PCR result from the human brain cDNA library, as in Reaction E of Figure 50. The upper 
band was not a PIP kinase product. The middle band of 327 bp was confirmed previously to 
be a IȖ_v3 product. The lower band of 249 bp was sequenced. 
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Somewhat surprisingly, the band in question was in fact not from IȖ_v6, but a product 
also containing some sequence of Exon 18. Moreover, because the primers used were 
Exons 16/17 and 19, a product containing Exon 18 in addition should in fact be IȖ_v3, 
giving the middle band of 327 bp (Figure 51). The lower band corresponded to a 
product that was 78 bp shorter, which was puzzling at first sight. 
A sequencing of these bands revealed that this product was in fact the result of 
promiscuous binding of the forward primer onto the IȖ_v2 cDNA in the templates. 
The 3’ half of the forward primer did not exactly anneal with the start of Exon 18, but 
its 5’ half was already annealed to the end of Exon 16; despite the mismatch on the 3’ 
end, the PCR reaction was able to proceed, giving the rest of the Exon 18, all the way 
through to the reverse primer binding site within Exon 19. Since Exons 17 and 18 
were of the same size, the product appeared as a IȖ_v6 band on the gel. 
Presumably, the concentration of IȖ_v6 was not as high as IȖ_v2 in the brain, and/or 
its structural conformation was not readily accessible for this particular set of human 
primers to anneal to. As a result, I needed to find another means of detecting IȖ_v6 
unambiguously, in case it was truly present. 
Another pair of primers was used for amplifying IȖ_v6 more specifically (that is, even 
exclusively to IȖ_v3). The forward primer spanned Exons 14/15, whereas the reverse 
annealed to Exons 19/17 (Figure 52). Only IȖ_v6 should be picked up by these 
primers as a genuine template, producing a fragment of 349 bp. 
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Figure 52 IȖ_v6-specific amplification from the human brain 
(a) PCR scheme. Primers used were 14/15 and 19/17, for amplifying IȖ_v6 specifically, 
producing a 349 bp fragment. (b) PCR result from the human brain cDNA library. 
 
 
The 349 bp band from Figure 52b was extracted, and sequencing revealed its identity 
to be IȖ_v6. The product consisted of the forward primer site in Exon 14, followed by 
Exons 15, 16, 17 and 19, all the way through to the reverse primer binding site. IȖ_v6 
was thus experimentally confirmed to be expressed in humans. 
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6.4. Expression Profile of PIP5KIȖ Spliceoforms in Human Tissues 
With the splice variants IȖ_v3 and IȖ_v6 directly demonstrated in humans for the first 
time and the presence of the equivalent “Exon 17” established, I next sought to reveal 
the tissue distribution of the different PIP5KIȖ spliceoforms in humans, especially 
IȖ_v3/6 (Figure 53). 
 
 
a 
 
b 
  
Figure 53 Amplification of IȖ_v3 and IȖ_v6 in human tissues 
(a) PCR scheme, forward primer spanned Exons 16/17, reverse Exon 19, for the amplification 
of IȖ_v3 and IȖ_v6 producing bands of 327 and 249 bp, respectively. (b) PCR result from the 
cDNA library of human tissues. 
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The band sizes corresponded correctly to the scenario of IȖ_v3/6 amplification. 
Sequencing revealed that the IȖ_v3 bands were genuine, whereas the apparent IȖ_v6 
bands were actually, once again, mis-primed PCR products of IȖ_v2. This was exactly 
the same case as described before for the PCR from the human brain cDNA library 
(Figure 51), where promiscuous binding of the forward primer to IȖ_v2 masked any 
potential IȖ_v6 detection. 
To overcome this problem, an alternative PCR paradigm was adopted. To match the 
same reverse primer, a new primer was designed to anneal within Exon 17 itself, 
therefore preventing any potential PCR elongation in the case of mismatch. Using 
these primer sets, I expected to see products of both Ȗ_v3 and Ȗ_v6 if they both 
existed. 
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Figure 54 Amplification of IȖ_v3 and IȖ_v6 in human tissues (second trial) 
(a) PCR scheme. Primers used were 17 and 19, for amplifying both IȖ_v3 and IȖ_v6, 
producing 299 and 221 bp fragments, respectively. (b) PCR result from the cDNA library of 
human tissues. (c) PCR result with 10x concentrated primers, which increased the ratio of 
IȖ_v6 recognition over IȖ_v3 dramatically. 
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Though the 221-bp bands were not very strong in intensity (Figure 54b), the shape of 
the band was discernible enough to be extracted from the gel, at least in the lanes of 
the brain, heart, kidney and liver. Sequencing result of all these samples confirmed the 
existence of the IȖ_v6 splice variant in the human. 
In trouble-shooting the conditions for using these primers, I discovered that if the 
primer concentration (of both the forward and reverse primers) was raised to 2 µM 
each (10x of the 0.2 µM as in the standard protocol, see Methods), the ratio of IȖ_v6 
amplification over IȖ_v3 was increased dramatically (Figure 54c), while IȖ_v3 was 
still expressed most strongly in the brain. Since the forward primer only recognised 
Exon 17, the 221-bp band could not possibly be produced by mismatching to any 
template other than Ȗ_v6 itself. This result, confirmed by sequencing, provided further 
evidence for the widespread existence of Ȗ_v6 in humans. 
The change between Figure 54b and c was very interesting, but the comparison 
between Ȗ_v3 and Ȗ_v6 cannot be quantitatively accurate, and so conclusions about 
the relative levels of the splice variants much await more detailed studies with 
quantitative real-time PCR. 
 
In conclusion, I have confirmed the existence of both IȖ_v3 and IȖ_v6 in the human. 
Not only is this interesting in the light of the co-existence of Ȗ_v4 and Ȗ_v5 in the 
human (overlapping in their exon sequences with Exon 17), but it also adds to our 
knowledge base about alternative 5’ splice site exons. This is the second most 
important alternative splicing mechanism to exon-skipping[220], and creates typically 
subtle changes in mRNA (instead of retention or omission of much longer nucleotide 
sequences), and these may play decisive roles in development and human diseases 
(e.g. [221]). 
This study extends (if not potentially completes) our knowledge of PIP5KIȖ 
spliceoforms that exist in the human, potentially in a spectrum of tissue types and at 
different developmental stages (Figure 55). The alternative splicing profile as 
proposed at the start of this chapter is proven to be correct (Figure 49a). Indeed, 
IȖ_i3/6 and IȖ_i4/5 expression may be differentially regulated under specific 
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signalling pathways, and the global alternative splicing profile, just like transcription 
profiles, can reflect the tissue identity in mammalian cells[222]. 
 
 
 
Figure 55 Updated picture of PIP5KIȖ splice variants in the human 
 
 
6.5. List of Primers Used for Human Templates  
Below is a summary list of primers used in this Chapter, for the amplification of 
PIP5KIȖ from the human (Table 9). 
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Exon(s) Sequence 
14/15 forward GACAGGATGGCAG GCCGCAGGAGGAG 
16/17 forward GCCACCGACATCTACTTT TTCACGGATGGGAGGTAC 
17 forward GATTTACTCTCCCCGCCATCGCCGAC 
17 reverse CAGTCGGCGATGGCGGGG 
16c reverse GCTGCGGTCACTTAC AGTCCCCGAG 
18/17 reverse CTCTCATCGGTGGG AGTCCCCGAGGC 
19/16 reverse GGGCTGCATAGAAATTA AAAGTAG 
GGGCTGCATAGAAATTA AGTCCCCGAGGCGC 
19/17 reverse 
CGGGGGCTGCATAGAAATTA AGTCCC 
GGGGGCTGCATAGAAATTA TGTGTCG 
19/18 reverse 
GCTGCATAGAAATTA TGTGTCGCTCTCGCCGTCG 
CATCCGTGCAGGGGGAGGACGAG 
19 reverse 
GGAGCAGAAGTGGAGCTCGGCTCTGG 
Table 9 List of primers used for the amplification of PIP5KIȖ from the human 
The space within sequences illustrates the exon junction. 
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7.FurtherDiscussionsandRemarks
 
7.1. Discoveries and Conclusions from This Study 
In this study, I have to a significant degree reconciled the behavioural differences 
between IȖ_i2 and IȖ_i3, and attributed part of this to the previously undiscovered 
V443A mutation in our IȖ_i3 constructs. The IȖ_i3-specific 26-AA insert does not 
seem to be a simple PIP2-binding or phosphorylation site, as revealed by the 4R and 
5P mutants, respectively. 
The localisation of IȖ_i3, but not IȖ_i1 or IȖ_i2, is activity-dependent, and 
independent of PI4P-binding. The lipid kinase activity per se of IȖ_i3 is not 
implicated in the enzyme’s localisation and phosphorylation, unlike initially 
speculated[167, 179]. Rather, the membrane localisation may be autophosphorylation-
dependent, and this in turn is both necessary and sufficient for the enzyme to achieve 
its apparently full phosphorylation pattern in vivo, while at the membrane. 
Along with IȖ_v3, a novel splice variant has been discovered to exist in both rodents 
and humans. Their tissue expression profiles have been addressed at the mRNA level, 
and preliminary data have also been obtained on the IȖ_i6 protein’s possible 
endogenous distribution, both subcellularly and in tissues (e.g. the brain). Importantly, 
the co-existence of both splice variants with IȖ_i4 and IȖ_i5 presents an interesting 
case of overlapping exons (by alternative 5’ splice sites) in humans. 
 
 
7.2. Useful Experimental Tools Developed During This Study 
Several useful tools and methods have been developed that are not only beneficial to 
this study, but also for future investigations. For example, the activation loop mutants 
(E410A, T412D, T412A) specifically impair the enzyme’s substrate-binding and lipid 
kinase activity, while leaving the protein kinase activity unaltered, and this is a step 
forward from the previously used D316K (and K188A) mutants. The PM and E111L 
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mutants provide a way of directly interferering with the enzyme’s subcellular 
localisation, forcing it on or off the plasma membrane, while leaving other properties 
largely unchanged. The V443A (as well as the reciprocal A443V) mutation can be 
used as another tool that subtly decreases (or increases) the enzyme’s affinity for the 
plasma membrane, independently of other regulatory mechanisms, and hence helps to 
reveal behavioural differences that are otherwise not immediately apparent. 
The discovery and cloning of IȖ_i6 is a significant advance. The range of IȖ_i1/2/3/6 
expression vectors we now have is a comprehensive toolbox for investigating the 
functions of the 26-AA peptides, corresponding to either Exon 17 (IȖ_i3/6 insert) or 
Exon 18 (IȖ_i2 tail). This, perhaps with the help of my 4R and 5P mutants, will likely 
give new insights into the significance of IȖ’s C-terminal variations. 
The specifically developed antibody against IȖ_i3’s 26-AA insert (E2139) has been 
optimised and with refinement may become a tool to investigate the subcellular and 
tissue distribution of endogenous IȖ_i6, as well as its phosphorylation pattern or other 
association properties using Western blot. 
Furthemore, a protocol for co-immunoprecipitating PIP5Ks with Rac has been 
devised and optimised, which detects the endogenous protein association directly 
using Western blot for the first time, free of contaminating signals from the antibodies. 
This may be useful for future studies on PIP5K’s membrane dynamics, as well as 
binding partner identification. 
 
 
7.3. Potential Future Directions 
Here I briefly discuss several potential directions for future experiments, to follow up 
on the present study. Should time and resources permit, they may provide important 
insight into the functions and regulatons of PIP5Ks. 
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7.3.1.SignificanceofAlternativeSplicing
Based on our current picture of IȖ’s alternative splicing, we can perceive IȖ_i1/2/3/6 
as an elegant 2 x 2 matrix regarding their usage of the C-terminal peptide (IȖ_i4/5 are 
human-specific and hence not considered here). In other words, the gene can have on 
its C-terminus (following Exon 16) either no further peptide (IȖ_i1), or the 26-AA 
from Exon 17 (IȖ_i6), or the 26-AA from Exon 18 (IȖ_i2), or both (IȖ_i3). We now 
know that both 26-AA peptides may be included independently of the other. 
We already know that the C-terminus of IȖ_i2 is implicated in certain functions e.g. 
talin-binding (see Introduction), and that the IȖ_i3-specific 26-AA insert conveys 
other unique properties e.g. possible autophosphorylation-dependency of membrane 
localisation. In response to different developmental or physiological stimuli, 
alternative splicing may give rise to functional deiversity at the protein level, in the 
important signalling and metabolic pathways regulated by PIP5KIȖ. Combined with 
the tissue distribution of these different splice variants, it would be interesting to 
know whether the alternative splicing profile (i.e., presence or absence of either of the 
26-AA peptides) dictates a tissue identity or fate during development, e.g. whether the 
IȖ_i3 insert is physiologically relevant to neuron development. It is therefore also 
important to understand the functions and regulations of IȖ_i6. 
Ultimately, it would be interesting to better characterise the alternative splicing profile 
of IȖ, and determine whether IȖ_i3, IȖ_i6 and the more ubiquitous spliceoform IȖ_i2 
may be expressed in the same neuron in vivo, for example by using single-cell PCR. 
 
 
7.3.2.BacktotheNeurons
We have examined and discussed many aspects of PIP5KIȖ_i3’s behaviour in HEK-
293 cells. While HEK-293 is a convenient mammalian expression system that allows 
easy maintenance and transfection, and provides informative insight into the 
physiological IȖ_i3 in the nervous system, it is still considerably different from the 
neurons. 
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In the near future, the subcellular localisation of IȖ_i3 and its effect on proliferation 
should be tested on neuronal cultures. Regions in the cerebellum and cerebral cortex, 
especially the forebrain, have been demonstrated to express IȖ_i3[167]. Existing 
primary culturing techniques of cerebellar granule cells[167] will be a convenient way 
of achieving that. We would like to test whether IȖ_i3(V) D316K, a true dominant 
negative enzyme as opposed to IȖ_i3(A) D316K as reported before[167], also 
significantly compromises neuronal survival and alters their morphology compared to 
IȖ_i2(V) D316K. Since IȖ_i3(V) D316K and IȖ_i3(A) D316K have different 
subcellular localisations, this would address the question whether this detrimental 
effect of IȖ_i3(A) is due to the 26-AA insert, or the cytosolic distribution which 
potentially interferes with the cytoskeleton. The PM-tagged IȖ_i3(A) D316K, which is 
still catalytically inactive but is now membrane-bound, can also help in this context, 
e.g. to address whether the inactive enzyme strips the Rac off the membrane, which 
might lead to physiological consequences. 
Presumably, an inducible overexpression system (such as the tet-on/off system[223, 
224] or the Rapalogue-inducible FKBP/FRB dimerisation system[225]) may be 
helpful. It will be useful to transfect the neurons at the time of plating, but turn on the 
desired gene expression only when the primary culture has been properly developed 
into the suitable confluence and neurite connections. This would then eliminate any 
potential side effects caused by other PIP5KIȖ-sensitive factors during development 
(because of prolonged exposure to the overexpressed transgene), but not IȖ itself in 
the functional neuron. 
 
 
7.3.3.AnotherHypothesisontheEnzyme’sActivityǦdependent
Localisation
We have seen that the IȖ_i3 localisation is dependent on its activity. Another perhaps 
remote possibility underlying this would be that a molecule of PIP5KIȖ_i3 binds PI4P 
on the endomembrane in the cytoplasm (e.g. Golgi or cytoplasmic vesicles), turns it 
into PIP2, and then gets associated with the PM while the PIP2 product itself becomes 
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inserted in the PM. This mechanism would also be protein molecule-specific, 
consistent with previous findings[179]. Of course, from the E410A data we know that 
the substrate binding does not affect IȖ_i3’s steady state localisation, but this may not 
have been a limiting factor in the above proposed mechanism, which is nevertheless 
activity-dependent. However, this hypothesis may not be very physiologically feasible, 
if we agree to the current evidence that most of the substrate PI4P is in fact already in 
the PM[68], and not just only in the Golgi, as people initially considered. 
One way of testing this hypothesis may be to make a tandem construct of two IȖ_i3, 
one active and one inactive, linked together. The localisation of such a conjugate 
protein would inform us whether the previously observed cytosolic localisation of 
inactive IȖ_i3 was because it simply did not have the mechanism to insert into the 
membrane, or whether it was positively retained in the cytoplasm (as would be 
explained by the above hypothesis, where inactive enzyme remains bound to 
uncatalysed PI4P in the cytosol). 
 
 
7.3.4.PhosphorylationSiteIdentification
There are many aspects of the in vivo phosphorylation pattern that we did not 
understand. The “overall” phosphorylation is likely to be an ensemble of multiple 
phosphorylation events, potentially in a cooperative manner. This is complicated by 
the fact that some phosphorylations may not actually cause a mobility shift in SDS-
PAGE, and are hence not detectable using our method. It is not known what sites are 
involved in the phosphorylation of wild type IȖ_i2 or IȖ_i3, except for the very few 
residues identified in particular kinase pathways, which when impaired still leave the 
overall phosphorylation pattern largely unchanged[164]. On that note, it is not clear 
which kinase pathways converge onto PIP5KIȖ to produce the overall 
phosphorylation under different circumstances, or whether part of the in vivo 
phosphorylation observed is due to autophosphorylation. 
A two-dimension gel (based on e.g. protein mass, protein complex mass in the native 
state or isoelectric point) may be able to tease apart the originally inseparable 
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phosphorylation band, into multiple states arising from modifications at different 
combinations of residues[226, 227]. Moreover, we may consider the possibility of 
identifying these sites systematically, for example, by mass spectroscopy or in vivo 
incubation with radioactive ATP followed by Edman sequencing[228-232]. 
 
 
7.3.5.AutophosphorylationorCrossPhosphorylation
The autophosphorylation activity that we have observed is clearly dependent on the 
enzyme’s catalytic ability, as revealed by the D316K (and K188A) mutants. However, 
a remote possibility to explain the above phenomenon may be that the enzyme is co-
immunoprecipitated with another enzyme partner from the mammalian cell lysate, 
which is activated by the PIP5Ks and then phosphorylates PIP5Ks in return. 
This caveat may be overcome by using recombinant proteins made by a bacterial 
expression vector. However, a negative result from the subsequent 
autophosphorylation assay does not necessarily validate the above hypothesis. The 
protein may not have folded properly, acquired the appropriate post-translational 
modifications or, indeed, pulled down other co-factors that are absent from the 
bacteria, which do not phosphorylate the PIP5K directly but serve as activators (e.g. 
Rac, as demonstrated in this study). 
 
 
7.3.6.StructuralModel
So far, although some structural features are known for PIP4KIIȕ with emphasis on 
the catalytic and dimerisation mechanism[98], there are no good crystal structure of 
Type I PIP kinases available. De novo prediction is limited in its reliability and 
accuracy[233]. Even though homology or comparative modelling is possible 
nowadays through programs such as Swiss-Model, M4T, 3D-JIGSAW and I-
TASSER, the homology between Type I and Type II PIP kinases is largely conserved 
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only over the catalytic core of the enzymes. The C-terminal portion of the protein is 
unstructured in the published IIȕ model, making it meaningless to simulate the C-
terminal structure of PIP5KIȖ by homology, where the IȖ_i3-specific insert also 
happens to be. 
Ultimately, a good crystal structure of PIP5KIȖ (and its different splice variants) 
would be tremendously helpful, in verifying my “natively disordered domain” 
hypothesis of the IȖ_i3-specific insert, and elucidating how the enzyme functions are 
regulated physiologically. 
 
 
7.3.7.ImmobilityandInsolubility
In this study, we have tacitly used FRAP as a general indicator of PIP5K’s mobility 
on the plasma membrane, which was helpful as far as providing an empirical method 
of assessing the differential behaviours of different constructs. Because of the 
incomplete recovery and possibly multiple PM-binding states of IȖ_i3, its mobility 
was not easily characterised in terms of diffusion and time constants, but may instead 
be described by the mobile fraction and half time of recovery as in [205]. A similar 
method used by Dr Luisa Giudici (unpublished) was Triton X-100 solubility, where 
IȖ_i3 constructs tended to be more insoluble than their IȖ_i2 counterparts.  
We do not yet know exactly what specific factors underly these behaviours, and 
whether they are attributable to associations with lipid rafts, actin cytoskeleton or 
other binding partners. Time permitting, a screen of binding partners may be helpful 
for addressing this question, using e.g. electron microscopy, high performance liquid 
chromatography (HPLC), co-immunoprecipitation or yeast two-hybrid systems. 
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8.Appendix–SequenceAlignments
 
ClustalW alignment between rat (purple), mouse (orange) and human (green) sequences of 
PIP5KIȖ. * represents AA identity and dots AA similarity. 
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ClustalW alignment of all human PIP kinase paralogue sequences. From top to bottom in each 
panel: PIP4KIIĮ, PIP4KIIȕ, PIP4KIIȖ, PIP5KIȕ, PIP5KIȖ, PIP5KIĮ, PIP5KL1. * represents 
AA identity and dots AA similarity. 
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